Familial Hypercholesterolemia

Mendelian MONDO:0005439 Pathograph 63 Dyslipidemia Cardiovascular Disease

Familial hypercholesterolemia (FH) is a common autosomal dominant disorder of lipid metabolism characterized by significantly elevated serum low-density lipoprotein (LDL) cholesterol levels from birth, leading to premature atherosclerotic cardiovascular disease. Most cases are caused by mutations in LDLR encoding the LDL receptor, though mutations in APOB, PCSK9, LDLRAP1, and rarely APOE also contribute. Heterozygous FH (HeFH) affects approximately 1 in 250 individuals, making it one of the most common Mendelian disorders. Homozygous FH (HoFH) is rare (~1 in 250,000-360,000) but causes severe cardiovascular disease in childhood. The severity broadly reflects gene dosage and residual LDL receptor pathway activity. Lifelong LDL cholesterol-lowering treatment with combination therapy substantially improves cardiovascular outcomes and longevity. Recent LDLR-independent therapies such as evinacumab (anti-ANGPTL3) have expanded treatment options for HoFH patients with minimal residual LDLR function.

Ask OpenScientist

Ask a research question about Familial Hypercholesterolemia. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

👪

Inheritance

Autosomal Dominant HP:0000006

The majority of FH cases follow autosomal dominant inheritance due to mutations in LDLR, APOB, or PCSK9. Clinical severity depends on the causative gene and specific mutation, and is further modulated by polygenic background and lifestyle.

Autosomal dominant inheritance Penetrance: COMPLETE Expressivity: VARIABLE

Show evidence (1 reference)

PMID:29219151 SUPPORT Human Clinical

"Most cases are caused by autosomal dominant mutations in LDLR, which encodes the LDL receptor, although mutations in other genes coding for proteins involved in cholesterol metabolism or LDLR function and processing, such as APOB and PCSK9, can also be causative, although less frequently."

Confirms autosomal dominant inheritance as the primary mode.

Autosomal Recessive HP:0000007

Rare autosomal recessive FH is caused by biallelic loss-of-function mutations in LDLRAP1 (encoding the LDL receptor adaptor protein 1/ARH), which is required for clathrin-mediated endocytosis of the LDLR-LDL complex.

Autosomal recessive inheritance

Show evidence (1 reference)

DOI:10.3390/ijms24043224 SUPPORT Human Clinical

"Variants in the LDLRAP1 gene causes FH with a recessive inheritance and a specific APOE variant was described as causative of FH, contributing to increase FH genetic heterogeneity."

Confirms LDLRAP1 as the cause of autosomal recessive FH.

◆

Subtypes

Heterozygous Familial Hypercholesterolemia

~99%

Caused by a single pathogenic allele in LDLR, APOB, or PCSK9. LDL-C typically 190-400 mg/dL. Untreated males may develop coronary events by age 40-50, females by age 50-60. Prevalence approximately 1:250-300. Responds well to statin-based combination therapy.

Show evidence (1 reference)

PMID:29219151 SUPPORT Human Clinical

"Familial hypercholesterolaemia is a common inherited disorder characterized by abnormally elevated serum levels of low-density lipoprotein (LDL) cholesterol from birth, which in time can lead to cardiovascular disease (CVD)."

HeFH is the common form, with elevated LDL-C leading to premature CVD.

Homozygous Familial Hypercholesterolemia MONDO:0018328

~1:250,000-360,000

Caused by two pathogenic alleles (true homozygotes or compound heterozygotes). LDL-C typically >500 mg/dL (>10 mmol/L). Atherosclerosis often presents during childhood or adolescence with aortic valve disease and coronary events. Requires aggressive multi-pronged LDL-lowering therapy including apheresis and LDLR-independent agents.

Show evidence (1 reference)

DOI:10.1093/eurheartj/ehad197 SUPPORT Human Clinical

"This 2023 statement updates clinical guidance for homozygous familial hypercholesterolaemia (HoFH), explains the genetic complexity, and provides pragmatic recommendations to address inequities in HoFH care worldwide."

EAS 2023 consensus provides clinical guidance for HoFH including diagnostic criteria and multi-pronged therapy.

⚙

Pathophysiology

LDLR Functional Defect

Pathogenic LDLR variants reduce receptor synthesis, trafficking, ligand binding, internalization, or recycling, lowering functional LDL receptor abundance on hepatocytes and weakening the core LDL clearance pathway.

hepatocyte link

LDLR link

low-density lipoprotein particle clearance link receptor-mediated endocytosis link

liver link

Downstream

Reduced Hepatic LDL Clearance Loss of functional LDLR directly reduces receptor-mediated uptake of circulating LDL particles.

Show evidence (1 reference)

PMID:1301956 SUPPORT Human Clinical

"Mutations disrupting the function of this receptor produce autosomal dominant familial hypercholesterolemia (FH)."

Establishes LDLR dysfunction as a primary genetic mechanism in FH.

APOB-LDLR Binding Defect

Pathogenic APOB variants leave the receptor pathway present but impair binding of apoB-containing LDL particles to LDLR, creating a ligand-side failure of hepatic LDL uptake.

hepatocyte link

APOB link

low-density lipoprotein particle clearance link

liver link

Downstream

Reduced Hepatic LDL Clearance Defective LDL particle binding prevents normal receptor-mediated clearance despite preserved receptor expression.

Show evidence (1 reference)

PMID:24404629 SUPPORT Human Clinical

"The molecular diagnosis of FH can be established by identification of heterozygous or biallelic pathogenic variants in APOB (variants that impair binding of LDL-C to the LDL receptor), LDLR, or PCSK9 (gain of function); or rarely, identification of biallelic pathogenic variants in LDLRAP1."

Identifies APOB-mediated defective LDLR binding as a monogenic FH mechanism.

PCSK9 Gain-of-Function

Gain-of-function PCSK9 variants create a dominant mechanism of FH by increasing the rate at which LDLR is removed from the hepatocyte surface.

hepatocyte link

PCSK9 link

receptor-mediated endocytosis link

liver link

Downstream

PCSK9-Mediated LDLR Degradation PCSK9 gain-of-function turns the inherited defect into accelerated post-endocytic LDLR degradation.

Show evidence (1 reference)

PMID:24404629 SUPPORT Human Clinical

Establishes PCSK9 gain-of-function as one of the monogenic starting points of FH.

LDLRAP1-Related LDL Uptake Defect

Biallelic LDLRAP1 variants define a rarer recessive route into the same LDLR pathway failure, showing that FH can also start at a genetically disrupted LDL uptake step without a primary LDLR coding defect.

hepatocyte link

LDLRAP1 link

low-density lipoprotein particle clearance link

liver link

Downstream

Reduced Hepatic LDL Clearance LDLRAP1-related FH converges on the same proximal defect of impaired LDL uptake.

Show evidence (1 reference)

DOI:10.3390/ijms24043224 SUPPORT Human Clinical

"Variants in the LDLRAP1 gene causes FH with a recessive inheritance and a specific APOE variant was described as causative of FH, contributing to increase FH genetic heterogeneity."

Establishes LDLRAP1-related FH as a distinct genetic entry point into the LDLR pathway.

APOE-Related Lipoprotein Clearance Defect

Rare APOE variants can create an FH-like phenotype by disrupting clearance of apoE-containing lipoproteins, providing an uncommon genetic route into the same impaired lipoprotein-clearance axis.

hepatocyte link

APOE link

cholesterol metabolic process link ⚠ ABNORMAL low-density lipoprotein particle clearance link ↓ DECREASED

liver link

Downstream

Reduced Hepatic LDL Clearance APOE-related FH phenocopies converge on impaired receptor-mediated clearance of atherogenic lipoproteins.

Show evidence (1 reference)

DOI:10.3390/ijms24043224 SUPPORT Human Clinical

"a specific APOE variant was described as causative of FH, contributing to increase FH genetic heterogeneity."

Establishes APOE-related FH as a rare genetic contributor to FH heterogeneity.

PCSK9-Mediated LDLR Degradation

Excess PCSK9 activity accelerates degradation of mature LDL receptors after endocytosis, leaving fewer receptors available on hepatocytes to clear LDL from the circulation.

hepatocyte link

receptor-mediated endocytosis link

liver link

Downstream

Reduced Hepatic LDL Clearance Accelerated destruction of mature LDLR leaves too few surface receptors for normal LDL clearance.

Show evidence (1 reference)

DOI:10.1073/pnas.0409736102 SUPPORT In Vitro

"PCSK9 overexpression had no effect on LDLR synthesis but caused a dramatic increase in the degradation of the mature LDLR"

Directly demonstrates the degradative mechanism by which PCSK9 reduces LDLR availability.

Reduced Hepatic LDL Clearance

Despite different causal genes, monogenic FH converges on impaired hepatic uptake and lysosomal processing of LDL particles, so plasma LDL remains elevated from birth.

hepatocyte link

low-density lipoprotein particle clearance link receptor-mediated endocytosis link

liver link

Downstream

Elevated Circulating LDL Cholesterol When hepatocytes cannot clear LDL efficiently, circulating LDL-C accumulates lifelong.

Show evidence (1 reference)

PMID:1301956 SUPPORT Human Clinical

"The low density lipoprotein (LDL) receptor is a cell surface transmembrane protein that mediates the uptake and lysosomal degradation of plasma LDL, thereby providing cholesterol to cells."

Defines the normal clearance step that is disrupted across monogenic FH mechanisms.

Elevated Circulating LDL Cholesterol

Lifelong LDL-C excess is the central biochemical phenotype of FH and the immediate driver of arterial and extra-arterial cholesterol deposition.

cholesterol homeostasis link

Downstream

Hypercholesterolemia Lifelong elevation of circulating LDL-C manifests clinically as hypercholesterolemia.

Increased LDL Cholesterol Concentration The same LDL-C excess is captured by the more specific HPO phenotype for increased LDL cholesterol concentration.

LDL Cholesterol (LDL-C) Measured LDL-C is the biochemical biomarker corresponding to the elevated circulating LDL cholesterol mechanism.

Oxidized LDL Infiltration of Arterial Intima Persistently elevated LDL loads the arterial wall and initiates intimal lipid retention.

Extra-arterial Cholesterol Deposition The same chronic LDL excess also drives lipid deposition in tendon, skin, cornea, and valve tissue.

Show evidence (1 reference)

PMID:29219151 SUPPORT Human Clinical

Establishes lifelong LDL-C elevation as the core biochemical phenotype of FH.

Oxidized LDL Infiltration of Arterial Intima

Oxidized LDL infiltrates and accumulates in the arterial intima, establishing the initiating lipid milieu for FH-associated atherogenesis.

endothelial cell link

inflammatory response link

tunica intima link

Downstream

Macrophage Recruitment to Arterial Intima Intimal oxidized LDL promotes leukocyte attraction and macrophage influx.

Show evidence (1 reference)

PMID:30165986 SUPPORT Human Clinical

"Because atherogenic lipoproteins play a central causal role in the initiation and progression of atherosclerosis, maintaining optimal lipid levels is necessary to achieve ideal cardiovascular health."

Supports LDL-driven lipoprotein burden as an initiating event in arterial atherogenesis.

Macrophage Recruitment to Arterial Intima

Inflammatory signaling within the lipid-rich intima recruits macrophages to early arterial lesions.

macrophage link endothelial cell link

inflammatory response link

tunica intima link

Downstream

Macrophage-Derived Foam Cell Formation Recruited macrophages internalize oxidized lipoproteins and transition toward foam cells.

Show evidence (1 reference)

DOI:10.3390/nu16132156 SUPPORT Human Clinical

"Disruption in any of these steps results in pathophysiological abnormalities such as dyslipidemia, obesity, insulin resistance, inflammation, atherosclerosis, peripheral artery disease, and cardiovascular diseases."

Supports inflammation-coupled transition from lipid imbalance to arterial immune-cell pathology.

Macrophage-Derived Foam Cell Formation

Macrophages in lipid-rich intima accumulate oxidized lipoproteins and differentiate into foam cells.

macrophage-derived foam cell link macrophage link

macrophage-derived foam cell differentiation link

tunica intima link

Downstream

Atherosclerotic Plaque Development Foam-cell accumulation drives fatty-streak maturation and plaque development.

Show evidence (1 reference)

DOI:10.1038/s41467-024-46336-2 SUPPORT Model Organism

"Adenylyl cyclase-associated protein 1 (CAP1) is the main binding partner of PCSK9 and indispensable for the inflammatory action of PCSK9, including induction of cytokines, Toll like receptor 4, and scavenger receptors, enhancing the uptake of oxidized LDL."

Supports enhanced oxidized-LDL uptake as a proximate mechanism for foam cell formation.

Atherosclerotic Plaque Development

Chronic intimal lipid retention and inflammation result in atherosclerotic plaque formation as a major arterial consequence of lifelong LDL excess in FH.

endothelial cell link vascular smooth muscle cell link

inflammatory response link

tunica intima link

Downstream

Premature Atherosclerotic Cardiovascular Disease Ongoing plaque growth produces early coronary, cerebrovascular, and peripheral vascular disease.

Atherosclerosis Chronic intimal lipid retention and inflammation are the structural basis for generalized atherosclerosis in FH.

Coronary Artery Atherosclerosis FH plaque deposition prominently affects the coronary arteries.

Peripheral Arterial Stenosis Systemic atherosclerotic plaque burden can narrow peripheral arteries.

Show evidence (2 references)

DOI:10.3390/nu16132156 SUPPORT Human Clinical

Confirms the pathological link between lipoprotein dysregulation and atherosclerosis.

PMID:28444290 SUPPORT Human Clinical

"Consistent evidence from numerous and multiple different types of clinical and genetic studies unequivocally establishes that LDL causes ASCVD."

The EAS consensus statement establishes LDL as a causal driver of atherosclerotic cardiovascular disease.

Premature Atherosclerotic Cardiovascular Disease

The arterial branch culminates in premature coronary artery disease, angina, myocardial infarction, stroke, and peripheral arterial disease, with earlier and more severe presentations in biallelic disease.

Downstream

Premature Coronary Artery Disease Premature CAD is the dominant clinical expression of FH-associated atherosclerotic cardiovascular disease.

Angina Pectoris Coronary atherosclerotic disease can manifest as angina.

Myocardial Infarction Advanced coronary plaque disease increases risk for premature myocardial infarction.

Ischemic Stroke Cerebrovascular involvement is a less common consequence of the same atherosclerotic burden.

Show evidence (2 references)

DOI:10.3390/ijms25031637 SUPPORT Human Clinical

"Nevertheless, a significantly more severe phenomenon is leading to the premature onset of cardiovascular disease (CVD) and its clinical implications, such as cardiac events, stroke or vascular dementia, even at a relatively young age."

This node captures the major clinical cardiovascular consequences of lifelong LDL-driven atherosclerosis.

PMID:24404629 SUPPORT Human Clinical

"Individuals with a more severe phenotype, often as a result of biallelic variants, can present with very significant elevations in LDL-C (>500 mg/dL), early-onset coronary artery disease (CAD; presenting as early as childhood in some), and calcific aortic valve disease."

GeneReviews shows how more severe genetic forms of FH accelerate clinical cardiovascular disease.

Extra-arterial Cholesterol Deposition

Chronic LDL excess also drives cholesterol deposition outside the arterial wall, creating the visible stigmata of FH and contributing to valvular disease.

Downstream

Tendon and Cutaneous Cholesterol Deposition Cholesterol deposition in tendons and skin explains tendon xanthomas, cutaneous xanthomas, and periorbital xanthelasma.

Corneal Cholesterol Deposition Corneal peripheral deposition explains premature corneal arcus.

Aortic Valve Lipid Deposition and Calcification In severe FH, valvular and aortic root deposition produces calcific aortic valve disease.

Show evidence (1 reference)

PMID:24404629 SUPPORT Human Clinical

"Xanthomas (cholesterol deposits in tendons) may be visible in the Achilles tendons or tendons of the hands and worsen with age as a result of extremely high cholesterol levels. Xanthelasmas (yellowish, waxy deposits) can occur around the eyelids."

Documents the clinically visible extra-arterial cholesterol deposition phenotype in FH.

Tendon and Cutaneous Cholesterol Deposition

Cholesterol-rich deposits accumulate in the Achilles and hand tendons and in the skin and eyelids, producing tendon xanthomas, cutaneous xanthomas, and xanthelasma.

Downstream

Tendon Xanthomas Tendon cholesterol deposition produces clinically visible tendon xanthomas.

Cutaneous Xanthomas Severe chronic LDL-C excess can also produce cholesterol-rich deposits in the skin.

Xanthelasma Cholesterol deposition around the eyelids produces xanthelasma.

Show evidence (2 references)

PMID:24404629 SUPPORT Human Clinical

Explains the tendon and eyelid deposition phenotypes that make FH clinically recognizable.

DOI:10.3390/ijms25031637 SUPPORT Human Clinical

"A chronically elevated concentration of LDL-C in the plasma leads to the occurrence of certain abnormalities, such as xanthomas in the tendons and skin, as well as corneal arcus."

Extends the same deposition logic to skin xanthomas in FH.

Corneal Cholesterol Deposition

Lipid deposition at the peripheral cornea produces premature corneal arcus, especially when LDL exposure begins early in life.

Downstream

Corneal Arcus Peripheral corneal cholesterol deposition is the anatomical basis of premature corneal arcus in FH.

Show evidence (1 reference)

PMID:24404629 SUPPORT Human Clinical

"Individuals with FH may develop corneal arcus (white, gray, or blue opaque ring in the corneal margin as a result of cholesterol deposition) at a younger age than those without FH."

Directly maps the pathologic process to the corneal arcus phenotype.

Aortic Valve Lipid Deposition and Calcification

In severe, especially biallelic FH, chronic lipid deposition in the aortic root and valve contributes to early calcific aortic valve disease.

Downstream

Aortic Valve Stenosis Severe FH can produce calcific aortic valve disease, clinically captured as aortic valve stenosis.

Show evidence (1 reference)

PMID:24404629 SUPPORT Human Clinical

Supports a distinct valvular deposition branch in severe FH.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

Cardiovascular 8

Premature Coronary Artery Disease VERY_FREQUENT Premature coronary artery atherosclerosis (HP:0005181)

Show evidence (1 reference)

PMID:29219151 SUPPORT Human Clinical

"common diagnostic features are an elevated LDL cholesterol level and a family history of hypercholesterolaemia or (premature) CVD."

Premature cardiovascular disease is a key diagnostic feature of FH.

Coronary Artery Atherosclerosis VERY_FREQUENT Coronary artery atherosclerosis (HP:0001677)

Show evidence (1 reference)

PMID:24404629 SUPPORT Human Clinical

"Familial hypercholesterolemia (FH) is characterized by significantly elevated low-density lipoprotein cholesterol (LDL-C) that leads to atherosclerotic plaque deposition in the coronary arteries and proximal aorta at an early age and increases the risk of premature cardiovascular events such as..."

Confirms atherosclerotic plaque deposition in coronary arteries as a hallmark of FH.

Angina Pectoris FREQUENT Angina pectoris (HP:0001681)

Show evidence (1 reference)

PMID:24404629 SUPPORT Human Clinical

"increases the risk of premature cardiovascular events such as angina and myocardial infarction"

Angina is listed as a premature cardiovascular event in FH.

Myocardial Infarction FREQUENT Myocardial infarction (HP:0001658)

Show evidence (1 reference)

PMID:24404629 SUPPORT Human Clinical

"increases the risk of premature cardiovascular events such as angina and myocardial infarction"

Myocardial infarction is listed as a key cardiovascular event in FH.

Aortic Valve Stenosis OCCASIONAL Aortic valve stenosis (HP:0001650)

Show evidence (1 reference)

PMID:24404629 SUPPORT Human Clinical

GeneReviews directly identifies calcific aortic valve disease as a feature of severe (biallelic) FH.

Atherosclerosis VERY_FREQUENT Atherosclerosis (HP:0002621)

Show evidence (1 reference)

PMID:32205033 SUPPORT Human Clinical

"All FH patients are at high risk for premature cardiovascular disease (CVD) events due to their genetically determined lifelong exposure to high LDL-C levels."

Lifelong LDL-C exposure drives generalized atherosclerosis in FH.

Peripheral Arterial Stenosis OCCASIONAL Peripheral arterial stenosis (HP:0004950)

Show evidence (1 reference)

PMID:18243212 PARTIAL Human Clinical

"Prevalence of PCVD was 21.9% (30.2% in males and 14.5% in women, P<0.001). Mean age of onset of cardiovascular event was 42.1 years in males and 50.8 years in females."

This study reports high prevalence of premature cardiovascular disease in FH generally, but does not specifically quantify peripheral arterial stenosis. Peripheral vascular involvement is inferred as part of the generalized atherosclerotic burden.

Ischemic Stroke OCCASIONAL Ischemic stroke (HP:0002140)

Show evidence (1 reference)

PMID:24404629 SUPPORT Human Clinical

"stroke occurs more rarely"

GeneReviews notes stroke as a less common but recognized cardiovascular manifestation of FH.

Eye 1

Corneal Arcus OCCASIONAL Corneal arcus (HP:0001084)

Show evidence (1 reference)

DOI:10.3390/ijms25031637 SUPPORT Human Clinical

"A chronically elevated concentration of LDL-C in the plasma leads to the occurrence of certain abnormalities, such as xanthomas in the tendons and skin, as well as corneal arcus."

Corneal arcus is a recognized clinical feature of FH.

Head and Neck 1

Xanthelasma OCCASIONAL Xanthelasma (HP:0001114)

Show evidence (1 reference)

PMID:24404629 SUPPORT Human Clinical

"Xanthelasmas (yellowish, waxy deposits) can occur around the eyelids."

GeneReviews confirms xanthelasma as a clinical feature of FH.

Integument 2

Tendon Xanthomas FREQUENT Tendon xanthomatosis (HP:0010874)

Show evidence (2 references)

DOI:10.3390/ijms25031637 SUPPORT Human Clinical

"A chronically elevated concentration of LDL-C in the plasma leads to the occurrence of certain abnormalities, such as xanthomas in the tendons and skin, as well as corneal arcus."

Tendon and skin xanthomas are characteristic manifestations of chronic LDL-C elevation.

PMID:10357843 SUPPORT Human Clinical

"In this large family, the degree of hypercholesterolemia, prevalence of tendon xanthomata, and occurrence of early coronary disease were indistinguishable from the other families studied."

HPOA-linked FH3 pedigree study independently confirms tendon xanthomata as a recurring clinical manifestation of monogenic FH.

Cutaneous Xanthomas OCCASIONAL Xanthomatosis (HP:0000991)

Show evidence (1 reference)

DOI:10.3390/ijms25031637 SUPPORT Human Clinical

"A chronically elevated concentration of LDL-C in the plasma leads to the occurrence of certain abnormalities, such as xanthomas in the tendons and skin, as well as corneal arcus."

Documents skin xanthomas as a cutaneous manifestation of severe chronic LDL-C elevation in FH.

Metabolism 2

Hypercholesterolemia OBLIGATE Hypercholesterolemia (HP:0003124)

Show evidence (1 reference)

PMID:29219151 SUPPORT Human Clinical

Elevated LDL cholesterol from birth is the defining feature of FH.

Context-specific annotations (2)

Genetic HETEROZYGOUS

Heterozygous FH

LDL-C typically 190-400 mg/dL

Show evidence (1 reference)

PMID:29219151 SUPPORT Human Clinical

Elevated LDL cholesterol from birth is the defining feature.

Genetic HOMOZYGOUS Severe

Homozygous FH

LDL-C typically >500 mg/dL (>13 mmol/L)

Show evidence (1 reference)

DOI:10.1111/cts.13836 SUPPORT Human Clinical

"Homozygous familial hypercholesterolemia (HoFH) is a rare and serious genetic condition characterized by premature cardiovascular disease due to severely elevated low‐density lipoprotein cholesterol (LDL‐C)."

Confirms severely elevated LDL-C as the hallmark of HoFH.

Increased LDL Cholesterol Concentration OBLIGATE Increased LDL cholesterol concentration (HP:0003141)

Show evidence (2 references)

PMID:1301956 SUPPORT Human Clinical

"Affected individuals have elevated plasma levels of LDL, which causes premature coronary atherosclerosis."

OMIM/HPOA-linked review directly identifies elevated plasma LDL as the defining biochemical abnormality in FH.

PMID:10205269 SUPPORT Human Clinical

"Autosomal dominant hypercholesterolemia (ADH), one of the most frequent hereditary disorders, is characterized by an isolated elevation of LDL particles that leads to premature mortality from cardiovascular complications."

HPOA-linked FH3 study confirms that isolated LDL particle elevation is the characteristic biochemical phenotype.

🧬

Genetic Associations

LDLR (Pathogenic Mutations)

Autosomal Dominant

Show evidence (2 references)

PMID:29219151 SUPPORT Human Clinical

"Most cases are caused by autosomal dominant mutations in LDLR, which encodes the LDL receptor"

LDLR mutations are the most frequent genetic cause of FH.

DOI:10.3390/ijms24043224 SUPPORT Human Clinical

"Genetics of Familial Hypercholesterolemia (FH) is ascribable to pathogenic variants in genes encoding proteins leading to an impaired LDL uptake by the LDL receptor (LDLR)."

Confirms that LDLR variants lead to impaired LDL uptake.

APOB (Pathogenic Mutations)

Autosomal Dominant

Show evidence (2 references)

DOI:10.3390/ijms24043224 SUPPORT Human Clinical

"Genetics of Familial Hypercholesterolemia (FH) is ascribable to pathogenic variants in genes encoding proteins leading to an impaired LDL uptake by the LDL receptor (LDLR)."

APOB is one of the genes whose variants lead to impaired LDL uptake.

PMID:29219151 SUPPORT Human Clinical

"mutations in other genes coding for proteins involved in cholesterol metabolism or LDLR function and processing, such as APOB and PCSK9, can also be causative, although less frequently."

Confirms APOB as a less frequent but established cause of FH.

PCSK9 (Gain-of-Function Mutations)

Autosomal Dominant

Show evidence (2 references)

DOI:10.1073/pnas.0409736102 SUPPORT In Vitro

"Overexpression of PCSK9 in HepG2 cells caused a decrease in whole-cell and cell-surface LDLR levels. PCSK9 overexpression had no effect on LDLR synthesis but caused a dramatic increase in the degradation of the mature LDLR"

Demonstrates the mechanism by which PCSK9 gain-of-function mutations cause FH through increased LDLR degradation.

DOI:10.1111/joim.13577 SUPPORT Human Clinical

"PCSK9 discovery in FH by Abifadel et al."

Traces the discovery of PCSK9 as a causative gene in FH.

LDLRAP1 (Loss-of-Function Mutations)

Autosomal Recessive

Show evidence (1 reference)

DOI:10.3390/ijms24043224 SUPPORT Human Clinical

"Variants in the LDLRAP1 gene causes FH with a recessive inheritance and a specific APOE variant was described as causative of FH, contributing to increase FH genetic heterogeneity."

Confirms LDLRAP1 as the cause of autosomal recessive FH.

APOE (Rare Causative Variants)

Autosomal Dominant

Show evidence (1 reference)

DOI:10.3390/ijms24043224 SUPPORT Human Clinical

"a specific APOE variant was described as causative of FH, contributing to increase FH genetic heterogeneity."

Confirms rare APOE variants as contributors to FH genetic heterogeneity.

Polygenic Hypercholesterolemia (Phenocopy or Modifier)

Show evidence (1 reference)

DOI:10.3390/ijms24043224 SUPPORT Human Clinical

"The presence of several common variants was also considered a genetic basis of FH and several polygenic risk scores (PRS) have been described. The presence of a variant in modifier genes or high PRS in HeFH further exacerbates the phenotype, partially justifying its variability among patients."

Polygenic risk scores contribute to phenotypic variability in FH.

💊

Treatments

High-Intensity Statin Therapy

Action: targeted therapy Ontology label: Targeted Therapy NCIT:C93352

Agent: statin ↗

Statins are the first-line therapy for FH, reducing LDL cholesterol by inhibiting HMG-CoA reductase, which upregulates hepatic LDLR expression. High-intensity statins (atorvastatin 40-80mg, rosuvastatin 20-40mg) can reduce LDL-C by 50-60%. Initiated at diagnosis in adults, and in children from age 8-10. Efficacy depends on residual LDLR function; Class 1 (null) LDLR mutations in HoFH show minimal response since there is no receptor to upregulate. APOB and PCSK9 gain-of-function FH respond well to statins.

Mechanism Target:

INHIBITS Elevated Circulating LDL Cholesterol — Statins are first-line lifelong LDL-lowering therapy for FH, lowering the core circulating LDL-C abnormality.

Show evidence (1 reference)

PMID:29219151 SUPPORT Human Clinical

"Lifelong LDL cholesterol-lowering treatment substantially improves CVD-free survival and longevity. Statins are the first-line therapy"

This directly supports statins as first-line treatment aimed at lowering LDL cholesterol in FH.

Show evidence (2 references)

PMID:29219151 SUPPORT Human Clinical

"Statins are the first-line therapy, but additional drugs, such as ezetimibe, bile acid sequestrants, PCSK9 inhibitors and other emerging therapies, are often required."

Statins confirmed as first-line therapy with additional agents often needed.

PMID:29219151 SUPPORT Human Clinical

"Lifelong LDL cholesterol-lowering treatment substantially improves CVD-free survival and longevity."

Confirms the critical importance of lifelong LDL-lowering therapy.

Ezetimibe

Action: targeted therapy Ontology label: Targeted Therapy NCIT:C93352

Agent: ezetimibe ↗

Ezetimibe inhibits intestinal cholesterol absorption via the NPC1L1 transporter, providing an additional 15-20% LDL-C reduction on top of statin therapy. Recommended as second-line add-on therapy when statin monotherapy is insufficient to reach LDL-C targets. Effective across all FH genotypes as its mechanism is independent of LDLR.

Mechanism Target:

INHIBITS Elevated Circulating LDL Cholesterol — Ezetimibe is an LDL-C-lowering add-on therapy that helps reduce the central biochemical abnormality when statin therapy is insufficient.

Show evidence (1 reference)

DOI:10.1111/cts.13836 SUPPORT Human Clinical

"Treatment options such as statins, lomitapide, ezetimibe, proprotein convertase subtilisin/kexin type 9 inhibitors, and apheresis help lower LDL‐C"

The HoFH review lists ezetimibe among treatment options that lower LDL-C.

Show evidence (1 reference)

PMID:29219151 SUPPORT Human Clinical

"Statins are the first-line therapy, but additional drugs, such as ezetimibe, bile acid sequestrants, PCSK9 inhibitors and other emerging therapies, are often required."

Ezetimibe is listed as an important add-on therapy for FH.

Bile Acid Sequestrants

Action: Pharmacotherapy NCIT:C15986

Agent: bile acid sequestrant ↗

Bile acid sequestrants are non-systemic antilipidemic agents that bind bile acids in the gut, increase fecal bile acid loss, and promote hepatic cholesterol conversion to bile acids. In FH they can be used as additional LDL-C-lowering therapy when statins and other agents are insufficient or when pregnancy limits other pharmacologic options.

Mechanism Target:

INHIBITS Elevated Circulating LDL Cholesterol — Bile acid sequestrants are part of the additional drug armamentarium used to lower LDL cholesterol in FH.

Show evidence (1 reference)

PMID:29219151 SUPPORT Human Clinical

"Statins are the first-line therapy, but additional drugs, such as ezetimibe, bile acid sequestrants, PCSK9 inhibitors and other emerging therapies, are often required."

The FH primer identifies bile acid sequestrants among additional drugs often required after first-line statins.

Show evidence (1 reference)

PMID:29219151 SUPPORT Human Clinical

"Statins are the first-line therapy, but additional drugs, such as ezetimibe, bile acid sequestrants, PCSK9 inhibitors and other emerging therapies, are often required."

Bile acid sequestrants are explicitly listed as additional FH therapy in this overview.

PCSK9 Inhibitor Therapy

Action: Pharmacotherapy NCIT:C15986

Agent: PCSK9 inhibitor ↗ alirocumab ↗ evolocumab ↗

Monoclonal antibodies targeting PCSK9 (evolocumab, alirocumab) prevent PCSK9-mediated LDLR degradation, increasing LDLR recycling and LDL clearance. Provide additional 50-60% LDL-C reduction on top of maximally tolerated statin and ezetimibe. Most effective in patients with residual LDLR function (receptor-defective rather than receptor-negative HoFH, and all HeFH). Patients with PCSK9 gain-of-function mutations respond particularly well. Limited efficacy in receptor-negative (null) HoFH.

Mechanism Target:

INHIBITS PCSK9-Mediated LDLR Degradation — PCSK9 inhibitors block the PCSK9 pathway that removes LDL receptors from the hepatocyte surface, improving LDL-C clearance when residual LDLR function exists.

Show evidence (1 reference)

PMID:32197277 SUPPORT Human Clinical

"Monoclonal antibodies directed against proprotein convertase subtilisin-kexin type 9 (PCSK9) have been shown to reduce LDL cholesterol levels by more than 50%"

Anti-PCSK9 monoclonal antibodies reduce LDL cholesterol by targeting the PCSK9 axis.

Show evidence (1 reference)

DOI:10.1111/joim.13577 SUPPORT Human Clinical

"the very rapid availability of PCSK9 inhibitors."

Traces the rapid translation of PCSK9 genetics into therapeutic PCSK9 inhibitors.

Inclisiran

Action: Pharmacotherapy NCIT:C15986

Agent: inclisiran ↗

A small interfering RNA (siRNA) that targets hepatic PCSK9 mRNA, reducing PCSK9 synthesis at the translational level. Administered subcutaneously every 6 months after initial loading doses, providing sustained LDL-C lowering of approximately 50%. Offers advantages in adherence due to infrequent dosing. Like PCSK9 monoclonal antibodies, efficacy depends on residual LDLR function.

Mechanism Target:

INHIBITS PCSK9-Mediated LDLR Degradation — Inclisiran inhibits hepatic PCSK9 synthesis, reducing the PCSK9-driven LDLR degradation mechanism.

Show evidence (1 reference)

PMID:32197277 SUPPORT Human Clinical

"a twice-yearly injection of inclisiran, a small interfering RNA, was shown to inhibit hepatic synthesis of PCSK9 in adults with heterozygous familial hypercholesterolemia."

The ORION-9 abstract directly states that inclisiran inhibits hepatic PCSK9 synthesis.

Show evidence (1 reference)

PMID:32197277 SUPPORT Human Clinical

"Among adults with heterozygous familial hypercholesterolemia, those who received inclisiran had significantly lower levels of LDL cholesterol than those who received placebo, with an infrequent dosing regimen and an acceptable safety profile."

ORION-9 phase 3 trial demonstrates significant LDL-C reduction with inclisiran in HeFH patients.

Bempedoic Acid

Action: targeted therapy Ontology label: Targeted Therapy NCIT:C93352

Agent: bempedoic acid ↗

An ATP citrate lyase inhibitor that reduces cholesterol biosynthesis upstream of HMG-CoA reductase. Provides 15-25% additional LDL-C reduction when added to maximally tolerated statins. As a prodrug activated only in the liver, it avoids statin-associated muscle side effects. Useful in statin-intolerant FH patients.

Mechanism Target:

INHIBITS Elevated Circulating LDL Cholesterol — Bempedoic acid lowers LDL-C in HeFH and therefore targets the central biochemical abnormality downstream of impaired LDL clearance.

Show evidence (1 reference)

PMID:38341323 SUPPORT Human Clinical

"Bempedoic acid significantly lowered LDL-C at week 12 vs. placebo regardless of HeFH status (with HeFH, -21.2%; without HeFH, -18.2% [both P<0.0001])."

The pooled phase 3 analysis supports LDL-C lowering in HeFH.

Show evidence (1 reference)

PMID:38341323 SUPPORT Human Clinical

"Bempedoic acid significantly lowered LDL-C at week 12 vs. placebo regardless of HeFH status (with HeFH, -21.2%; without HeFH, -18.2% [both P<0.0001])."

Pooled phase 3 data showing significant LDL-C lowering with bempedoic acid in HeFH patients.

Evinacumab (Anti-ANGPTL3)

Action: Pharmacotherapy NCIT:C15986

Agent: evinacumab ↗

A fully human monoclonal antibody against ANGPTL3 (angiopoietin-like protein 3). Evinacumab works through an LDLR-independent mechanism, lowering LDL-C by approximately 50% at 15 mg/kg IV every 4 weeks. This is critical for HoFH patients with null LDLR mutations who do not respond to LDLR-dependent therapies. Long-term real-world data show sustained LDL-C reduction (56% at 6 months, sustained over 3.5 years) and improved cardiovascular event-free survival. Approved for pediatric patients age 5 and older with HoFH.

Mechanism Target:

INHIBITS Elevated Circulating LDL Cholesterol — Evinacumab lowers LDL-C through an LDLR-independent ANGPTL3 pathway, making it useful when the upstream LDLR-clearance defect is severe.

Show evidence (1 reference)

DOI:10.1111/cts.13836 SUPPORT Human Clinical

"Evinacumab is a first‐in‐class human monoclonal antibody that specifically binds to ANGPTL3 to prevent its inhibition of LPL and EL. In clinical trials, a 15 mg/kg intravenous dose every 4 weeks has shown a mean percent change from baseline in LDL‐C of ~50% in adult, adolescent, and pediatric..."

The review explains the ANGPTL3 mechanism and LDL-C reduction in HoFH.

Show evidence (3 references)

DOI:10.1111/cts.13836 SUPPORT Human Clinical

Demonstrates evinacumab mechanism and efficacy across age groups in HoFH.

DOI:10.1161/atvbaha.123.320609 SUPPORT Human Clinical

"Real-life, long-term evinacumab adjunctive to lipid-lowering therapy including lipoprotein apheresis led to sustained low-density lipoprotein cholesterol lowering and improved cardiovascular event–free survival of patients with HoFH."

Long-term real-world data showing sustained LDL-C lowering and improved CV outcomes with evinacumab in HoFH.

DOI:10.1161/circulationaha.123.065529 SUPPORT Human Clinical

"Evinacumab constitutes a new treatment for pediatric patients with HoFH and inadequately controlled LDL-C despite optimized lipid-lowering therapy, lowering LDL-C levels by nearly half in these extremely high-risk and difficult-to-treat individuals."

Demonstrates evinacumab efficacy in pediatric HoFH patients aged 5-11.

Lomitapide

Action: Pharmacotherapy NCIT:C15986

Agent: lomitapide ↗

An oral microsomal triglyceride transfer protein (MTP) inhibitor that reduces hepatic VLDL secretion, thereby lowering LDL-C. Approved for HoFH as adjunctive therapy. Works independently of LDLR function. Requires careful monitoring for hepatotoxicity and gastrointestinal side effects, and a low-fat diet to minimize steatorrhea.

Mechanism Target:

INHIBITS Elevated Circulating LDL Cholesterol — Lomitapide is part of HoFH LDL-C-lowering combination therapy, reducing the same elevated LDL-C endpoint.

Show evidence (1 reference)

DOI:10.1093/eurheartj/ehad197 SUPPORT Human Clinical

"Addition of novel, efficacious therapies (i.e. inhibitors of proprotein convertase subtilisin/kexin type 9, followed by evinacumab and/or lomitapide) offers potential to attain LDL-C goal or reduce the need for LA."

EAS guidance lists lomitapide among therapies used to attain LDL-C goals in HoFH.

Show evidence (1 reference)

DOI:10.1093/eurheartj/ehad197 SUPPORT Human Clinical

Lomitapide is part of the EAS-recommended multi-pronged therapy for HoFH.

Mipomersen

Action: Pharmacotherapy NCIT:C15986

Agent: mipomersen ↗

Second-generation 2'-O-methoxyethyl chimeric antisense oligonucleotide that hybridizes with APOB mRNA and recruits RNase H1 to degrade the transcript, suppressing hepatic apolipoprotein B-100 synthesis and the secretion of VLDL particles that mature into LDL. FDA-approved (Kynamro, 2013) as an adjunctive therapy for homozygous familial hypercholesterolemia in patients already on maximally tolerated lipid-lowering therapy. Works independently of LDLR function, so it retains efficacy in receptor-negative HoFH where statins fail. Marketed in the US until 2018; the mechanism remains a foundational reference point for subsequent apoB- and PCSK9-targeted RNA therapeutics. Principal safety signals are transaminase elevations / hepatic steatosis and injection-site reactions.

Mechanism Target:

INHIBITS Elevated Circulating LDL Cholesterol — Mipomersen lowers the same elevated LDL-C endpoint as the other HoFH adjunctive pharmacotherapies, but does so by suppressing the upstream hepatic supply of apoB-containing lipoproteins rather than by enhancing LDLR-mediated clearance.

Show evidence (1 reference)

PMID:20227758 SUPPORT Human Clinical

"The mean percentage change in LDL cholesterol concentration was significantly greater with mipomersen (-24.7%, 95% CI -31.6 to -17.7) than with placebo (-3.3%, -12.1 to 5.5; p=0.0003)."

Pivotal phase 3 randomized placebo-controlled trial in HoFH demonstrated a significant LDL-C reduction with mipomersen vs placebo, supporting the INHIBITS effect on the Elevated Circulating LDL Cholesterol target.

Show evidence (2 references)

PMID:38914784 SUPPORT Human Clinical

"mipomersen (for familial hypercholesterolemia)"

Comprehensive FDA-approved-ASO mechanism review classifies mipomersen among the RNase H-dependent ASOs and lists familial hypercholesterolemia as its approved indication.

PMID:20227758 SUPPORT Human Clinical

"Inhibition of apolipoprotein B synthesis by mipomersen represents a novel, effective therapy to reduce LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia who are already receiving lipid-lowering drugs, including high-dose statins."

Pivotal Phase 3 HoFH trial conclusion confirming mipomersen's apoB- synthesis-inhibition mechanism and its therapeutic role as an adjunct to statin therapy in HoFH.

LDL Apheresis

Action: lipoprotein apheresis Ontology label: Pheresis NCIT:C15191

Extracorporeal removal of LDL particles from the blood, typically performed every 1-2 weeks. Used particularly in homozygous FH and severe heterozygous FH when pharmacotherapy is insufficient. Can acutely lower LDL-C by 50-75% per session, but levels rebound between sessions. Combination with pharmacotherapy can reduce rebound. For HoFH with null mutations, apheresis may be lifesaving when started in childhood.

Mechanism Target:

INHIBITS Elevated Circulating LDL Cholesterol — Lipoprotein apheresis directly removes LDL particles and is foundational LDL-C-lowering therapy in severe HoFH.

Show evidence (1 reference)

DOI:10.1093/eurheartj/ehad197 SUPPORT Human Clinical

"Combination LDL-C-lowering therapy—both pharmacologic intervention and lipoprotein apheresis (LA)—is foundational."

The consensus statement directly describes apheresis as foundational LDL-C-lowering therapy.

Show evidence (1 reference)

DOI:10.1093/eurheartj/ehad197 SUPPORT Human Clinical

"Combination LDL-C-lowering therapy—both pharmacologic intervention and lipoprotein apheresis (LA)—is foundational."

Lipoprotein apheresis is a foundational treatment for HoFH.

Liver Transplantation

Action: liver transplantation MAXO:0001175

Liver transplantation provides a functional LDLR and can normalize LDL-C in severe HoFH. Reserved for patients with receptor-negative HoFH who fail all other therapies. The donor liver provides fully functional LDLR, achieving near-complete correction of LDL-C. However, transplant-related morbidity and need for lifelong immunosuppression limit this to the most severe refractory cases.

Mechanism Target:

MODULATES Reduced Hepatic LDL Clearance — Liver transplantation attempts to alter the hepatic clearance defect in receptor-negative HoFH, but published follow-up shows it is not reliably curative and is reserved as a last resort.

Show evidence (1 reference)

PMID:35471728 PARTIAL Human Clinical

"Liver transplant is sometimes used with curative intent."

The case-series abstract supports liver transplant as an attempted disease-modifying intervention, while the treatment entry notes the incomplete and last-resort nature of the effect.

Show evidence (1 reference)

PMID:35471728 PARTIAL Human Clinical

"Liver transplant did not enable attainment of recommended LDL-C targets in most patients with HoFH, and the majority of patients still required post-transplant LLT. Liver transplant was not curative in most of the patients with HoFH followed. Guidelines suggest that transplant is a treatment of..."

Case series of 9 HoFH patients shows liver transplant is not curative in most cases, with 33% mortality and ongoing LLT needed. Supports use as last resort only.

Dietary Modification

Action: dietary intervention MAXO:0000088

Heart-healthy dietary patterns are foundational but insufficient as sole therapy in FH. Key dietary interventions include: reduction of saturated fat to <7% of total calories, elimination of trans fats, increase in dietary fiber (especially soluble fiber from oats, legumes, psyllium), incorporation of plant stanols/sterols (2g/day can reduce LDL-C by 6-15%), omega-3 fatty acids from fish, and a Mediterranean-style diet rich in fruits, vegetables, whole grains, and olive oil. Dietary modification can provide an additional 10-15% LDL-C reduction on top of pharmacotherapy.

Mechanism Target:

MODULATES Elevated Circulating LDL Cholesterol — Diet is foundational prevention and risk-factor management, but LDL-C reduction is modest because FH is genetically determined.

Show evidence (1 reference)

PMID:24404629 SUPPORT Human Clinical

"Heart-healthy diet (including reduced intake of saturated fat and increased intake of soluble fiber to 10-20 g/day)"

GeneReviews recommends heart-healthy diet as prevention of primary manifestations in FH.

Show evidence (2 references)

PMID:24404629 SUPPORT Human Clinical

"Heart-healthy diet (including reduced intake of saturated fat and increased intake of soluble fiber to 10-20 g/day)"

GeneReviews recommends heart-healthy diet with reduced saturated fat and increased soluble fiber as prevention of primary manifestations.

PMID:37543519 PARTIAL Human Clinical

"we found no evidence of an association between the HLS and concentrations of LDL-cholesterol (β = 0.04, 95% CI = -0.08, 0.15 mmol/L; P = 0.54). However, the HLS was favorably associated with HbA1c levels"

Healthy lifestyle showed no statistically significant association with LDL-C in FH (P=0.54), consistent with the genetic basis of hypercholesterolemia. However, favorable associations with HbA1c and trends for HDL-C suggest dietary modification benefits other CVD risk factors even if LDL-C reduction is modest.

Exercise and Physical Activity

Action: aerobic exercise therapy MAXO:0000065

Regular aerobic exercise (at least 150 minutes/week of moderate-intensity or 75 minutes/week of vigorous-intensity activity) is recommended for all FH patients. Exercise improves HDL-C, insulin sensitivity, endothelial function, and overall cardiovascular fitness. While exercise has modest direct effects on LDL-C, its cardiovascular benefits extend beyond lipid lowering through improved arterial compliance and reduced inflammation.

Mechanism Target:

MODULATES Premature Atherosclerotic Cardiovascular Disease — Exercise is recommended to reduce CAD risk factors downstream of lifelong LDL-C burden, even though direct LDL-C effects are limited.

Show evidence (1 reference)

PMID:24404629 SUPPORT Human Clinical

"reduce CAD risk factors including cessation of smoking, regular physical activity, healthy diet, and weight control"

GeneReviews lists regular physical activity as part of reducing CAD risk factors in FH.

Show evidence (2 references)

PMID:24404629 SUPPORT Human Clinical

"increased physical activity"

GeneReviews lists increased physical activity as prevention of primary manifestations in FH.

PMID:37543519 SUPPORT Human Clinical

"A healthy lifestyle score (HLS), ranging from 0 to 5, was calculated per adherence to 5 lifestyle habits: 1) not smoking; 2) being physically active (≥150 min/week of moderate or vigorous physical activity)"

Physical activity (>=150 min/week) is a component of healthy lifestyle favorably associated with CVD risk factors in FH.

Smoking Cessation

Action: tobacco cessation counseling MAXO:0000081

Smoking cessation is critically important for FH patients given the synergistic cardiovascular risk of smoking and hypercholesterolemia. Tobacco cessation counseling, nicotine replacement therapy, and pharmacotherapy (varenicline, bupropion) should be offered to all FH patients who smoke.

Mechanism Target:

INHIBITS Premature Atherosclerotic Cardiovascular Disease — Smoking cessation reduces an important modifier of FH-associated atherosclerotic event risk.

Show evidence (1 reference)

PMID:17054804 SUPPORT Human Clinical

"The risk of atherosclerotic events due to smoking was estimated as 2.1 (95% confidence interval 1.5; 2.9)."

Smoking approximately doubles atherosclerotic event risk in FH, so cessation targets the cardiovascular event pathway.

Show evidence (2 references)

PMID:17054804 SUPPORT Human Clinical

"it appears to take 6 to 9 years before the excess risk is reduced to zero. The risk of atherosclerotic events due to smoking was estimated as 2.1 (95% confidence interval 1.5; 2.9)."

Smoking doubles atherosclerotic event risk in FH; cessation reduces excess risk over 6-9 years, emphasizing the importance of early cessation.

PMID:24404629 SUPPORT Human Clinical

"no smoking"

GeneReviews lists no smoking as prevention of primary manifestations in FH.

Nutritional Counseling

Action: nutrition counseling MAXO:0000623

Ongoing nutritional counseling by registered dietitians specializing in lipid management is recommended for all FH patients. Counseling covers practical dietary modifications, reading food labels, restaurant choices, recipe modification, and long-term adherence strategies. Especially important for patients on lomitapide who require strict low-fat diets.

Mechanism Target:

MODULATES Elevated Circulating LDL Cholesterol — Nutrition counseling operationalizes the heart-healthy diet used to manage LDL-C and CAD risk factors in FH.

Show evidence (1 reference)

PMID:24404629 SUPPORT Human Clinical

"Heart-healthy diet (including reduced intake of saturated fat and increased intake of soluble fiber to 10-20 g/day)"

The dietary prescription provides the target for counseling by a lipid-focused dietitian.

Show evidence (1 reference)

PMID:24404629 SUPPORT Human Clinical

"Heart-healthy diet (including reduced intake of saturated fat and increased intake of soluble fiber to 10-20 g/day)"

GeneReviews recommends specific dietary targets requiring nutritional counseling to implement effectively.

Genetic Counseling and Cascade Screening

Action: genetic counseling MAXO:0000079

Cascade screening of first-degree relatives is recommended for early identification and treatment of affected family members. Genetic testing can identify the causative mutation and enable predictive testing in family members. The yield of cascade screening is approximately 50% for first-degree relatives of an affected individual (autosomal dominant). Early identification allows treatment initiation before significant atherosclerotic burden develops.

Mechanism Target:

INHIBITS Premature Atherosclerotic Cardiovascular Disease — Genetic counseling and cascade screening enable early diagnosis and treatment before atherosclerotic morbidity accumulates in relatives.

Show evidence (1 reference)

PMID:24404629 SUPPORT Human Clinical

"Early diagnosis and treatment of first-degree and second-degree relatives at risk for FH can reduce morbidity and mortality."

GeneReviews directly supports cascade identification and treatment as reducing downstream morbidity and mortality.

Show evidence (2 references)

PMID:29219151 SUPPORT Human Clinical

"Cascade screening can contribute to early diagnosis of the disease in family members of an affected individual, which is crucial because familial hypercholesterolaemia can be asymptomatic for decades."

Cascade screening of family members is crucial for early diagnosis.

DOI:10.1111/joim.13577 SUPPORT Human Clinical

"Improving prevention, diagnosis, and treatment and making them more accessible to all patients will help reduce the lifelong burden of the disease."

Emphasizes the importance of improving prevention and early diagnosis to reduce the lifelong burden of FH.

🌍

Environmental Factors

High Saturated Fat Diet

Dietary modification is foundational but insufficient as sole therapy.

Dietary intake high in saturated fat and cholesterol exacerbates LDL-C levels in FH patients. While FH is genetically determined, dietary factors significantly modulate the degree of hypercholesterolemia and cardiovascular risk. A heart-healthy diet with reduced saturated fat (<7% of calories), reduced trans fats, and increased plant stanols/sterols can lower LDL-C by 10-15% on top of genetic baseline.

Show evidence (1 reference)

PMID:24404629 SUPPORT Human Clinical

"Agents/circumstances to avoid: Smoking, high intake of saturated and trans unsaturated fat, sedentary lifestyle, obesity, hypertension, and diabetes mellitus."

GeneReviews identifies high saturated and trans fat intake as an agent/circumstance to avoid in FH.

Smoking and Tobacco Use

Concomitant risk factor

Cigarette smoking is a major modifiable cardiovascular risk factor that compounds the already elevated atherosclerotic risk in FH. Smoking promotes endothelial dysfunction, oxidative modification of LDL, and thrombogenesis. The combination of FH and smoking dramatically accelerates cardiovascular events. Smoking cessation is strongly recommended for all FH patients.

Show evidence (2 references)

PMID:15554949 SUPPORT Human Clinical

"smoking (RR 1.67, 95% CI 1.40-1.99)"

Smoking is an independent CVD risk factor in FH with RR 1.67 in a cohort of 2400 FH patients.

PMID:17054804 SUPPORT Human Clinical

"The risk of atherosclerotic events due to smoking was estimated as 2.1 (95% confidence interval 1.5; 2.9)."

Smoking approximately doubles the risk of atherosclerotic events in FH patients.

Physical Inactivity

Concomitant risk factor

Sedentary lifestyle contributes to increased cardiovascular risk in FH patients through multiple mechanisms including reduced HDL-C, increased insulin resistance, and impaired endothelial function. Regular aerobic exercise can modestly improve lipid profiles and cardiovascular fitness even in the setting of genetic hypercholesterolemia.

Show evidence (2 references)

PMID:24404629 SUPPORT Human Clinical

"Agents/circumstances to avoid: Smoking, high intake of saturated and trans unsaturated fat, sedentary lifestyle, obesity, hypertension, and diabetes mellitus."

GeneReviews identifies sedentary lifestyle as an agent/circumstance to avoid in FH.

PMID:37543519 SUPPORT Human Clinical

"being physically active (≥150 min/week of moderate or vigorous physical activity)"

Physical activity is a key component of the healthy lifestyle score favorably associated with CVD risk factors in FH.

Obesity and Metabolic Syndrome

Concomitant risk factor (HP:0001513 Obesity; MONDO:0011565 metabolic syndrome X)

Obesity and its associated metabolic derangements (insulin resistance, hypertriglyceridemia, low HDL-C) compound the cardiovascular risk of FH. Visceral adiposity promotes systemic inflammation and dyslipidemia that worsen the atherosclerotic burden from baseline LDL-C elevation.

Show evidence (1 reference)

PMID:24404629 SUPPORT Human Clinical

"Agents/circumstances to avoid: Smoking, high intake of saturated and trans unsaturated fat, sedentary lifestyle, obesity, hypertension, and diabetes mellitus."

GeneReviews identifies obesity as an agent/circumstance to avoid in FH.

Diabetes Mellitus

Concomitant risk factor (MONDO:0005015 diabetes mellitus; HP:0000819 Diabetes mellitus)

Co-existing diabetes mellitus markedly increases cardiovascular risk in FH patients. Hyperglycemia accelerates glycation of LDL particles, making them more atherogenic, and promotes endothelial dysfunction.

Show evidence (2 references)

PMID:15554949 SUPPORT Human Clinical

"diabetes mellitus (RR 2.19, 95% CI 1.36-3.54)"

Diabetes is an independent CVD risk factor in FH with RR 2.19, the highest relative risk among classical risk factors studied.

PMID:24404629 SUPPORT Human Clinical

"Agents/circumstances to avoid: Smoking, high intake of saturated and trans unsaturated fat, sedentary lifestyle, obesity, hypertension, and diabetes mellitus."

GeneReviews identifies diabetes mellitus as an agent/circumstance to avoid in FH.

Hypertension

Concomitant risk factor

Concomitant hypertension is an independent cardiovascular risk factor that compounds FH-related atherosclerotic risk. Elevated blood pressure promotes endothelial damage and increases LDL entry into the arterial wall.

Show evidence (2 references)

PMID:15554949 SUPPORT Human Clinical

"hypertension (RR 1.36, 95% CI 1.06-1.75)"

Hypertension is an independent CVD risk factor in FH with RR 1.36 in a cohort of 2400 FH patients.

PMID:24404629 SUPPORT Human Clinical

"Agents/circumstances to avoid: Smoking, high intake of saturated and trans unsaturated fat, sedentary lifestyle, obesity, hypertension, and diabetes mellitus."

GeneReviews identifies hypertension as an agent/circumstance to avoid in FH.

Social Determinants of Health

Socioeconomic disparities significantly affect FH outcomes. Limited access to healthcare, genetic testing, specialist lipid clinics, and expensive therapies (PCSK9 inhibitors, evinacumab) creates inequities in diagnosis and treatment. The EAS 2023 consensus specifically addresses inequities in HoFH care worldwide and recommends creation of national screening programmes and education to improve awareness. Low health literacy, food insecurity, and inability to afford medications contribute to suboptimal outcomes.

Show evidence (1 reference)

DOI:10.1093/eurheartj/ehad197 SUPPORT Human Clinical

"To improve HoFH care around the world, the statement recommends the creation of national screening programmes, education to improve awareness, and management guidelines that account for the local realities of care, including access to specialist centres, treatments, and cost."

The EAS 2023 consensus explicitly addresses socioeconomic disparities and access barriers in FH care globally.

Occupational Factors

Sedentary occupations that limit physical activity may compound cardiovascular risk in FH, given that physical activity (>=150 min/week) is a component of healthy lifestyle scores favorably associated with CVD risk factors (PMID:37543519). However, no direct evidence links specific occupational factors to FH outcomes.

Sedentary occupations that limit physical activity and promote prolonged sitting contribute to cardiovascular risk in FH patients. Shift work has been associated with adverse cardiovascular outcomes and may compound FH-related risk. High-stress occupations may increase cardiovascular risk through catecholamine-mediated hemodynamic stress. Occupational exposures to air pollution (traffic, industrial) may also accelerate atherosclerosis.

Alcohol Consumption

Concomitant risk factor

Excessive alcohol intake can worsen lipid profiles (particularly triglycerides) and contribute to cardiovascular risk in FH. However, moderate alcohol intake has not been shown to significantly worsen FH outcomes and may have neutral or slight beneficial effects on HDL-C.

Show evidence (1 reference)

PMID:37543519 SUPPORT Human Clinical

"having a light to moderate alcohol consumption (men: 1-30 g/day; women: 1-15 g/day)"

Light to moderate alcohol consumption is included as a component of the healthy lifestyle score in FH, suggesting excessive consumption is unfavorable.

🔬

Biochemical Markers

LDL Cholesterol (LDL-C) (Elevated)

Context: LDL-C is the primary diagnostic and treatment-response biomarker in FH. GeneReviews lists measurement of LDL-C concentration as a way to clarify diagnosis in at-risk relatives, and therapeutic guidance centers on reducing LDL-C levels.

Pathograph Readouts

Readout Of Elevated Circulating LDL Cholesterol Positive Diagnostic

Elevated measured LDL-C directly reports the central biochemical abnormality caused by reduced hepatic LDL clearance.

Show evidence (1 reference)

PMID:24404629 SUPPORT Human Clinical

"A clinical diagnosis of FH can be established in a proband with characteristic clinical features and significantly elevated LDL-C levels"

GeneReviews identifies significantly elevated LDL-C levels as central to clinical diagnosis.

Readout Of Reduced Hepatic LDL Clearance Positive Diagnostic

High LDL-C is the observable plasma consequence of impaired hepatic LDL uptake by the LDL receptor pathway.

Show evidence (1 reference)

DOI:10.3390/ijms24043224 SUPPORT Human Clinical

"Genetics of Familial Hypercholesterolemia (FH) is ascribable to pathogenic variants in genes encoding proteins leading to an impaired LDL uptake by the LDL receptor (LDLR)."

FH gene defects converge on impaired LDL uptake, making elevated LDL-C a diagnostic readout of reduced clearance.

Show evidence (2 references)

PMID:29219151 SUPPORT Human Clinical

Confirms LDL cholesterol elevation from birth as the defining biochemical abnormality in FH.

PMID:24404629 SUPPORT Human Clinical

"measurement of LDL-C concentration"

GeneReviews identifies LDL-C concentration measurement as a diagnostic approach for at-risk family members.

{ }

Source YAML

click to show

name: Familial Hypercholesterolemia
creation_date: "2026-03-06T00:00:00Z"
updated_date: "2026-05-21T19:15:00Z"
description: >
  Familial hypercholesterolemia (FH) is a common autosomal dominant disorder of
  lipid metabolism characterized by significantly elevated serum low-density
  lipoprotein (LDL) cholesterol levels from birth, leading to premature
  atherosclerotic cardiovascular disease. Most cases are caused by mutations in
  LDLR encoding the LDL receptor, though mutations in APOB, PCSK9, LDLRAP1,
  and rarely APOE also contribute. Heterozygous FH (HeFH) affects approximately
  1 in 250 individuals, making it one of the most common Mendelian disorders.
  Homozygous FH (HoFH) is rare (~1 in 250,000-360,000) but causes severe
  cardiovascular disease in childhood. The severity broadly reflects gene dosage
  and residual LDL receptor pathway activity. Lifelong LDL cholesterol-lowering
  treatment with combination therapy substantially improves cardiovascular
  outcomes and longevity. Recent LDLR-independent therapies such as evinacumab
  (anti-ANGPTL3) have expanded treatment options for HoFH patients with minimal
  residual LDLR function.
category: Mendelian
disease_term:
  preferred_term: Familial Hypercholesterolemia
  term:
    id: MONDO:0005439
    label: familial hypercholesterolemia
parents:
- Dyslipidemia
- Cardiovascular Disease
has_subtypes:
- name: Heterozygous Familial Hypercholesterolemia
  description: >
    Caused by a single pathogenic allele in LDLR, APOB, or PCSK9. LDL-C
    typically 190-400 mg/dL. Untreated males may develop coronary events by
    age 40-50, females by age 50-60. Prevalence approximately 1:250-300.
    Responds well to statin-based combination therapy.
  subtype_frequency: "~99%"
  evidence:
  - reference: PMID:29219151
    reference_title: "Familial hypercholesterolaemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Familial hypercholesterolaemia is a common inherited disorder characterized by abnormally elevated serum levels of low-density lipoprotein (LDL) cholesterol from birth, which in time can lead to cardiovascular disease (CVD)."
    explanation: HeFH is the common form, with elevated LDL-C leading to premature CVD.
- name: Homozygous Familial Hypercholesterolemia
  description: >
    Caused by two pathogenic alleles (true homozygotes or compound heterozygotes).
    LDL-C typically >500 mg/dL (>10 mmol/L). Atherosclerosis often presents during
    childhood or adolescence with aortic valve disease and coronary events.
    Requires aggressive multi-pronged LDL-lowering therapy including apheresis
    and LDLR-independent agents.
  subtype_term:
    preferred_term: homozygous familial hypercholesterolemia
    term:
      id: MONDO:0018328
      label: homozygous familial hypercholesterolemia
  subtype_frequency: "~1:250,000-360,000"
  evidence:
  - reference: DOI:10.1093/eurheartj/ehad197
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This 2023 statement updates clinical guidance for homozygous familial hypercholesterolaemia (HoFH), explains the genetic complexity, and provides pragmatic recommendations to address inequities in HoFH care worldwide."
    explanation: EAS 2023 consensus provides clinical guidance for HoFH including diagnostic criteria and multi-pronged therapy.
inheritance:
- name: Autosomal Dominant
  inheritance_term:
    preferred_term: Autosomal dominant inheritance
    term:
      id: HP:0000006
      label: Autosomal dominant inheritance
  penetrance: COMPLETE
  expressivity: VARIABLE
  description: >
    The majority of FH cases follow autosomal dominant inheritance due to mutations
    in LDLR, APOB, or PCSK9. Clinical severity depends on the causative gene and
    specific mutation, and is further modulated by polygenic background and lifestyle.
  evidence:
  - reference: PMID:29219151
    reference_title: "Familial hypercholesterolaemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Most cases are caused by autosomal dominant mutations in LDLR, which encodes the LDL receptor, although mutations in other genes coding for proteins involved in cholesterol metabolism or LDLR function and processing, such as APOB and PCSK9, can also be causative, although less frequently."
    explanation: Confirms autosomal dominant inheritance as the primary mode.
- name: Autosomal Recessive
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  description: >
    Rare autosomal recessive FH is caused by biallelic loss-of-function mutations
    in LDLRAP1 (encoding the LDL receptor adaptor protein 1/ARH), which is required
    for clathrin-mediated endocytosis of the LDLR-LDL complex.
  evidence:
  - reference: DOI:10.3390/ijms24043224
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Variants in the LDLRAP1 gene causes FH with a recessive inheritance and a specific APOE variant was described as causative of FH, contributing to increase FH genetic heterogeneity."
    explanation: Confirms LDLRAP1 as the cause of autosomal recessive FH.
prevalence:
- population: Global (heterozygous)
  percentage: "0.3-0.4"
  notes: Heterozygous FH affects approximately 1 in 250-300 individuals.
  evidence:
  - reference: DOI:10.3390/ijms24043224
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The HeFH is the most common genetic disease in humans, being the prevalence about 1:300."
    explanation: Confirms HeFH prevalence estimate of approximately 1 in 300.
- population: Global (homozygous)
  percentage: "0.0003-0.0006"
  notes: Homozygous FH affects approximately 1 in 250,000-360,000 individuals. Higher prevalence in founder populations (e.g., Afrikaners, French Canadians, Lebanese, Finns).
progression:
- phase: Onset
  age_range: From birth/conception
  notes: >
    LDL cholesterol is elevated from birth (from conception in HoFH). Clinical
    cardiovascular events typically occur in adulthood for HeFH (males age 40-50,
    females 50-60 if untreated) and in childhood/adolescence for HoFH.
- phase: Subclinical Atherosclerosis
  age_range: Childhood to young adulthood
  notes: >
    Cumulative LDL exposure leads to progressive subendothelial lipid deposition
    and early atherosclerotic changes. Carotid intima-media thickness is
    increased in FH children compared to controls.
- phase: Clinical Cardiovascular Disease
  age_range: Variable (HoFH childhood; HeFH mid-adulthood)
  notes: >
    Progressive atherosclerotic plaque burden leads to premature coronary heart
    disease, aortic valve disease (especially in HoFH), peripheral vascular
    disease, and cerebrovascular disease. CAD risk is 10-20x higher than
    non-FH individuals.
pathophysiology:
- name: LDLR Functional Defect
  description: >
    Pathogenic LDLR variants reduce receptor synthesis, trafficking, ligand
    binding, internalization, or recycling, lowering functional LDL receptor
    abundance on hepatocytes and weakening the core LDL clearance pathway.
  genes:
  - preferred_term: LDLR
    term:
      id: hgnc:6547
      label: LDLR
  cell_types:
  - preferred_term: hepatocyte
    term:
      id: CL:0000182
      label: hepatocyte
  biological_processes:
  - preferred_term: low-density lipoprotein particle clearance
    term:
      id: GO:0034383
      label: low-density lipoprotein particle clearance
  - preferred_term: receptor-mediated endocytosis
    term:
      id: GO:0006898
      label: receptor-mediated endocytosis
  locations:
  - preferred_term: liver
    term:
      id: UBERON:0002107
      label: liver
  downstream:
  - target: Reduced Hepatic LDL Clearance
    description: Loss of functional LDLR directly reduces receptor-mediated uptake of circulating LDL particles.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:1301956
      reference_title: "Molecular genetics of the LDL receptor gene in familial hypercholesterolemia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The low density lipoprotein (LDL) receptor is a cell surface transmembrane protein that mediates the uptake and lysosomal degradation of plasma LDL, thereby providing cholesterol to cells."
      explanation: When LDLR function is impaired, the core hepatic LDL uptake step fails.
  evidence:
  - reference: PMID:1301956
    reference_title: "Molecular genetics of the LDL receptor gene in familial hypercholesterolemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Mutations disrupting the function of this receptor produce autosomal dominant familial hypercholesterolemia (FH)."
    explanation: Establishes LDLR dysfunction as a primary genetic mechanism in FH.
- name: APOB-LDLR Binding Defect
  description: >
    Pathogenic APOB variants leave the receptor pathway present but impair
    binding of apoB-containing LDL particles to LDLR, creating a ligand-side
    failure of hepatic LDL uptake.
  genes:
  - preferred_term: APOB
    term:
      id: hgnc:603
      label: APOB
  cell_types:
  - preferred_term: hepatocyte
    term:
      id: CL:0000182
      label: hepatocyte
  biological_processes:
  - preferred_term: low-density lipoprotein particle clearance
    term:
      id: GO:0034383
      label: low-density lipoprotein particle clearance
  locations:
  - preferred_term: liver
    term:
      id: UBERON:0002107
      label: liver
  downstream:
  - target: Reduced Hepatic LDL Clearance
    description: Defective LDL particle binding prevents normal receptor-mediated clearance despite preserved receptor expression.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:24404629
      reference_title: "Familial Hypercholesterolemia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The molecular diagnosis of FH can be established by identification of heterozygous or biallelic pathogenic variants in APOB (variants that impair binding of LDL-C to the LDL receptor), LDLR, or PCSK9 (gain of function); or rarely, identification of biallelic pathogenic variants in LDLRAP1."
      explanation: GeneReviews explicitly frames APOB-related FH as defective LDLR binding.
  evidence:
  - reference: PMID:24404629
    reference_title: "Familial Hypercholesterolemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The molecular diagnosis of FH can be established by identification of heterozygous or biallelic pathogenic variants in APOB (variants that impair binding of LDL-C to the LDL receptor), LDLR, or PCSK9 (gain of function); or rarely, identification of biallelic pathogenic variants in LDLRAP1."
    explanation: Identifies APOB-mediated defective LDLR binding as a monogenic FH mechanism.
- name: PCSK9 Gain-of-Function
  description: >
    Gain-of-function PCSK9 variants create a dominant mechanism of FH by
    increasing the rate at which LDLR is removed from the hepatocyte surface.
  genes:
  - preferred_term: PCSK9
    term:
      id: hgnc:20001
      label: PCSK9
  cell_types:
  - preferred_term: hepatocyte
    term:
      id: CL:0000182
      label: hepatocyte
  biological_processes:
  - preferred_term: receptor-mediated endocytosis
    term:
      id: GO:0006898
      label: receptor-mediated endocytosis
  locations:
  - preferred_term: liver
    term:
      id: UBERON:0002107
      label: liver
  downstream:
  - target: PCSK9-Mediated LDLR Degradation
    description: PCSK9 gain-of-function turns the inherited defect into accelerated post-endocytic LDLR degradation.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:24404629
      reference_title: "Familial Hypercholesterolemia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The molecular diagnosis of FH can be established by identification of heterozygous or biallelic pathogenic variants in APOB (variants that impair binding of LDL-C to the LDL receptor), LDLR, or PCSK9 (gain of function); or rarely, identification of biallelic pathogenic variants in LDLRAP1."
      explanation: GeneReviews identifies PCSK9 gain-of-function as a root genetic cause of FH.
  evidence:
  - reference: PMID:24404629
    reference_title: "Familial Hypercholesterolemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The molecular diagnosis of FH can be established by identification of heterozygous or biallelic pathogenic variants in APOB (variants that impair binding of LDL-C to the LDL receptor), LDLR, or PCSK9 (gain of function); or rarely, identification of biallelic pathogenic variants in LDLRAP1."
    explanation: Establishes PCSK9 gain-of-function as one of the monogenic starting points of FH.
- name: LDLRAP1-Related LDL Uptake Defect
  description: >
    Biallelic LDLRAP1 variants define a rarer recessive route into the same LDLR
    pathway failure, showing that FH can also start at a genetically disrupted
    LDL uptake step without a primary LDLR coding defect.
  genes:
  - preferred_term: LDLRAP1
    term:
      id: hgnc:18640
      label: LDLRAP1
  cell_types:
  - preferred_term: hepatocyte
    term:
      id: CL:0000182
      label: hepatocyte
  biological_processes:
  - preferred_term: low-density lipoprotein particle clearance
    term:
      id: GO:0034383
      label: low-density lipoprotein particle clearance
  locations:
  - preferred_term: liver
    term:
      id: UBERON:0002107
      label: liver
  downstream:
  - target: Reduced Hepatic LDL Clearance
    description: LDLRAP1-related FH converges on the same proximal defect of impaired LDL uptake.
    causal_link_type: DIRECT
    evidence:
    - reference: DOI:10.3390/ijms24043224
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Genetics of Familial Hypercholesterolemia (FH) is ascribable to pathogenic variants in genes encoding proteins leading to an impaired LDL uptake by the LDL receptor (LDLR)."
      explanation: The review frames the shared proximal defect across FH genes as impaired LDL uptake.
  evidence:
  - reference: DOI:10.3390/ijms24043224
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Variants in the LDLRAP1 gene causes FH with a recessive inheritance and a specific APOE variant was described as causative of FH, contributing to increase FH genetic heterogeneity."
    explanation: Establishes LDLRAP1-related FH as a distinct genetic entry point into the LDLR pathway.
- name: APOE-Related Lipoprotein Clearance Defect
  description: >
    Rare APOE variants can create an FH-like phenotype by disrupting clearance
    of apoE-containing lipoproteins, providing an uncommon genetic route into
    the same impaired lipoprotein-clearance axis.
  genes:
  - preferred_term: APOE
    term:
      id: hgnc:613
      label: APOE
  cell_types:
  - preferred_term: hepatocyte
    term:
      id: CL:0000182
      label: hepatocyte
  biological_processes:
  - preferred_term: cholesterol metabolic process
    term:
      id: GO:0008203
      label: cholesterol metabolic process
    modifier: ABNORMAL
  - preferred_term: low-density lipoprotein particle clearance
    term:
      id: GO:0034383
      label: low-density lipoprotein particle clearance
    modifier: DECREASED
  locations:
  - preferred_term: liver
    term:
      id: UBERON:0002107
      label: liver
  downstream:
  - target: Reduced Hepatic LDL Clearance
    description: >
      APOE-related FH phenocopies converge on impaired receptor-mediated
      clearance of atherogenic lipoproteins.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - impaired apoE-containing lipoprotein clearance
    evidence:
    - reference: DOI:10.3390/ijms24043224
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "a specific APOE variant was described as causative of FH, contributing to increase FH genetic heterogeneity."
      explanation: >
        The review identifies rare APOE variation as a causative FH mechanism;
        the node links that rare mechanism into the shared LDL-clearance axis.
  evidence:
  - reference: DOI:10.3390/ijms24043224
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "a specific APOE variant was described as causative of FH, contributing to increase FH genetic heterogeneity."
    explanation: >
      Establishes APOE-related FH as a rare genetic contributor to FH
      heterogeneity.
- name: PCSK9-Mediated LDLR Degradation
  description: >
    Excess PCSK9 activity accelerates degradation of mature LDL receptors after
    endocytosis, leaving fewer receptors available on hepatocytes to clear LDL
    from the circulation.
  cell_types:
  - preferred_term: hepatocyte
    term:
      id: CL:0000182
      label: hepatocyte
  biological_processes:
  - preferred_term: receptor-mediated endocytosis
    term:
      id: GO:0006898
      label: receptor-mediated endocytosis
  locations:
  - preferred_term: liver
    term:
      id: UBERON:0002107
      label: liver
  downstream:
  - target: Reduced Hepatic LDL Clearance
    description: Accelerated destruction of mature LDLR leaves too few surface receptors for normal LDL clearance.
    causal_link_type: DIRECT
    evidence:
    - reference: DOI:10.1073/pnas.0409736102
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "Overexpression of PCSK9 in HepG2 cells caused a decrease in whole-cell and cell-surface LDLR levels."
      explanation: Reduced hepatocyte surface LDLR directly predicts impaired hepatic LDL clearance.
  evidence:
  - reference: DOI:10.1073/pnas.0409736102
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "PCSK9 overexpression had no effect on LDLR synthesis but caused a dramatic increase in the degradation of the mature LDLR"
    explanation: Directly demonstrates the degradative mechanism by which PCSK9 reduces LDLR availability.
- name: Reduced Hepatic LDL Clearance
  description: >
    Despite different causal genes, monogenic FH converges on impaired hepatic
    uptake and lysosomal processing of LDL particles, so plasma LDL remains
    elevated from birth.
  cell_types:
  - preferred_term: hepatocyte
    term:
      id: CL:0000182
      label: hepatocyte
  biological_processes:
  - preferred_term: low-density lipoprotein particle clearance
    term:
      id: GO:0034383
      label: low-density lipoprotein particle clearance
  - preferred_term: receptor-mediated endocytosis
    term:
      id: GO:0006898
      label: receptor-mediated endocytosis
  locations:
  - preferred_term: liver
    term:
      id: UBERON:0002107
      label: liver
  downstream:
  - target: Elevated Circulating LDL Cholesterol
    description: When hepatocytes cannot clear LDL efficiently, circulating LDL-C accumulates lifelong.
    causal_link_type: DIRECT
    evidence:
    - reference: DOI:10.3390/ijms24043224
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Genetics of Familial Hypercholesterolemia (FH) is ascribable to pathogenic variants in genes encoding proteins leading to an impaired LDL uptake by the LDL receptor (LDLR)."
      explanation: The shared proximal effect of the causal genes is impaired LDL uptake.
  evidence:
  - reference: PMID:1301956
    reference_title: "Molecular genetics of the LDL receptor gene in familial hypercholesterolemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The low density lipoprotein (LDL) receptor is a cell surface transmembrane protein that mediates the uptake and lysosomal degradation of plasma LDL, thereby providing cholesterol to cells."
    explanation: Defines the normal clearance step that is disrupted across monogenic FH mechanisms.
- name: Elevated Circulating LDL Cholesterol
  description: >
    Lifelong LDL-C excess is the central biochemical phenotype of FH and the
    immediate driver of arterial and extra-arterial cholesterol deposition.
  biological_processes:
  - preferred_term: cholesterol homeostasis
    term:
      id: GO:0042632
      label: cholesterol homeostasis
  chemical_entities:
  - preferred_term: low-density lipoprotein cholesterol
    term:
      id: CHEBI:47774
      label: low-density lipoprotein cholesterol
    modifier: INCREASED
  downstream:
  - target: Hypercholesterolemia
    description: >
      Lifelong elevation of circulating LDL-C manifests clinically as
      hypercholesterolemia.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:29219151
      reference_title: "Familial hypercholesterolaemia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Familial hypercholesterolaemia is a common inherited disorder characterized by abnormally elevated serum levels of low-density lipoprotein (LDL) cholesterol from birth, which in time can lead to cardiovascular disease (CVD)."
      explanation: >
        The defining biochemical abnormality of FH is elevated LDL cholesterol
        from birth, which maps directly to the hypercholesterolemia phenotype.
  - target: Increased LDL Cholesterol Concentration
    description: >
      The same LDL-C excess is captured by the more specific HPO phenotype for
      increased LDL cholesterol concentration.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:1301956
      reference_title: "Molecular genetics of the LDL receptor gene in familial hypercholesterolemia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Affected individuals have elevated plasma levels of LDL, which causes premature coronary atherosclerosis."
      explanation: >
        Elevated plasma LDL is the specific biochemical phenotype represented
        by increased LDL cholesterol concentration.
  - target: LDL Cholesterol (LDL-C)
    description: >
      Measured LDL-C is the biochemical biomarker corresponding to the elevated
      circulating LDL cholesterol mechanism.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:24404629
      reference_title: "Familial Hypercholesterolemia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "A clinical diagnosis of FH can be established in a proband with characteristic clinical features and significantly elevated LDL-C levels"
      explanation: >
        GeneReviews identifies significantly elevated LDL-C levels as the
        diagnostic biochemical readout of the elevated LDL-C mechanism.
  - target: Oxidized LDL Infiltration of Arterial Intima
    description: Persistently elevated LDL loads the arterial wall and initiates intimal lipid retention.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - subendothelial LDL retention and oxidative modification
    evidence:
    - reference: PMID:24404629
      reference_title: "Familial Hypercholesterolemia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Familial hypercholesterolemia (FH) is characterized by significantly elevated low-density lipoprotein cholesterol (LDL-C) that leads to atherosclerotic plaque deposition in the coronary arteries and proximal aorta at an early age and increases the risk of premature cardiovascular events such as angina and myocardial infarction"
      explanation: Connects LDL-C excess to early arterial plaque deposition.
  - target: Extra-arterial Cholesterol Deposition
    description: The same chronic LDL excess also drives lipid deposition in tendon, skin, cornea, and valve tissue.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - chronic tissue retention of cholesterol-rich lipoproteins
    evidence:
    - reference: DOI:10.3390/ijms25031637
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "A chronically elevated concentration of LDL-C in the plasma leads to the occurrence of certain abnormalities, such as xanthomas in the tendons and skin, as well as corneal arcus."
      explanation: Chronic LDL excess is the proximal cause of extra-arterial cholesterol deposition phenotypes.
  evidence:
  - reference: PMID:29219151
    reference_title: "Familial hypercholesterolaemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Familial hypercholesterolaemia is a common inherited disorder characterized by abnormally elevated serum levels of low-density lipoprotein (LDL) cholesterol from birth, which in time can lead to cardiovascular disease (CVD)."
    explanation: Establishes lifelong LDL-C elevation as the core biochemical phenotype of FH.
- name: Oxidized LDL Infiltration of Arterial Intima
  description: >
    Oxidized LDL infiltrates and accumulates in the arterial intima, establishing the
    initiating lipid milieu for FH-associated atherogenesis.
  cell_types:
  - preferred_term: endothelial cell
    term:
      id: CL:0000115
      label: endothelial cell
  biological_processes:
  - preferred_term: inflammatory response
    term:
      id: GO:0006954
      label: inflammatory response
  locations:
  - preferred_term: tunica intima
    term:
      id: UBERON:0002523
      label: tunica intima
  downstream:
  - target: Macrophage Recruitment to Arterial Intima
    description: Intimal oxidized LDL promotes leukocyte attraction and macrophage influx.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - endothelial activation and chemokine-mediated monocyte recruitment
    evidence:
    - reference: PMID:30165986
      reference_title: "Impact of Lipids on Cardiovascular Health: JACC Health Promotion Series."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Because atherogenic lipoproteins play a central causal role in the initiation and progression of atherosclerosis, maintaining optimal lipid levels is necessary to achieve ideal cardiovascular health.
      explanation: Supports atherogenic lipoprotein-driven initiation of arterial inflammatory cascades.
  evidence:
  - reference: PMID:30165986
    reference_title: "Impact of Lipids on Cardiovascular Health: JACC Health Promotion Series."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Because atherogenic lipoproteins play a central causal role in the initiation and progression of atherosclerosis, maintaining optimal lipid levels is necessary to achieve ideal cardiovascular health.
    explanation: Supports LDL-driven lipoprotein burden as an initiating event in arterial atherogenesis.
- name: Macrophage Recruitment to Arterial Intima
  description: >
    Inflammatory signaling within the lipid-rich intima recruits macrophages to
    early arterial lesions.
  cell_types:
  - preferred_term: macrophage
    term:
      id: CL:0000235
      label: macrophage
  - preferred_term: endothelial cell
    term:
      id: CL:0000115
      label: endothelial cell
  biological_processes:
  - preferred_term: inflammatory response
    term:
      id: GO:0006954
      label: inflammatory response
  locations:
  - preferred_term: tunica intima
    term:
      id: UBERON:0002523
      label: tunica intima
  downstream:
  - target: Macrophage-Derived Foam Cell Formation
    description: Recruited macrophages internalize oxidized lipoproteins and transition toward foam cells.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - scavenger receptor-mediated oxidized LDL uptake
    evidence:
    - reference: DOI:10.1038/s41467-024-46336-2
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: Adenylyl cyclase-associated protein 1 (CAP1) is the main binding partner of PCSK9 and indispensable for the inflammatory action of PCSK9, including induction of cytokines, Toll like receptor 4, and scavenger receptors, enhancing the uptake of oxidized LDL.
      explanation: Supports inflammatory signaling and enhanced oxidized-LDL uptake driving macrophage transition.
  evidence:
  - reference: DOI:10.3390/nu16132156
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Disruption in any of these steps results in pathophysiological abnormalities such as dyslipidemia, obesity, insulin resistance, inflammation, atherosclerosis, peripheral artery disease, and cardiovascular diseases.
    explanation: Supports inflammation-coupled transition from lipid imbalance to arterial immune-cell pathology.
- name: Macrophage-Derived Foam Cell Formation
  description: >
    Macrophages in lipid-rich intima accumulate oxidized lipoproteins and differentiate
    into foam cells.
  cell_types:
  - preferred_term: macrophage-derived foam cell
    term:
      id: CL:0000517
      label: macrophage derived foam cell
  - preferred_term: macrophage
    term:
      id: CL:0000235
      label: macrophage
  biological_processes:
  - preferred_term: macrophage-derived foam cell differentiation
    term:
      id: GO:0010742
      label: macrophage derived foam cell differentiation
  locations:
  - preferred_term: tunica intima
    term:
      id: UBERON:0002523
      label: tunica intima
  downstream:
  - target: Atherosclerotic Plaque Development
    description: Foam-cell accumulation drives fatty-streak maturation and plaque development.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - fatty-streak maturation with lipid-rich inflammatory lesion growth
    evidence:
    - reference: PMID:28444290
      reference_title: "Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Consistent evidence from numerous and multiple different types of clinical and genetic studies unequivocally establishes that LDL causes ASCVD.
      explanation: Supports LDL-driven downstream progression to clinical atherosclerotic disease.
  evidence:
  - reference: DOI:10.1038/s41467-024-46336-2
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Adenylyl cyclase-associated protein 1 (CAP1) is the main binding partner of PCSK9 and indispensable for the inflammatory action of PCSK9, including induction of cytokines, Toll like receptor 4, and scavenger receptors, enhancing the uptake of oxidized LDL.
    explanation: Supports enhanced oxidized-LDL uptake as a proximate mechanism for foam cell formation.
- name: Atherosclerotic Plaque Development
  description: >
    Chronic intimal lipid retention and inflammation result in atherosclerotic plaque
    formation as a major arterial consequence of lifelong LDL excess in FH.
  cell_types:
  - preferred_term: endothelial cell
    term:
      id: CL:0000115
      label: endothelial cell
  - preferred_term: vascular smooth muscle cell
    term:
      id: CL:0000359
      label: vascular associated smooth muscle cell
  biological_processes:
  - preferred_term: inflammatory response
    term:
      id: GO:0006954
      label: inflammatory response
  locations:
  - preferred_term: tunica intima
    term:
      id: UBERON:0002523
      label: tunica intima
  downstream:
  - target: Premature Atherosclerotic Cardiovascular Disease
    description: Ongoing plaque growth produces early coronary, cerebrovascular, and peripheral vascular disease.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - progressive arterial narrowing, plaque instability, and ischemic events
    evidence:
    - reference: DOI:10.3390/ijms25031637
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Nevertheless, a significantly more severe phenomenon is leading to the premature onset of cardiovascular disease (CVD) and its clinical implications, such as cardiac events, stroke or vascular dementia, even at a relatively young age."
      explanation: Summarizes the clinical cardiovascular outcome of chronic LDL-driven arterial disease in FH.
  - target: Atherosclerosis
    description: >
      Chronic intimal lipid retention and inflammation are the structural basis
      for generalized atherosclerosis in FH.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:28444290
      reference_title: "Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Consistent evidence from numerous and multiple different types of clinical and genetic studies unequivocally establishes that LDL causes ASCVD.
      explanation: >
        The EAS consensus supports LDL-driven atherosclerotic disease as the
        phenotype-level consequence of plaque development.
  - target: Coronary Artery Atherosclerosis
    description: >
      FH plaque deposition prominently affects the coronary arteries.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:24404629
      reference_title: "Familial Hypercholesterolemia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Familial hypercholesterolemia (FH) is characterized by significantly elevated low-density lipoprotein cholesterol (LDL-C) that leads to atherosclerotic plaque deposition in the coronary arteries and proximal aorta at an early age and increases the risk of premature cardiovascular events such as angina and myocardial infarction"
      explanation: >
        GeneReviews directly links elevated LDL-C to coronary plaque deposition
        in FH.
  - target: Peripheral Arterial Stenosis
    description: >
      Systemic atherosclerotic plaque burden can narrow peripheral arteries.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - generalized atherosclerosis
    evidence:
    - reference: DOI:10.3390/nu16132156
      supports: PARTIAL
      evidence_source: HUMAN_CLINICAL
      snippet: Disruption in any of these steps results in pathophysiological abnormalities such as dyslipidemia, obesity, insulin resistance, inflammation, atherosclerosis, peripheral artery disease, and cardiovascular diseases.
      explanation: >
        This supports peripheral artery disease as part of the broader
        dyslipidemia-atherosclerosis disease spectrum, though not specifically
        quantified for FH in the abstract.
  evidence:
  - reference: DOI:10.3390/nu16132156
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Disruption in any of these steps results in pathophysiological abnormalities such as dyslipidemia, obesity, insulin resistance, inflammation, atherosclerosis, peripheral artery disease, and cardiovascular diseases.
    explanation: Confirms the pathological link between lipoprotein dysregulation and atherosclerosis.
  - reference: PMID:28444290
    reference_title: "Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Consistent evidence from numerous and multiple different types of clinical and genetic studies unequivocally establishes that LDL causes ASCVD.
    explanation: The EAS consensus statement establishes LDL as a causal driver of atherosclerotic cardiovascular disease.
- name: Premature Atherosclerotic Cardiovascular Disease
  description: >
    The arterial branch culminates in premature coronary artery disease, angina,
    myocardial infarction, stroke, and peripheral arterial disease, with earlier
    and more severe presentations in biallelic disease.
  evidence:
  - reference: DOI:10.3390/ijms25031637
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Nevertheless, a significantly more severe phenomenon is leading to the premature onset of cardiovascular disease (CVD) and its clinical implications, such as cardiac events, stroke or vascular dementia, even at a relatively young age."
    explanation: This node captures the major clinical cardiovascular consequences of lifelong LDL-driven atherosclerosis.
  - reference: PMID:24404629
    reference_title: "Familial Hypercholesterolemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Individuals with a more severe phenotype, often as a result of biallelic variants, can present with very significant elevations in LDL-C (>500 mg/dL), early-onset coronary artery disease (CAD; presenting as early as childhood in some), and calcific aortic valve disease."
    explanation: GeneReviews shows how more severe genetic forms of FH accelerate clinical cardiovascular disease.
  downstream:
  - target: Premature Coronary Artery Disease
    description: >
      Premature CAD is the dominant clinical expression of FH-associated
      atherosclerotic cardiovascular disease.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:29219151
      reference_title: "Familial hypercholesterolaemia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "common diagnostic features are an elevated LDL cholesterol level and a family history of hypercholesterolaemia or (premature) CVD."
      explanation: >
        Premature cardiovascular disease is a core diagnostic feature of FH;
        the phenotype specifies the coronary presentation of that burden.
  - target: Angina Pectoris
    description: >
      Coronary atherosclerotic disease can manifest as angina.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:24404629
      reference_title: "Familial Hypercholesterolemia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "increases the risk of premature cardiovascular events such as angina and myocardial infarction"
      explanation: >
        GeneReviews lists angina as an FH-associated premature cardiovascular
        event.
  - target: Myocardial Infarction
    description: >
      Advanced coronary plaque disease increases risk for premature myocardial
      infarction.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:24404629
      reference_title: "Familial Hypercholesterolemia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "increases the risk of premature cardiovascular events such as angina and myocardial infarction"
      explanation: >
        GeneReviews lists myocardial infarction as a major FH-associated
        premature cardiovascular event.
  - target: Ischemic Stroke
    description: >
      Cerebrovascular involvement is a less common consequence of the same
      atherosclerotic burden.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - cerebrovascular atherosclerosis
    evidence:
    - reference: PMID:24404629
      reference_title: "Familial Hypercholesterolemia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "stroke occurs more rarely"
      explanation: >
        GeneReviews identifies stroke as a rarer cardiovascular manifestation
        of FH.
- name: Extra-arterial Cholesterol Deposition
  description: >
    Chronic LDL excess also drives cholesterol deposition outside the arterial
    wall, creating the visible stigmata of FH and contributing to valvular
    disease.
  downstream:
  - target: Tendon and Cutaneous Cholesterol Deposition
    description: Cholesterol deposition in tendons and skin explains tendon xanthomas, cutaneous xanthomas, and periorbital xanthelasma.
    causal_link_type: DIRECT
    evidence:
    - reference: DOI:10.3390/ijms25031637
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "A chronically elevated concentration of LDL-C in the plasma leads to the occurrence of certain abnormalities, such as xanthomas in the tendons and skin, as well as corneal arcus."
      explanation: Provides a direct bridge from LDL excess to tendon and cutaneous xanthomatous phenotypes.
  - target: Corneal Cholesterol Deposition
    description: Corneal peripheral deposition explains premature corneal arcus.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:24404629
      reference_title: "Familial Hypercholesterolemia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Individuals with FH may develop corneal arcus (white, gray, or blue opaque ring in the corneal margin as a result of cholesterol deposition) at a younger age than those without FH."
      explanation: Directly explains corneal arcus as corneal cholesterol deposition.
  - target: Aortic Valve Lipid Deposition and Calcification
    description: In severe FH, valvular and aortic root deposition produces calcific aortic valve disease.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - valvular lipid retention followed by fibrocalcific remodeling
    evidence:
    - reference: PMID:24404629
      reference_title: "Familial Hypercholesterolemia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Individuals with a more severe phenotype, often as a result of biallelic variants, can present with very significant elevations in LDL-C (>500 mg/dL), early-onset coronary artery disease (CAD; presenting as early as childhood in some), and calcific aortic valve disease."
      explanation: Connects severe LDL burden in biallelic FH to calcific aortic valve disease.
  evidence:
  - reference: PMID:24404629
    reference_title: "Familial Hypercholesterolemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Xanthomas (cholesterol deposits in tendons) may be visible in the Achilles tendons or tendons of the hands and worsen with age as a result of extremely high cholesterol levels. Xanthelasmas (yellowish, waxy deposits) can occur around the eyelids."
    explanation: Documents the clinically visible extra-arterial cholesterol deposition phenotype in FH.
- name: Tendon and Cutaneous Cholesterol Deposition
  description: >
    Cholesterol-rich deposits accumulate in the Achilles and hand tendons and in
    the skin and eyelids, producing tendon xanthomas, cutaneous xanthomas, and
    xanthelasma.
  evidence:
  - reference: PMID:24404629
    reference_title: "Familial Hypercholesterolemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Xanthomas (cholesterol deposits in tendons) may be visible in the Achilles tendons or tendons of the hands and worsen with age as a result of extremely high cholesterol levels. Xanthelasmas (yellowish, waxy deposits) can occur around the eyelids."
    explanation: Explains the tendon and eyelid deposition phenotypes that make FH clinically recognizable.
  - reference: DOI:10.3390/ijms25031637
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A chronically elevated concentration of LDL-C in the plasma leads to the occurrence of certain abnormalities, such as xanthomas in the tendons and skin, as well as corneal arcus."
    explanation: Extends the same deposition logic to skin xanthomas in FH.
  downstream:
  - target: Tendon Xanthomas
    description: >
      Tendon cholesterol deposition produces clinically visible tendon
      xanthomas.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:24404629
      reference_title: "Familial Hypercholesterolemia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Xanthomas (cholesterol deposits in tendons) may be visible in the Achilles tendons or tendons of the hands and worsen with age as a result of extremely high cholesterol levels."
      explanation: >
        GeneReviews directly defines tendon xanthomas as cholesterol deposits
        in tendons in FH.
  - target: Cutaneous Xanthomas
    description: >
      Severe chronic LDL-C excess can also produce cholesterol-rich deposits in
      the skin.
    causal_link_type: DIRECT
    evidence:
    - reference: DOI:10.3390/ijms25031637
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "A chronically elevated concentration of LDL-C in the plasma leads to the occurrence of certain abnormalities, such as xanthomas in the tendons and skin, as well as corneal arcus."
      explanation: >
        The review links chronic LDL-C elevation to skin xanthomas.
  - target: Xanthelasma
    description: >
      Cholesterol deposition around the eyelids produces xanthelasma.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:24404629
      reference_title: "Familial Hypercholesterolemia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Xanthelasmas (yellowish, waxy deposits) can occur around the eyelids."
      explanation: >
        GeneReviews lists xanthelasma as periocular cholesterol deposition in
        FH.
- name: Corneal Cholesterol Deposition
  description: >
    Lipid deposition at the peripheral cornea produces premature corneal arcus,
    especially when LDL exposure begins early in life.
  evidence:
  - reference: PMID:24404629
    reference_title: "Familial Hypercholesterolemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Individuals with FH may develop corneal arcus (white, gray, or blue opaque ring in the corneal margin as a result of cholesterol deposition) at a younger age than those without FH."
    explanation: Directly maps the pathologic process to the corneal arcus phenotype.
  downstream:
  - target: Corneal Arcus
    description: >
      Peripheral corneal cholesterol deposition is the anatomical basis of
      premature corneal arcus in FH.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:24404629
      reference_title: "Familial Hypercholesterolemia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Individuals with FH may develop corneal arcus (white, gray, or blue opaque ring in the corneal margin as a result of cholesterol deposition) at a younger age than those without FH."
      explanation: >
        GeneReviews explicitly explains corneal arcus as cholesterol deposition
        in the corneal margin.
- name: Aortic Valve Lipid Deposition and Calcification
  description: >
    In severe, especially biallelic FH, chronic lipid deposition in the aortic
    root and valve contributes to early calcific aortic valve disease.
  evidence:
  - reference: PMID:24404629
    reference_title: "Familial Hypercholesterolemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Individuals with a more severe phenotype, often as a result of biallelic variants, can present with very significant elevations in LDL-C (>500 mg/dL), early-onset coronary artery disease (CAD; presenting as early as childhood in some), and calcific aortic valve disease."
    explanation: Supports a distinct valvular deposition branch in severe FH.
  downstream:
  - target: Aortic Valve Stenosis
    description: >
      Severe FH can produce calcific aortic valve disease, clinically captured
      as aortic valve stenosis.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:24404629
      reference_title: "Familial Hypercholesterolemia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Individuals with a more severe phenotype, often as a result of biallelic variants, can present with very significant elevations in LDL-C (>500 mg/dL), early-onset coronary artery disease (CAD; presenting as early as childhood in some), and calcific aortic valve disease."
      explanation: >
        GeneReviews directly supports calcific aortic valve disease as a severe
        FH manifestation.
phenotypes:
- category: Metabolic
  name: Hypercholesterolemia
  frequency: OBLIGATE
  diagnostic: true
  description: >
    Markedly elevated LDL cholesterol levels from birth. Heterozygous FH typically
    shows LDL-C of 190-400 mg/dL (4.9-10.3 mmol/L); homozygous FH shows LDL-C
    >500 mg/dL (>13 mmol/L). LDL-C >10 mmol/L (>400 mg/dL) is suggestive of HoFH.
  phenotype_term:
    preferred_term: Hypercholesterolemia
    term:
      id: HP:0003124
      label: Hypercholesterolemia
  phenotype_contexts:
  - genetic_context:
      zygosity: HETEROZYGOUS
      description: Heterozygous FH
    notes: LDL-C typically 190-400 mg/dL
    evidence:
    - reference: PMID:29219151
      reference_title: "Familial hypercholesterolaemia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Familial hypercholesterolaemia is a common inherited disorder characterized by abnormally elevated serum levels of low-density lipoprotein (LDL) cholesterol from birth, which in time can lead to cardiovascular disease (CVD)."
      explanation: Elevated LDL cholesterol from birth is the defining feature.
  - genetic_context:
      zygosity: HOMOZYGOUS
      description: Homozygous FH
    severity: Severe
    notes: LDL-C typically >500 mg/dL (>13 mmol/L)
    evidence:
    - reference: DOI:10.1111/cts.13836
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Homozygous familial hypercholesterolemia (HoFH) is a rare and serious genetic condition characterized by premature cardiovascular disease due to severely elevated low‐density lipoprotein cholesterol (LDL‐C)."
      explanation: Confirms severely elevated LDL-C as the hallmark of HoFH.
  evidence:
  - reference: PMID:29219151
    reference_title: "Familial hypercholesterolaemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Familial hypercholesterolaemia is a common inherited disorder characterized by abnormally elevated serum levels of low-density lipoprotein (LDL) cholesterol from birth, which in time can lead to cardiovascular disease (CVD)."
    explanation: Elevated LDL cholesterol from birth is the defining feature of FH.
- category: Metabolic
  name: Increased LDL Cholesterol Concentration
  frequency: OBLIGATE
  diagnostic: true
  description: >
    Isolated elevation of circulating low-density lipoprotein particles is the
    core biochemical abnormality in familial hypercholesterolemia and is present
    from birth.
  phenotype_term:
    preferred_term: Increased LDL cholesterol concentration
    term:
      id: HP:0003141
      label: Increased LDL cholesterol concentration
  evidence:
  - reference: PMID:1301956
    reference_title: "Molecular genetics of the LDL receptor gene in familial hypercholesterolemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Affected individuals have elevated plasma levels of LDL, which causes premature coronary atherosclerosis."
    explanation: OMIM/HPOA-linked review directly identifies elevated plasma LDL as the defining biochemical abnormality in FH.
  - reference: PMID:10205269
    reference_title: "A third major locus for autosomal dominant hypercholesterolemia maps to 1p34.1-p32."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Autosomal dominant hypercholesterolemia (ADH), one of the most frequent hereditary disorders, is characterized by an isolated elevation of LDL particles that leads to premature mortality from cardiovascular complications."
    explanation: HPOA-linked FH3 study confirms that isolated LDL particle elevation is the characteristic biochemical phenotype.
- category: Cardiovascular
  name: Premature Coronary Artery Disease
  frequency: VERY_FREQUENT
  description: >
    Premature atherosclerotic coronary artery disease is the major cause of
    morbidity and mortality in FH. CAD risk is 10-20 times higher than non-FH
    individuals. Untreated heterozygous males may develop coronary events by
    age 40-50; homozygous patients may develop them in childhood.
  phenotype_term:
    preferred_term: Premature coronary artery atherosclerosis
    term:
      id: HP:0005181
      label: Premature coronary artery atherosclerosis
  evidence:
  - reference: PMID:29219151
    reference_title: "Familial hypercholesterolaemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "common diagnostic features are an elevated LDL cholesterol level and a family history of hypercholesterolaemia or (premature) CVD."
    explanation: Premature cardiovascular disease is a key diagnostic feature of FH.
- category: Cardiovascular
  name: Coronary Artery Atherosclerosis
  frequency: VERY_FREQUENT
  description: >
    Progressive atherosclerotic narrowing of coronary arteries from cumulative
    LDL exposure. The extent and severity correlate with lifetime LDL-C
    exposure (LDL-C x years).
  phenotype_term:
    preferred_term: Coronary artery atherosclerosis
    term:
      id: HP:0001677
      label: Coronary artery atherosclerosis
  evidence:
  - reference: PMID:24404629
    reference_title: "Familial Hypercholesterolemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Familial hypercholesterolemia (FH) is characterized by significantly elevated low-density lipoprotein cholesterol (LDL-C) that leads to atherosclerotic plaque deposition in the coronary arteries and proximal aorta at an early age and increases the risk of premature cardiovascular events such as angina and myocardial infarction"
    explanation: Confirms atherosclerotic plaque deposition in coronary arteries as a hallmark of FH.
- category: Cardiovascular
  name: Angina Pectoris
  frequency: FREQUENT
  description: >
    Exertional chest pain from myocardial ischemia due to coronary
    atherosclerosis. Often the presenting symptom of FH-related coronary
    artery disease.
  phenotype_term:
    preferred_term: Angina pectoris
    term:
      id: HP:0001681
      label: Angina pectoris
  evidence:
  - reference: PMID:24404629
    reference_title: "Familial Hypercholesterolemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "increases the risk of premature cardiovascular events such as angina and myocardial infarction"
    explanation: Angina is listed as a premature cardiovascular event in FH.
- category: Cardiovascular
  name: Myocardial Infarction
  frequency: FREQUENT
  description: >
    Acute myocardial infarction from coronary plaque rupture and thrombosis.
    Occurs prematurely in FH, often as the first cardiovascular event.
  phenotype_term:
    preferred_term: Myocardial infarction
    term:
      id: HP:0001658
      label: Myocardial infarction
  evidence:
  - reference: PMID:24404629
    reference_title: "Familial Hypercholesterolemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "increases the risk of premature cardiovascular events such as angina and myocardial infarction"
    explanation: Myocardial infarction is listed as a key cardiovascular event in FH.
- category: Cardiovascular
  name: Aortic Valve Stenosis
  frequency: OCCASIONAL
  subtype: Homozygous Familial Hypercholesterolemia
  description: >
    Calcific aortic valve stenosis from cholesterol deposition, particularly
    prominent in homozygous FH. Supravalvular aortic stenosis can also occur
    from cholesterol deposition in the aortic root.
  phenotype_term:
    preferred_term: Aortic valve stenosis
    term:
      id: HP:0001650
      label: Aortic valve stenosis
  evidence:
  - reference: PMID:24404629
    reference_title: "Familial Hypercholesterolemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Individuals with a more severe phenotype, often as a result of biallelic variants, can present with very significant elevations in LDL-C (>500 mg/dL), early-onset coronary artery disease (CAD; presenting as early as childhood in some), and calcific aortic valve disease."
    explanation: GeneReviews directly identifies calcific aortic valve disease as a feature of severe (biallelic) FH.
- category: Cardiovascular
  name: Atherosclerosis
  frequency: VERY_FREQUENT
  description: >
    Generalized atherosclerosis affecting multiple vascular beds including
    coronary, carotid, aortic, and peripheral arteries.
  phenotype_term:
    preferred_term: Atherosclerosis
    term:
      id: HP:0002621
      label: Atherosclerosis
  evidence:
  - reference: PMID:32205033
    reference_title: "Why patients with familial hypercholesterolemia are at high cardiovascular risk? Beyond LDL-C levels."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "All FH patients are at high risk for premature cardiovascular disease (CVD) events due to their genetically determined lifelong exposure to high LDL-C levels."
    explanation: Lifelong LDL-C exposure drives generalized atherosclerosis in FH.
- category: Cardiovascular
  name: Peripheral Arterial Stenosis
  frequency: OCCASIONAL
  description: >
    Atherosclerotic narrowing of peripheral arteries, particularly in the
    lower extremities, contributing to claudication and limb ischemia.
  phenotype_term:
    preferred_term: Peripheral arterial stenosis
    term:
      id: HP:0004950
      label: Peripheral arterial stenosis
  evidence:
  - reference: PMID:18243212
    reference_title: "Cardiovascular disease in familial hypercholesterolaemia: influence of low-density lipoprotein receptor mutation type and classic risk factors."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Prevalence of PCVD was 21.9% (30.2% in males and 14.5% in women, P<0.001). Mean age of onset of cardiovascular event was 42.1 years in males and 50.8 years in females."
    explanation: This study reports high prevalence of premature cardiovascular disease in FH generally, but does not specifically quantify peripheral arterial stenosis. Peripheral vascular involvement is inferred as part of the generalized atherosclerotic burden.
- category: Cardiovascular
  name: Ischemic Stroke
  frequency: OCCASIONAL
  description: >
    Cerebrovascular atherosclerotic disease and ischemic stroke from carotid
    or intracranial atherosclerosis.
  phenotype_term:
    preferred_term: Ischemic stroke
    term:
      id: HP:0002140
      label: Ischemic stroke
  evidence:
  - reference: PMID:24404629
    reference_title: "Familial Hypercholesterolemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "stroke occurs more rarely"
    explanation: GeneReviews notes stroke as a less common but recognized cardiovascular manifestation of FH.
- category: Dermatologic
  name: Tendon Xanthomas
  frequency: FREQUENT
  diagnostic: true
  description: >
    Xanthomas (lipid deposits) in tendons, particularly the Achilles tendon and
    extensor tendons of the hands, are pathognomonic for FH, though they develop
    over decades and may not be present in younger patients. Correlate with
    cumulative LDL burden and disease severity.
  phenotype_term:
    preferred_term: Tendon xanthomatosis
    term:
      id: HP:0010874
      label: Tendon xanthomatosis
  evidence:
  - reference: DOI:10.3390/ijms25031637
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A chronically elevated concentration of LDL-C in the plasma leads to the occurrence of certain abnormalities, such as xanthomas in the tendons and skin, as well as corneal arcus."
    explanation: Tendon and skin xanthomas are characteristic manifestations of chronic LDL-C elevation.
  - reference: PMID:10357843
    reference_title: "Evidence for a third genetic locus causing familial hypercholesterolemia. A non-LDLR, non-APOB kindred."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In this large family, the degree of hypercholesterolemia, prevalence of tendon xanthomata, and occurrence of early coronary disease were indistinguishable from the other families studied."
    explanation: HPOA-linked FH3 pedigree study independently confirms tendon xanthomata as a recurring clinical manifestation of monogenic FH.
- category: Dermatologic
  name: Cutaneous Xanthomas
  frequency: OCCASIONAL
  subtype: Homozygous Familial Hypercholesterolemia
  description: >
    Cholesterol-rich cutaneous xanthomas can occur in severe FH, especially in
    homozygous disease with extreme lifelong LDL elevation.
  phenotype_term:
    preferred_term: Cutaneous xanthomas
    term:
      id: HP:0000991
      label: Xanthomatosis
  evidence:
  - reference: DOI:10.3390/ijms25031637
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A chronically elevated concentration of LDL-C in the plasma leads to the occurrence of certain abnormalities, such as xanthomas in the tendons and skin, as well as corneal arcus."
    explanation: Documents skin xanthomas as a cutaneous manifestation of severe chronic LDL-C elevation in FH.
- category: Dermatologic
  name: Xanthelasma
  frequency: OCCASIONAL
  description: >
    Yellowish cholesterol deposits around the eyelids. While not specific to FH,
    xanthelasma in combination with elevated LDL-C supports clinical diagnosis.
  phenotype_term:
    preferred_term: Xanthelasma
    term:
      id: HP:0001114
      label: Xanthelasma
  evidence:
  - reference: PMID:24404629
    reference_title: "Familial Hypercholesterolemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Xanthelasmas (yellowish, waxy deposits) can occur around the eyelids."
    explanation: GeneReviews confirms xanthelasma as a clinical feature of FH.
- category: Ophthalmologic
  name: Corneal Arcus
  frequency: OCCASIONAL
  description: >
    A grey-white arc or ring of lipid deposition at the periphery of the cornea.
    Premature corneal arcus (before age 45) is a diagnostic sign of FH and is
    included in the DLCN diagnostic criteria.
  phenotype_term:
    preferred_term: Corneal arcus
    term:
      id: HP:0001084
      label: Corneal arcus
  evidence:
  - reference: DOI:10.3390/ijms25031637
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A chronically elevated concentration of LDL-C in the plasma leads to the occurrence of certain abnormalities, such as xanthomas in the tendons and skin, as well as corneal arcus."
    explanation: Corneal arcus is a recognized clinical feature of FH.
biochemical:
- name: LDL Cholesterol (LDL-C)
  biomarker_term:
    preferred_term: LDL cholesterol
    term:
      id: CHEBI:47774
      label: low-density lipoprotein cholesterol
  presence: Elevated
  frequency: OBLIGATE
  specificity: >
    Diagnostic biochemical marker for FH when interpreted with age, family
    history, and genotype; levels are typically markedly elevated from birth.
  context: >
    LDL-C is the primary diagnostic and treatment-response biomarker in FH.
    GeneReviews lists measurement of LDL-C concentration as a way to clarify
    diagnosis in at-risk relatives, and therapeutic guidance centers on
    reducing LDL-C levels.
  readouts:
  - target: Elevated Circulating LDL Cholesterol
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: >
      Elevated measured LDL-C directly reports the central biochemical
      abnormality caused by reduced hepatic LDL clearance.
    evidence:
    - reference: PMID:24404629
      reference_title: "Familial Hypercholesterolemia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "A clinical diagnosis of FH can be established in a proband with characteristic clinical features and significantly elevated LDL-C levels"
      explanation: >
        GeneReviews identifies significantly elevated LDL-C levels as central
        to clinical diagnosis.
  - target: Reduced Hepatic LDL Clearance
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: >
      High LDL-C is the observable plasma consequence of impaired hepatic LDL
      uptake by the LDL receptor pathway.
    evidence:
    - reference: DOI:10.3390/ijms24043224
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Genetics of Familial Hypercholesterolemia (FH) is ascribable to pathogenic variants in genes encoding proteins leading to an impaired LDL uptake by the LDL receptor (LDLR)."
      explanation: >
        FH gene defects converge on impaired LDL uptake, making elevated LDL-C
        a diagnostic readout of reduced clearance.
  evidence:
  - reference: PMID:29219151
    reference_title: "Familial hypercholesterolaemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Familial hypercholesterolaemia is a common inherited disorder characterized by abnormally elevated serum levels of low-density lipoprotein (LDL) cholesterol from birth, which in time can lead to cardiovascular disease (CVD)."
    explanation: >
      Confirms LDL cholesterol elevation from birth as the defining biochemical
      abnormality in FH.
  - reference: PMID:24404629
    reference_title: "Familial Hypercholesterolemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "measurement of LDL-C concentration"
    explanation: >
      GeneReviews identifies LDL-C concentration measurement as a diagnostic
      approach for at-risk family members.
genetic:
- name: LDLR
  gene_term:
    preferred_term: LDLR
    term:
      id: hgnc:6547
      label: LDLR
  association: Pathogenic Mutations
  presence: Positive
  frequency: "~85-90%"
  inheritance:
  - name: Autosomal Dominant
    inheritance_term:
      preferred_term: Autosomal dominant inheritance
      term:
        id: HP:0000006
        label: Autosomal dominant inheritance
  notes: >
    Mutations in LDLR on chromosome 19p13.2 account for the majority of FH cases
    (~85-90%). Over 2000 different LDLR mutations have been described. LDLR
    variants are classified into five mechanistic classes: (1) null alleles with
    no receptor synthesis, (2) transport-defective alleles with impaired ER-to-Golgi
    processing, (3) binding-defective alleles with reduced LDL affinity,
    (4) internalization-defective alleles with impaired clustering in clathrin-coated
    pits, and (5) recycling-defective alleles with failure to release LDL and
    recycle to the cell surface. Class 1 (null) mutations generally cause the most
    severe phenotype, particularly in homozygous state, as they result in absent
    LDLR protein.
  variants:
  - name: Class 1 - Null mutations
    description: >
      No LDLR protein synthesized. Most severe class. Large deletions,
      frameshift, and nonsense mutations. Homozygous null patients have
      minimal response to statins since there is no residual receptor to upregulate.
    type: "null"
    clinical_significance: PATHOGENIC
  - name: Class 2 - Transport-defective
    description: >
      LDLR protein synthesized but fails to properly fold or transport from ER
      to Golgi. Receptor is retained intracellularly and degraded.
    type: missense
    clinical_significance: PATHOGENIC
  - name: Class 3 - Binding-defective
    description: >
      LDLR reaches cell surface but cannot bind LDL particles normally.
      Mutations affect the ligand-binding domain (repeats 2-7).
    type: missense
    clinical_significance: PATHOGENIC
  - name: Class 4 - Internalization-defective
    description: >
      LDLR binds LDL but fails to cluster in clathrin-coated pits for
      endocytosis. Mutations typically affect the cytoplasmic NPXY motif.
    type: missense
    clinical_significance: PATHOGENIC
  - name: Class 5 - Recycling-defective
    description: >
      LDLR internalizes LDL but fails to release it in the endosome and
      does not recycle back to the cell surface. Receptor is degraded
      along with the ligand.
    type: missense
    clinical_significance: PATHOGENIC
  evidence:
  - reference: PMID:29219151
    reference_title: "Familial hypercholesterolaemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Most cases are caused by autosomal dominant mutations in LDLR, which encodes the LDL receptor"
    explanation: LDLR mutations are the most frequent genetic cause of FH.
  - reference: DOI:10.3390/ijms24043224
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Genetics of Familial Hypercholesterolemia (FH) is ascribable to pathogenic variants in genes encoding proteins leading to an impaired LDL uptake by the LDL receptor (LDLR)."
    explanation: Confirms that LDLR variants lead to impaired LDL uptake.
- name: APOB
  gene_term:
    preferred_term: APOB
    term:
      id: hgnc:603
      label: APOB
  association: Pathogenic Mutations
  presence: Positive
  frequency: "~5-10%"
  inheritance:
  - name: Autosomal Dominant
    inheritance_term:
      preferred_term: Autosomal dominant inheritance
      term:
        id: HP:0000006
        label: Autosomal dominant inheritance
  notes: >
    Mutations in APOB, encoding apolipoprotein B-100, reduce binding of LDL
    particles to the LDL receptor. The most common variant is R3500Q in exon 26,
    which reduces LDLR binding affinity. APOB-related FH (also called familial
    defective apolipoprotein B) tends to produce a milder phenotype than LDLR
    mutations, with better response to statin therapy since LDLR can still
    be upregulated.
  variants:
  - name: R3500Q (p.Arg3527Gln)
    description: >
      The most common APOB mutation causing FH. Missense variant in exon 26
      that reduces apoB-100 binding to LDLR by approximately 90%. Generally
      produces a milder phenotype than most LDLR mutations.
    type: missense
    clinical_significance: PATHOGENIC
  - name: R3500W (p.Arg3527Trp)
    description: >
      Less common APOB variant affecting the same residue as R3500Q.
      Also impairs LDL binding to LDLR.
    type: missense
    clinical_significance: PATHOGENIC
  evidence:
  - reference: DOI:10.3390/ijms24043224
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Genetics of Familial Hypercholesterolemia (FH) is ascribable to pathogenic variants in genes encoding proteins leading to an impaired LDL uptake by the LDL receptor (LDLR)."
    explanation: APOB is one of the genes whose variants lead to impaired LDL uptake.
  - reference: PMID:29219151
    reference_title: "Familial hypercholesterolaemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "mutations in other genes coding for proteins involved in cholesterol metabolism or LDLR function and processing, such as APOB and PCSK9, can also be causative, although less frequently."
    explanation: Confirms APOB as a less frequent but established cause of FH.
- name: PCSK9
  gene_term:
    preferred_term: PCSK9
    term:
      id: hgnc:20001
      label: PCSK9
  association: Gain-of-Function Mutations
  presence: Positive
  frequency: "<5%"
  inheritance:
  - name: Autosomal Dominant
    inheritance_term:
      preferred_term: Autosomal dominant inheritance
      term:
        id: HP:0000006
        label: Autosomal dominant inheritance
  notes: >
    Gain-of-function mutations in PCSK9 increase degradation of LDL receptors,
    reducing LDL clearance. PCSK9 binds the extracellular domain of LDLR and
    directs the complex to lysosomal degradation instead of allowing receptor
    recycling. Patients with PCSK9 gain-of-function mutations respond well to
    PCSK9 inhibitor therapy. Conversely, loss-of-function PCSK9 variants are
    associated with lower LDL-C and reduced cardiovascular risk.
  variants:
  - name: D374Y (p.Asp374Tyr)
    description: >
      One of the most severe PCSK9 gain-of-function mutations. Increases PCSK9
      affinity for LDLR, leading to enhanced receptor degradation and severe
      hypercholesterolemia. Excellent response to PCSK9 inhibitor therapy.
    type: missense
    clinical_significance: PATHOGENIC
  - name: S127R (p.Ser127Arg)
    description: >
      French Canadian founder mutation. Gain-of-function variant producing a
      moderately severe FH phenotype.
    type: missense
    clinical_significance: PATHOGENIC
  - name: F216L (p.Phe216Leu)
    description: >
      Gain-of-function variant associated with FH. Enhances PCSK9-mediated
      LDLR degradation.
    type: missense
    clinical_significance: PATHOGENIC
  evidence:
  - reference: DOI:10.1073/pnas.0409736102
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Overexpression of PCSK9 in HepG2 cells caused a decrease in whole-cell and cell-surface LDLR levels. PCSK9 overexpression had no effect on LDLR synthesis but caused a dramatic increase in the degradation of the mature LDLR"
    explanation: Demonstrates the mechanism by which PCSK9 gain-of-function mutations cause FH through increased LDLR degradation.
  - reference: DOI:10.1111/joim.13577
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "PCSK9 discovery in FH by Abifadel et al."
    explanation: Traces the discovery of PCSK9 as a causative gene in FH.
- name: LDLRAP1
  gene_term:
    preferred_term: LDLRAP1
    term:
      id: hgnc:18640
      label: LDLRAP1
  association: Loss-of-Function Mutations
  presence: Positive
  frequency: "<1%"
  inheritance:
  - name: Autosomal Recessive
    inheritance_term:
      preferred_term: Autosomal recessive inheritance
      term:
        id: HP:0000007
        label: Autosomal recessive inheritance
  notes: >
    Biallelic loss-of-function mutations in LDLRAP1 (also known as ARH) cause
    autosomal recessive hypercholesterolemia. LDLRAP1 encodes an adaptor protein
    required for clathrin-mediated endocytosis of the LDLR-LDL complex. Without
    functional LDLRAP1, LDLR cannot be properly internalized via clathrin-coated
    pits despite normal receptor expression. Phenotype can be as severe as HoFH
    but may be somewhat milder. Patients typically respond to statin therapy since
    LDLR can still be upregulated and can function in cell types that do not
    depend on ARH (e.g., fibroblasts).
  evidence:
  - reference: DOI:10.3390/ijms24043224
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Variants in the LDLRAP1 gene causes FH with a recessive inheritance and a specific APOE variant was described as causative of FH, contributing to increase FH genetic heterogeneity."
    explanation: Confirms LDLRAP1 as the cause of autosomal recessive FH.
- name: APOE
  gene_term:
    preferred_term: APOE
    term:
      id: hgnc:613
      label: APOE
  association: Rare Causative Variants
  presence: Positive
  frequency: "Very rare"
  inheritance:
  - name: Autosomal Dominant
    inheritance_term:
      preferred_term: Autosomal dominant inheritance
      term:
        id: HP:0000006
        label: Autosomal dominant inheritance
  notes: >
    Rare specific APOE variants (e.g., p.Leu167del) can cause an FH-like
    phenotype through impaired clearance of apoE-containing lipoproteins.
    These are considered FH phenocopies and contribute to the genetic
    heterogeneity of FH.
  evidence:
  - reference: DOI:10.3390/ijms24043224
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "a specific APOE variant was described as causative of FH, contributing to increase FH genetic heterogeneity."
    explanation: Confirms rare APOE variants as contributors to FH genetic heterogeneity.
- name: Polygenic Hypercholesterolemia
  association: Phenocopy or Modifier
  presence: Positive
  notes: >
    Some clinically suspected FH cases prove to be polygenic
    hypercholesterolemia rather than true monogenic FH, reflecting the cumulative
    effect of multiple common LDL-C-raising variants. High polygenic risk can
    also exacerbate the phenotype in bona fide HeFH, partially explaining
    phenotypic variability among patients with the same pathogenic variant.
  evidence:
  - reference: DOI:10.3390/ijms24043224
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The presence of several common variants was also considered a genetic basis of FH and several polygenic risk scores (PRS) have been described. The presence of a variant in modifier genes or high PRS in HeFH further exacerbates the phenotype, partially justifying its variability among patients."
    explanation: Polygenic risk scores contribute to phenotypic variability in FH.
environmental:
- name: High Saturated Fat Diet
  description: >
    Dietary intake high in saturated fat and cholesterol exacerbates LDL-C
    levels in FH patients. While FH is genetically determined, dietary
    factors significantly modulate the degree of hypercholesterolemia and
    cardiovascular risk. A heart-healthy diet with reduced saturated fat
    (<7% of calories), reduced trans fats, and increased plant stanols/sterols
    can lower LDL-C by 10-15% on top of genetic baseline.
  effect: Exacerbates LDL-C elevation and accelerates atherosclerosis
  notes: Dietary modification is foundational but insufficient as sole therapy.
  evidence:
  - reference: PMID:24404629
    reference_title: "Familial Hypercholesterolemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Agents/circumstances to avoid: Smoking, high intake of saturated and trans unsaturated fat, sedentary lifestyle, obesity, hypertension, and diabetes mellitus."
    explanation: GeneReviews identifies high saturated and trans fat intake as an agent/circumstance to avoid in FH.
- name: Smoking and Tobacco Use
  notes: "Concomitant risk factor"
  description: >
    Cigarette smoking is a major modifiable cardiovascular risk factor that
    compounds the already elevated atherosclerotic risk in FH. Smoking promotes
    endothelial dysfunction, oxidative modification of LDL, and thrombogenesis.
    The combination of FH and smoking dramatically accelerates cardiovascular
    events. Smoking cessation is strongly recommended for all FH patients.
  exposure_term:
    preferred_term: exposure to tobacco smoking
    term:
      id: ECTO:6000029
      label: exposure to tobacco smoking
  effect: Synergistically increases cardiovascular risk with hypercholesterolemia
  evidence:
  - reference: PMID:15554949
    reference_title: "The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "smoking (RR 1.67, 95% CI 1.40-1.99)"
    explanation: Smoking is an independent CVD risk factor in FH with RR 1.67 in a cohort of 2400 FH patients.
  - reference: PMID:17054804
    reference_title: "Relative risk for cardiovascular atherosclerotic events after smoking cessation: 6-9 years excess risk in individuals with familial hypercholesterolemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The risk of atherosclerotic events due to smoking was estimated as 2.1 (95% confidence interval 1.5; 2.9)."
    explanation: Smoking approximately doubles the risk of atherosclerotic events in FH patients.
- name: Physical Inactivity
  notes: "Concomitant risk factor"
  description: >
    Sedentary lifestyle contributes to increased cardiovascular risk in FH
    patients through multiple mechanisms including reduced HDL-C, increased
    insulin resistance, and impaired endothelial function. Regular aerobic
    exercise can modestly improve lipid profiles and cardiovascular fitness
    even in the setting of genetic hypercholesterolemia.
  exposure_term:
    preferred_term: exposure to sedentary lifestyle
    term:
      id: ECTO:6000004
      label: exposure to sedentary lifestyle
  effect: Contributes to cardiovascular risk through reduced HDL and impaired endothelial function
  evidence:
  - reference: PMID:24404629
    reference_title: "Familial Hypercholesterolemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Agents/circumstances to avoid: Smoking, high intake of saturated and trans unsaturated fat, sedentary lifestyle, obesity, hypertension, and diabetes mellitus."
    explanation: GeneReviews identifies sedentary lifestyle as an agent/circumstance to avoid in FH.
  - reference: PMID:37543519
    reference_title: "Relationship between lifestyle habits and cardiovascular risk factors in familial hypercholesterolemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "being physically active (≥150 min/week of moderate or vigorous physical activity)"
    explanation: Physical activity is a key component of the healthy lifestyle score favorably associated with CVD risk factors in FH.
- name: Obesity and Metabolic Syndrome
  notes: "Concomitant risk factor (HP:0001513 Obesity; MONDO:0011565 metabolic syndrome X)"
  description: >
    Obesity and its associated metabolic derangements (insulin resistance,
    hypertriglyceridemia, low HDL-C) compound the cardiovascular risk of FH.
    Visceral adiposity promotes systemic inflammation and dyslipidemia that
    worsen the atherosclerotic burden from baseline LDL-C elevation.
  effect: Exacerbates cardiovascular risk through additional metabolic insults
  evidence:
  - reference: PMID:24404629
    reference_title: "Familial Hypercholesterolemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Agents/circumstances to avoid: Smoking, high intake of saturated and trans unsaturated fat, sedentary lifestyle, obesity, hypertension, and diabetes mellitus."
    explanation: GeneReviews identifies obesity as an agent/circumstance to avoid in FH.
- name: Diabetes Mellitus
  notes: "Concomitant risk factor (MONDO:0005015 diabetes mellitus; HP:0000819 Diabetes mellitus)"
  description: >
    Co-existing diabetes mellitus markedly increases cardiovascular risk in
    FH patients. Hyperglycemia accelerates glycation of LDL particles, making
    them more atherogenic, and promotes endothelial dysfunction.
  effect: Multiplies cardiovascular risk through enhanced atherogenicity of LDL and endothelial injury
  evidence:
  - reference: PMID:15554949
    reference_title: "The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "diabetes mellitus (RR 2.19, 95% CI 1.36-3.54)"
    explanation: Diabetes is an independent CVD risk factor in FH with RR 2.19, the highest relative risk among classical risk factors studied.
  - reference: PMID:24404629
    reference_title: "Familial Hypercholesterolemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Agents/circumstances to avoid: Smoking, high intake of saturated and trans unsaturated fat, sedentary lifestyle, obesity, hypertension, and diabetes mellitus."
    explanation: GeneReviews identifies diabetes mellitus as an agent/circumstance to avoid in FH.
- name: Hypertension
  notes: "Concomitant risk factor"
  description: >
    Concomitant hypertension is an independent cardiovascular risk factor that
    compounds FH-related atherosclerotic risk. Elevated blood pressure promotes
    endothelial damage and increases LDL entry into the arterial wall.
  effect: Increases rate of atherosclerotic plaque development and cardiovascular events
  evidence:
  - reference: PMID:15554949
    reference_title: "The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "hypertension (RR 1.36, 95% CI 1.06-1.75)"
    explanation: Hypertension is an independent CVD risk factor in FH with RR 1.36 in a cohort of 2400 FH patients.
  - reference: PMID:24404629
    reference_title: "Familial Hypercholesterolemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Agents/circumstances to avoid: Smoking, high intake of saturated and trans unsaturated fat, sedentary lifestyle, obesity, hypertension, and diabetes mellitus."
    explanation: GeneReviews identifies hypertension as an agent/circumstance to avoid in FH.
- name: Social Determinants of Health
  description: >
    Socioeconomic disparities significantly affect FH outcomes. Limited access
    to healthcare, genetic testing, specialist lipid clinics, and expensive
    therapies (PCSK9 inhibitors, evinacumab) creates inequities in diagnosis
    and treatment. The EAS 2023 consensus specifically addresses inequities
    in HoFH care worldwide and recommends creation of national screening
    programmes and education to improve awareness. Low health literacy, food
    insecurity, and inability to afford medications contribute to suboptimal
    outcomes.
  effect: Delayed diagnosis, undertreatment, and worse cardiovascular outcomes
  evidence:
  - reference: DOI:10.1093/eurheartj/ehad197
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "To improve HoFH care around the world, the statement recommends the creation of national screening programmes, education to improve awareness, and management guidelines that account for the local realities of care, including access to specialist centres, treatments, and cost."
    explanation: The EAS 2023 consensus explicitly addresses socioeconomic disparities and access barriers in FH care globally.
- name: Occupational Factors
  notes: >
    Sedentary occupations that limit physical activity may compound cardiovascular
    risk in FH, given that physical activity (>=150 min/week) is a component of
    healthy lifestyle scores favorably associated with CVD risk factors (PMID:37543519).
    However, no direct evidence links specific occupational factors to FH outcomes.
  description: >
    Sedentary occupations that limit physical activity and promote prolonged
    sitting contribute to cardiovascular risk in FH patients. Shift work has
    been associated with adverse cardiovascular outcomes and may compound
    FH-related risk. High-stress occupations may increase cardiovascular risk
    through catecholamine-mediated hemodynamic stress. Occupational exposures
    to air pollution (traffic, industrial) may also accelerate atherosclerosis.
  effect: Sedentary work patterns and occupational stress increase cardiovascular risk
- name: Alcohol Consumption
  notes: "Concomitant risk factor"
  description: >
    Excessive alcohol intake can worsen lipid profiles (particularly
    triglycerides) and contribute to cardiovascular risk in FH. However,
    moderate alcohol intake has not been shown to significantly worsen FH
    outcomes and may have neutral or slight beneficial effects on HDL-C.
  exposure_term:
    preferred_term: exposure to alcohol consumption
    term:
      id: ECTO:0001082
      label: exposure to alcohol consumption
  effect: Excessive intake worsens dyslipidemia; moderate intake has uncertain effects
  evidence:
  - reference: PMID:37543519
    reference_title: "Relationship between lifestyle habits and cardiovascular risk factors in familial hypercholesterolemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "having a light to moderate alcohol consumption (men: 1-30 g/day; women: 1-15 g/day)"
    explanation: Light to moderate alcohol consumption is included as a component of the healthy lifestyle score in FH, suggesting excessive consumption is unfavorable.
treatments:
- name: High-Intensity Statin Therapy
  description: >
    Statins are the first-line therapy for FH, reducing LDL cholesterol by
    inhibiting HMG-CoA reductase, which upregulates hepatic LDLR expression.
    High-intensity statins (atorvastatin 40-80mg, rosuvastatin 20-40mg) can
    reduce LDL-C by 50-60%. Initiated at diagnosis in adults, and in children
    from age 8-10. Efficacy depends on residual LDLR function; Class 1 (null)
    LDLR mutations in HoFH show minimal response since there is no receptor
    to upregulate. APOB and PCSK9 gain-of-function FH respond well to statins.
  treatment_term:
    preferred_term: targeted therapy
    term:
      id: NCIT:C93352
      label: Targeted Therapy
    therapeutic_agent:
    - preferred_term: statin
      term:
        id: CHEBI:87631
        label: statin
  target_mechanisms:
  - target: Elevated Circulating LDL Cholesterol
    treatment_effect: INHIBITS
    description: >
      Statins are first-line lifelong LDL-lowering therapy for FH, lowering
      the core circulating LDL-C abnormality.
    evidence:
    - reference: PMID:29219151
      reference_title: "Familial hypercholesterolaemia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Lifelong LDL cholesterol-lowering treatment substantially improves CVD-free survival and longevity. Statins are the first-line therapy"
      explanation: >
        This directly supports statins as first-line treatment aimed at
        lowering LDL cholesterol in FH.
  evidence:
  - reference: PMID:29219151
    reference_title: "Familial hypercholesterolaemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Statins are the first-line therapy, but additional drugs, such as ezetimibe, bile acid sequestrants, PCSK9 inhibitors and other emerging therapies, are often required."
    explanation: Statins confirmed as first-line therapy with additional agents often needed.
  - reference: PMID:29219151
    reference_title: "Familial hypercholesterolaemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Lifelong LDL cholesterol-lowering treatment substantially improves CVD-free survival and longevity."
    explanation: Confirms the critical importance of lifelong LDL-lowering therapy.
- name: Ezetimibe
  description: >
    Ezetimibe inhibits intestinal cholesterol absorption via the NPC1L1
    transporter, providing an additional 15-20% LDL-C reduction on top of
    statin therapy. Recommended as second-line add-on therapy when statin
    monotherapy is insufficient to reach LDL-C targets. Effective across
    all FH genotypes as its mechanism is independent of LDLR.
  treatment_term:
    preferred_term: targeted therapy
    term:
      id: NCIT:C93352
      label: Targeted Therapy
    therapeutic_agent:
    - preferred_term: ezetimibe
      term:
        id: NCIT:C47529
        label: Ezetimibe
  target_mechanisms:
  - target: Elevated Circulating LDL Cholesterol
    treatment_effect: INHIBITS
    description: >
      Ezetimibe is an LDL-C-lowering add-on therapy that helps reduce the
      central biochemical abnormality when statin therapy is insufficient.
    evidence:
    - reference: DOI:10.1111/cts.13836
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Treatment options such as statins, lomitapide, ezetimibe, proprotein convertase subtilisin/kexin type 9 inhibitors, and apheresis help lower LDL‐C"
      explanation: >
        The HoFH review lists ezetimibe among treatment options that lower
        LDL-C.
  evidence:
  - reference: PMID:29219151
    reference_title: "Familial hypercholesterolaemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Statins are the first-line therapy, but additional drugs, such as ezetimibe, bile acid sequestrants, PCSK9 inhibitors and other emerging therapies, are often required."
    explanation: Ezetimibe is listed as an important add-on therapy for FH.
- name: Bile Acid Sequestrants
  description: >
    Bile acid sequestrants are non-systemic antilipidemic agents that bind
    bile acids in the gut, increase fecal bile acid loss, and promote hepatic
    cholesterol conversion to bile acids. In FH they can be used as additional
    LDL-C-lowering therapy when statins and other agents are insufficient or
    when pregnancy limits other pharmacologic options.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: bile acid sequestrant
      term:
        id: NCIT:C98148
        label: Bile Acid Sequestrant
  target_mechanisms:
  - target: Elevated Circulating LDL Cholesterol
    treatment_effect: INHIBITS
    description: >
      Bile acid sequestrants are part of the additional drug armamentarium used
      to lower LDL cholesterol in FH.
    evidence:
    - reference: PMID:29219151
      reference_title: "Familial hypercholesterolaemia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Statins are the first-line therapy, but additional drugs, such as ezetimibe, bile acid sequestrants, PCSK9 inhibitors and other emerging therapies, are often required."
      explanation: >
        The FH primer identifies bile acid sequestrants among additional drugs
        often required after first-line statins.
  evidence:
  - reference: PMID:29219151
    reference_title: "Familial hypercholesterolaemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Statins are the first-line therapy, but additional drugs, such as ezetimibe, bile acid sequestrants, PCSK9 inhibitors and other emerging therapies, are often required."
    explanation: >
      Bile acid sequestrants are explicitly listed as additional FH therapy in
      this overview.
- name: PCSK9 Inhibitor Therapy
  description: >
    Monoclonal antibodies targeting PCSK9 (evolocumab, alirocumab) prevent
    PCSK9-mediated LDLR degradation, increasing LDLR recycling and LDL
    clearance. Provide additional 50-60% LDL-C reduction on top of
    maximally tolerated statin and ezetimibe. Most effective in patients
    with residual LDLR function (receptor-defective rather than
    receptor-negative HoFH, and all HeFH). Patients with PCSK9
    gain-of-function mutations respond particularly well. Limited
    efficacy in receptor-negative (null) HoFH.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: PCSK9 inhibitor
      term:
        id: NCIT:C190797
        label: PCSK9 Inhibitor
    - preferred_term: alirocumab
      term:
        id: NCIT:C174849
        label: Alirocumab
    - preferred_term: evolocumab
      term:
        id: NCIT:C174672
        label: Evolocumab
  target_mechanisms:
  - target: PCSK9-Mediated LDLR Degradation
    treatment_effect: INHIBITS
    description: >
      PCSK9 inhibitors block the PCSK9 pathway that removes LDL receptors from
      the hepatocyte surface, improving LDL-C clearance when residual LDLR
      function exists.
    evidence:
    - reference: PMID:32197277
      reference_title: "Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Monoclonal antibodies directed against proprotein convertase subtilisin-kexin type 9 (PCSK9) have been shown to reduce LDL cholesterol levels by more than 50%"
      explanation: >
        Anti-PCSK9 monoclonal antibodies reduce LDL cholesterol by targeting
        the PCSK9 axis.
  evidence:
  - reference: DOI:10.1111/joim.13577
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the very rapid availability of PCSK9 inhibitors."
    explanation: Traces the rapid translation of PCSK9 genetics into therapeutic PCSK9 inhibitors.
- name: Inclisiran
  therapeutic_modality: SIRNA
  description: >
    A small interfering RNA (siRNA) that targets hepatic PCSK9 mRNA, reducing
    PCSK9 synthesis at the translational level. Administered subcutaneously
    every 6 months after initial loading doses, providing sustained LDL-C
    lowering of approximately 50%. Offers advantages in adherence due to
    infrequent dosing. Like PCSK9 monoclonal antibodies, efficacy depends
    on residual LDLR function.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: inclisiran
      term:
        id: CHEBI:176399
        label: inclisiran
  target_mechanisms:
  - target: PCSK9-Mediated LDLR Degradation
    treatment_effect: INHIBITS
    description: >
      Inclisiran inhibits hepatic PCSK9 synthesis, reducing the PCSK9-driven
      LDLR degradation mechanism.
    evidence:
    - reference: PMID:32197277
      reference_title: "Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "a twice-yearly injection of inclisiran, a small interfering RNA, was shown to inhibit hepatic synthesis of PCSK9 in adults with heterozygous familial hypercholesterolemia."
      explanation: >
        The ORION-9 abstract directly states that inclisiran inhibits hepatic
        PCSK9 synthesis.
  evidence:
  - reference: PMID:32197277
    reference_title: "Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Among adults with heterozygous familial hypercholesterolemia, those who received inclisiran had significantly lower levels of LDL cholesterol than those who received placebo, with an infrequent dosing regimen and an acceptable safety profile."
    explanation: ORION-9 phase 3 trial demonstrates significant LDL-C reduction with inclisiran in HeFH patients.
- name: Bempedoic Acid
  description: >
    An ATP citrate lyase inhibitor that reduces cholesterol biosynthesis
    upstream of HMG-CoA reductase. Provides 15-25% additional LDL-C
    reduction when added to maximally tolerated statins. As a prodrug
    activated only in the liver, it avoids statin-associated muscle
    side effects. Useful in statin-intolerant FH patients.
  treatment_term:
    preferred_term: targeted therapy
    term:
      id: NCIT:C93352
      label: Targeted Therapy
    therapeutic_agent:
    - preferred_term: bempedoic acid
      term:
        id: CHEBI:149601
        label: bempedoic acid
  target_mechanisms:
  - target: Elevated Circulating LDL Cholesterol
    treatment_effect: INHIBITS
    description: >
      Bempedoic acid lowers LDL-C in HeFH and therefore targets the central
      biochemical abnormality downstream of impaired LDL clearance.
    evidence:
    - reference: PMID:38341323
      reference_title: "Efficacy and safety of bempedoic acid in patients with heterozygous familial hypercholesterolemia: analysis of pooled patient-level data from phase 3 clinical trials."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Bempedoic acid significantly lowered LDL-C at week 12 vs. placebo regardless of HeFH status (with HeFH, -21.2%; without HeFH, -18.2% [both P<0.0001])."
      explanation: >
        The pooled phase 3 analysis supports LDL-C lowering in HeFH.
  evidence:
  - reference: PMID:38341323
    reference_title: "Efficacy and safety of bempedoic acid in patients with heterozygous familial hypercholesterolemia: analysis of pooled patient-level data from phase 3 clinical trials."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Bempedoic acid significantly lowered LDL-C at week 12 vs. placebo regardless of HeFH status (with HeFH, -21.2%; without HeFH, -18.2% [both P<0.0001])."
    explanation: Pooled phase 3 data showing significant LDL-C lowering with bempedoic acid in HeFH patients.
- name: Evinacumab (Anti-ANGPTL3)
  description: >
    A fully human monoclonal antibody against ANGPTL3 (angiopoietin-like
    protein 3). Evinacumab works through an LDLR-independent mechanism,
    lowering LDL-C by approximately 50% at 15 mg/kg IV every 4 weeks.
    This is critical for HoFH patients with null LDLR mutations who do
    not respond to LDLR-dependent therapies. Long-term real-world data
    show sustained LDL-C reduction (56% at 6 months, sustained over
    3.5 years) and improved cardiovascular event-free survival.
    Approved for pediatric patients age 5 and older with HoFH.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: evinacumab
      term:
        id: NCIT:C20401
        label: Monoclonal Antibody
  target_mechanisms:
  - target: Elevated Circulating LDL Cholesterol
    treatment_effect: INHIBITS
    description: >
      Evinacumab lowers LDL-C through an LDLR-independent ANGPTL3 pathway,
      making it useful when the upstream LDLR-clearance defect is severe.
    evidence:
    - reference: DOI:10.1111/cts.13836
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Evinacumab is a first‐in‐class human monoclonal antibody that specifically binds to ANGPTL3 to prevent its inhibition of LPL and EL. In clinical trials, a 15 mg/kg intravenous dose every 4 weeks has shown a mean percent change from baseline in LDL‐C of ~50% in adult, adolescent, and pediatric patients with HoFH."
      explanation: >
        The review explains the ANGPTL3 mechanism and LDL-C reduction in HoFH.
  evidence:
  - reference: DOI:10.1111/cts.13836
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Evinacumab is a first‐in‐class human monoclonal antibody that specifically binds to ANGPTL3 to prevent its inhibition of LPL and EL. In clinical trials, a 15 mg/kg intravenous dose every 4 weeks has shown a mean percent change from baseline in LDL‐C of ~50% in adult, adolescent, and pediatric patients with HoFH."
    explanation: Demonstrates evinacumab mechanism and efficacy across age groups in HoFH.
  - reference: DOI:10.1161/atvbaha.123.320609
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Real-life, long-term evinacumab adjunctive to lipid-lowering therapy including lipoprotein apheresis led to sustained low-density lipoprotein cholesterol lowering and improved cardiovascular event–free survival of patients with HoFH."
    explanation: Long-term real-world data showing sustained LDL-C lowering and improved CV outcomes with evinacumab in HoFH.
  - reference: DOI:10.1161/circulationaha.123.065529
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Evinacumab constitutes a new treatment for pediatric patients with HoFH and inadequately controlled LDL-C despite optimized lipid-lowering therapy, lowering LDL-C levels by nearly half in these extremely high-risk and difficult-to-treat individuals."
    explanation: Demonstrates evinacumab efficacy in pediatric HoFH patients aged 5-11.
- name: Lomitapide
  description: >
    An oral microsomal triglyceride transfer protein (MTP) inhibitor that
    reduces hepatic VLDL secretion, thereby lowering LDL-C. Approved for
    HoFH as adjunctive therapy. Works independently of LDLR function.
    Requires careful monitoring for hepatotoxicity and gastrointestinal
    side effects, and a low-fat diet to minimize steatorrhea.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: lomitapide
      term:
        id: CHEBI:72297
        label: lomitapide
  target_mechanisms:
  - target: Elevated Circulating LDL Cholesterol
    treatment_effect: INHIBITS
    description: >
      Lomitapide is part of HoFH LDL-C-lowering combination therapy, reducing
      the same elevated LDL-C endpoint.
    evidence:
    - reference: DOI:10.1093/eurheartj/ehad197
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Addition of novel, efficacious therapies (i.e. inhibitors of proprotein convertase subtilisin/kexin type 9, followed by evinacumab and/or lomitapide) offers potential to attain LDL-C goal or reduce the need for LA."
      explanation: >
        EAS guidance lists lomitapide among therapies used to attain LDL-C
        goals in HoFH.
  evidence:
  - reference: DOI:10.1093/eurheartj/ehad197
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Addition of novel, efficacious therapies (i.e. inhibitors of proprotein convertase subtilisin/kexin type 9, followed by evinacumab and/or lomitapide) offers potential to attain LDL-C goal or reduce the need for LA."
    explanation: Lomitapide is part of the EAS-recommended multi-pronged therapy for HoFH.
- name: Mipomersen
  therapeutic_modality: ANTISENSE_OLIGONUCLEOTIDE
  aso_details:
    aso_mechanism: RNASE_H_KNOCKDOWN
    target_gene:
      preferred_term: APOB
      term:
        id: hgnc:603
        label: APOB
    target_transcript: APOB mRNA
    aso_chemistry: TWO_PRIME_O_METHOXYETHYL
    conjugation: UNCONJUGATED
  description: >
    Second-generation 2'-O-methoxyethyl chimeric antisense oligonucleotide
    that hybridizes with APOB mRNA and recruits RNase H1 to degrade the
    transcript, suppressing hepatic apolipoprotein B-100 synthesis and the
    secretion of VLDL particles that mature into LDL. FDA-approved (Kynamro,
    2013) as an adjunctive therapy for homozygous familial hypercholesterolemia
    in patients already on maximally tolerated lipid-lowering therapy. Works
    independently of LDLR function, so it retains efficacy in receptor-negative
    HoFH where statins fail. Marketed in the US until 2018; the mechanism
    remains a foundational reference point for subsequent apoB- and
    PCSK9-targeted RNA therapeutics. Principal safety signals are
    transaminase elevations / hepatic steatosis and injection-site reactions.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: mipomersen
      term:
        id: NCIT:C174575
        label: Mipomersen
  target_mechanisms:
  - target: Elevated Circulating LDL Cholesterol
    treatment_effect: INHIBITS
    description: >
      Mipomersen lowers the same elevated LDL-C endpoint as the other HoFH
      adjunctive pharmacotherapies, but does so by suppressing the upstream
      hepatic supply of apoB-containing lipoproteins rather than by enhancing
      LDLR-mediated clearance.
    evidence:
    - reference: PMID:20227758
      reference_title: "Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The mean percentage change in LDL cholesterol concentration was significantly greater with mipomersen (-24.7%, 95% CI -31.6 to -17.7) than with placebo (-3.3%, -12.1 to 5.5; p=0.0003)."
      explanation: >
        Pivotal phase 3 randomized placebo-controlled trial in HoFH demonstrated
        a significant LDL-C reduction with mipomersen vs placebo, supporting
        the INHIBITS effect on the Elevated Circulating LDL Cholesterol target.
  evidence:
  - reference: PMID:38914784
    reference_title: "Mechanisms of Action of the US Food and Drug Administration-Approved Antisense Oligonucleotide Drugs."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "mipomersen (for familial hypercholesterolemia)"
    explanation: >
      Comprehensive FDA-approved-ASO mechanism review classifies mipomersen
      among the RNase H-dependent ASOs and lists familial hypercholesterolemia
      as its approved indication.
  - reference: PMID:20227758
    reference_title: "Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Inhibition of apolipoprotein B synthesis by mipomersen represents a novel, effective therapy to reduce LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia who are already receiving lipid-lowering drugs, including high-dose statins."
    explanation: >
      Pivotal Phase 3 HoFH trial conclusion confirming mipomersen's apoB-
      synthesis-inhibition mechanism and its therapeutic role as an adjunct
      to statin therapy in HoFH.
- name: LDL Apheresis
  description: >
    Extracorporeal removal of LDL particles from the blood, typically
    performed every 1-2 weeks. Used particularly in homozygous FH and
    severe heterozygous FH when pharmacotherapy is insufficient. Can acutely
    lower LDL-C by 50-75% per session, but levels rebound between sessions.
    Combination with pharmacotherapy can reduce rebound. For HoFH with null
    mutations, apheresis may be lifesaving when started in childhood.
  treatment_term:
    preferred_term: lipoprotein apheresis
    term:
      id: NCIT:C15191
      label: Pheresis
  target_mechanisms:
  - target: Elevated Circulating LDL Cholesterol
    treatment_effect: INHIBITS
    description: >
      Lipoprotein apheresis directly removes LDL particles and is foundational
      LDL-C-lowering therapy in severe HoFH.
    evidence:
    - reference: DOI:10.1093/eurheartj/ehad197
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Combination LDL-C-lowering therapy—both pharmacologic intervention and lipoprotein apheresis (LA)—is foundational."
      explanation: >
        The consensus statement directly describes apheresis as foundational
        LDL-C-lowering therapy.
  evidence:
  - reference: DOI:10.1093/eurheartj/ehad197
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Combination LDL-C-lowering therapy—both pharmacologic intervention and lipoprotein apheresis (LA)—is foundational."
    explanation: Lipoprotein apheresis is a foundational treatment for HoFH.
- name: Liver Transplantation
  description: >
    Liver transplantation provides a functional LDLR and can normalize LDL-C
    in severe HoFH. Reserved for patients with receptor-negative HoFH who
    fail all other therapies. The donor liver provides fully functional LDLR,
    achieving near-complete correction of LDL-C. However, transplant-related
    morbidity and need for lifelong immunosuppression limit this to the most
    severe refractory cases.
  treatment_term:
    preferred_term: liver transplantation
    term:
      id: MAXO:0001175
      label: liver transplantation
  target_mechanisms:
  - target: Reduced Hepatic LDL Clearance
    treatment_effect: MODULATES
    description: >
      Liver transplantation attempts to alter the hepatic clearance defect in
      receptor-negative HoFH, but published follow-up shows it is not reliably
      curative and is reserved as a last resort.
    evidence:
    - reference: PMID:35471728
      reference_title: "Is Liver Transplant Curative in Homozygous Familial Hypercholesterolemia? A Review of Nine Global Cases."
      supports: PARTIAL
      evidence_source: HUMAN_CLINICAL
      snippet: "Liver transplant is sometimes used with curative intent."
      explanation: >
        The case-series abstract supports liver transplant as an attempted
        disease-modifying intervention, while the treatment entry notes the
        incomplete and last-resort nature of the effect.
  evidence:
  - reference: PMID:35471728
    reference_title: "Is Liver Transplant Curative in Homozygous Familial Hypercholesterolemia? A Review of Nine Global Cases."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Liver transplant did not enable attainment of recommended LDL-C targets in most patients with HoFH, and the majority of patients still required post-transplant LLT. Liver transplant was not curative in most of the patients with HoFH followed. Guidelines suggest that transplant is a treatment of last resort if contemporary treatments are not available or possible."
    explanation: Case series of 9 HoFH patients shows liver transplant is not curative in most cases, with 33% mortality and ongoing LLT needed. Supports use as last resort only.
- name: Dietary Modification
  description: >
    Heart-healthy dietary patterns are foundational but insufficient as sole
    therapy in FH. Key dietary interventions include: reduction of saturated
    fat to <7% of total calories, elimination of trans fats, increase in
    dietary fiber (especially soluble fiber from oats, legumes, psyllium),
    incorporation of plant stanols/sterols (2g/day can reduce LDL-C by
    6-15%), omega-3 fatty acids from fish, and a Mediterranean-style diet
    rich in fruits, vegetables, whole grains, and olive oil. Dietary
    modification can provide an additional 10-15% LDL-C reduction on top
    of pharmacotherapy.
  treatment_term:
    preferred_term: dietary intervention
    term:
      id: MAXO:0000088
      label: dietary intervention
  target_mechanisms:
  - target: Elevated Circulating LDL Cholesterol
    treatment_effect: MODULATES
    description: >
      Diet is foundational prevention and risk-factor management, but LDL-C
      reduction is modest because FH is genetically determined.
    evidence:
    - reference: PMID:24404629
      reference_title: "Familial Hypercholesterolemia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Heart-healthy diet (including reduced intake of saturated fat and increased intake of soluble fiber to 10-20 g/day)"
      explanation: >
        GeneReviews recommends heart-healthy diet as prevention of primary
        manifestations in FH.
  evidence:
  - reference: PMID:24404629
    reference_title: "Familial Hypercholesterolemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Heart-healthy diet (including reduced intake of saturated fat and increased intake of soluble fiber to 10-20 g/day)"
    explanation: GeneReviews recommends heart-healthy diet with reduced saturated fat and increased soluble fiber as prevention of primary manifestations.
  - reference: PMID:37543519
    reference_title: "Relationship between lifestyle habits and cardiovascular risk factors in familial hypercholesterolemia."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "we found no evidence of an association between the HLS and concentrations of LDL-cholesterol (β = 0.04, 95% CI = -0.08, 0.15 mmol/L; P = 0.54). However, the HLS was favorably associated with HbA1c levels"
    explanation: Healthy lifestyle showed no statistically significant association with LDL-C in FH (P=0.54), consistent with the genetic basis of hypercholesterolemia. However, favorable associations with HbA1c and trends for HDL-C suggest dietary modification benefits other CVD risk factors even if LDL-C reduction is modest.
- name: Exercise and Physical Activity
  description: >
    Regular aerobic exercise (at least 150 minutes/week of moderate-intensity
    or 75 minutes/week of vigorous-intensity activity) is recommended for all
    FH patients. Exercise improves HDL-C, insulin sensitivity, endothelial
    function, and overall cardiovascular fitness. While exercise has modest
    direct effects on LDL-C, its cardiovascular benefits extend beyond lipid
    lowering through improved arterial compliance and reduced inflammation.
  treatment_term:
    preferred_term: aerobic exercise therapy
    term:
      id: MAXO:0000065
      label: aerobic exercise therapy
  target_mechanisms:
  - target: Premature Atherosclerotic Cardiovascular Disease
    treatment_effect: MODULATES
    description: >
      Exercise is recommended to reduce CAD risk factors downstream of lifelong
      LDL-C burden, even though direct LDL-C effects are limited.
    evidence:
    - reference: PMID:24404629
      reference_title: "Familial Hypercholesterolemia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "reduce CAD risk factors including cessation of smoking, regular physical activity, healthy diet, and weight control"
      explanation: >
        GeneReviews lists regular physical activity as part of reducing CAD
        risk factors in FH.
  evidence:
  - reference: PMID:24404629
    reference_title: "Familial Hypercholesterolemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "increased physical activity"
    explanation: GeneReviews lists increased physical activity as prevention of primary manifestations in FH.
  - reference: PMID:37543519
    reference_title: "Relationship between lifestyle habits and cardiovascular risk factors in familial hypercholesterolemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A healthy lifestyle score (HLS), ranging from 0 to 5, was calculated per adherence to 5 lifestyle habits: 1) not smoking; 2) being physically active (≥150 min/week of moderate or vigorous physical activity)"
    explanation: Physical activity (>=150 min/week) is a component of healthy lifestyle favorably associated with CVD risk factors in FH.
- name: Smoking Cessation
  description: >
    Smoking cessation is critically important for FH patients given the
    synergistic cardiovascular risk of smoking and hypercholesterolemia.
    Tobacco cessation counseling, nicotine replacement therapy, and
    pharmacotherapy (varenicline, bupropion) should be offered to all
    FH patients who smoke.
  treatment_term:
    preferred_term: tobacco cessation counseling
    term:
      id: MAXO:0000081
      label: tobacco cessation counseling
  target_mechanisms:
  - target: Premature Atherosclerotic Cardiovascular Disease
    treatment_effect: INHIBITS
    description: >
      Smoking cessation reduces an important modifier of FH-associated
      atherosclerotic event risk.
    evidence:
    - reference: PMID:17054804
      reference_title: "Relative risk for cardiovascular atherosclerotic events after smoking cessation: 6-9 years excess risk in individuals with familial hypercholesterolemia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The risk of atherosclerotic events due to smoking was estimated as 2.1 (95% confidence interval 1.5; 2.9)."
      explanation: >
        Smoking approximately doubles atherosclerotic event risk in FH, so
        cessation targets the cardiovascular event pathway.
  evidence:
  - reference: PMID:17054804
    reference_title: "Relative risk for cardiovascular atherosclerotic events after smoking cessation: 6-9 years excess risk in individuals with familial hypercholesterolemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "it appears to take 6 to 9 years before the excess risk is reduced to zero. The risk of atherosclerotic events due to smoking was estimated as 2.1 (95% confidence interval 1.5; 2.9)."
    explanation: Smoking doubles atherosclerotic event risk in FH; cessation reduces excess risk over 6-9 years, emphasizing the importance of early cessation.
  - reference: PMID:24404629
    reference_title: "Familial Hypercholesterolemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "no smoking"
    explanation: GeneReviews lists no smoking as prevention of primary manifestations in FH.
- name: Nutritional Counseling
  description: >
    Ongoing nutritional counseling by registered dietitians specializing in
    lipid management is recommended for all FH patients. Counseling covers
    practical dietary modifications, reading food labels, restaurant choices,
    recipe modification, and long-term adherence strategies. Especially
    important for patients on lomitapide who require strict low-fat diets.
  treatment_term:
    preferred_term: nutrition counseling
    term:
      id: MAXO:0000623
      label: nutrition counseling
  target_mechanisms:
  - target: Elevated Circulating LDL Cholesterol
    treatment_effect: MODULATES
    description: >
      Nutrition counseling operationalizes the heart-healthy diet used to
      manage LDL-C and CAD risk factors in FH.
    evidence:
    - reference: PMID:24404629
      reference_title: "Familial Hypercholesterolemia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Heart-healthy diet (including reduced intake of saturated fat and increased intake of soluble fiber to 10-20 g/day)"
      explanation: >
        The dietary prescription provides the target for counseling by a
        lipid-focused dietitian.
  evidence:
  - reference: PMID:24404629
    reference_title: "Familial Hypercholesterolemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Heart-healthy diet (including reduced intake of saturated fat and increased intake of soluble fiber to 10-20 g/day)"
    explanation: GeneReviews recommends specific dietary targets requiring nutritional counseling to implement effectively.
- name: Genetic Counseling and Cascade Screening
  description: >
    Cascade screening of first-degree relatives is recommended for early
    identification and treatment of affected family members. Genetic testing
    can identify the causative mutation and enable predictive testing in
    family members. The yield of cascade screening is approximately 50% for
    first-degree relatives of an affected individual (autosomal dominant).
    Early identification allows treatment initiation before significant
    atherosclerotic burden develops.
  treatment_term:
    preferred_term: genetic counseling
    term:
      id: MAXO:0000079
      label: genetic counseling
  target_mechanisms:
  - target: Premature Atherosclerotic Cardiovascular Disease
    treatment_effect: INHIBITS
    description: >
      Genetic counseling and cascade screening enable early diagnosis and
      treatment before atherosclerotic morbidity accumulates in relatives.
    evidence:
    - reference: PMID:24404629
      reference_title: "Familial Hypercholesterolemia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Early diagnosis and treatment of first-degree and second-degree relatives at risk for FH can reduce morbidity and mortality."
      explanation: >
        GeneReviews directly supports cascade identification and treatment as
        reducing downstream morbidity and mortality.
  evidence:
  - reference: PMID:29219151
    reference_title: "Familial hypercholesterolaemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Cascade screening can contribute to early diagnosis of the disease in family members of an affected individual, which is crucial because familial hypercholesterolaemia can be asymptomatic for decades."
    explanation: Cascade screening of family members is crucial for early diagnosis.
  - reference: DOI:10.1111/joim.13577
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Improving prevention, diagnosis, and treatment and making them more accessible to all patients will help reduce the lifelong burden of the disease."
    explanation: Emphasizes the importance of improving prevention and early diagnosis to reduce the lifelong burden of FH.
datasets:
references:
- reference: PMID:24404629
  title: "Familial Hypercholesterolemia."
  tags:
  - GeneReviews
  findings: []

📚

References & Deep Research

References

PMID:24404629

Familial Hypercholesterolemia.

No top-level findings curated for this source.

Deep Research

Falcon ▸

Disease Pathophysiology Research Template

Edison Scientific Literature 49 citations 2026-03-10T20:50:42.171217

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Pathophysiology Research Template

Target Disease

Disease Name: Familial Hypercholesterolemia
MONDO ID: (if available)
Category: Mendelian

Research Objectives

Please provide a comprehensive research report on the pathophysiology of Familial Hypercholesterolemia. Focus on the molecular and cellular mechanisms underlying disease progression.

Required Information

1. Core Pathophysiology

What are the primary pathophysiological mechanisms?
What molecular pathways are dysregulated?
What cellular processes are affected?

2. Key Molecular Players

Genes/Proteins: Which genes are causally involved or implicated?
Chemical Entities: What metabolites, drugs, or small molecules are relevant?
Cell Types: Which cell types are primarily affected?
Anatomical Locations: Which tissues/organs are involved?

3. Biological Processes (for GO annotation)

What biological processes (GO terms) are disrupted?
Consider: signaling pathways, metabolic processes, cellular responses, transport, etc.

4. Cellular Components

Where in the cell do key processes occur?
Consider: organelles, membrane compartments, extracellular space, etc.

5. Disease Progression

What is the sequence of events from initial trigger to clinical manifestation?
Are there distinct stages or phases?

6. Phenotypic Manifestations

What are the key clinical phenotypes?
How do they relate to the underlying mechanisms?

Citation Requirements

Cite primary literature (PMID preferred) for all mechanistic claims
Prioritize recent reviews and landmark papers
Include direct quotes where possible to support key statements

Output Format

Structure your response as a narrative that could be used to populate a disease knowledge base entry with: - Pathophysiology description - Gene/protein annotations with ontology terms (HGNC, GO) - Phenotype associations (HP terms) - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Evidence items with PMIDs

Familial Hypercholesterolemia (FH) Pathophysiology Research Report (Mendelian)

Target disease: Familial hypercholesterolemia (FH)

Disease identifiers: MONDO:0007750 / “hypercholesterolemia, familial, 1” and related clinical entity “familial hypercholesterolemia” (EFO_0004911). Homozygous FH: MONDO:0018328. (fularski2024unveilingfamilialhypercholesterolemia—review pages 4-5)

1) Key concepts and definitions (current understanding)

Familial hypercholesterolemia is a mostly autosomal-dominant disorder of LDL-cholesterol (LDL-C) metabolism caused by pathogenic variants that reduce hepatic LDL clearance (primarily via LDL receptor–mediated uptake), leading to high LDL-C from early life and markedly increased atherosclerotic cardiovascular disease (ASCVD) risk. (abifadel2023geneticandmolecular pages 1-2, fularski2024unveilingfamilialhypercholesterolemia—review pages 2-4)

HeFH vs HoFH: FH severity broadly reflects gene dosage and residual LDL receptor pathway activity: heterozygous FH (HeFH) results from one pathogenic allele, while homozygous/bi-allelic FH (HoFH) results from two pathogenic alleles (true homozygotes or compound heterozygotes; or bi-allelic variants across loci). HoFH is characterized by “markedly elevated levels of low-density lipoprotein cholesterol (LDL-C) from conception” with accelerated ASCVD and early mortality if untreated. (cuchel20232023updateon pages 1-2, fularski2024unveilingfamilialhypercholesterolemia—review pages 2-4)

Diagnostic concepts (DLCN): The Dutch Lipid Clinic Network criteria assign points using family history, clinical signs, and LDL-C strata (e.g., LDL-C >8.5 mmol/L / ≥325 mg/dL gives the highest LDL-C score), plus molecular confirmation (8 points for a functional mutation in LDLR/APOB/PCSK9). (fularski2024unveilingfamilialhypercholesterolemia—review pages 1-2)

2) Core pathophysiology (molecular and cellular mechanisms)

2.1 Primary pathophysiological mechanism: impaired LDL particle clearance

The unifying mechanism is reduced clearance of apoB-containing LDL particles, resulting in chronic elevation of circulating LDL-C. The principal molecular defect is disruption of LDLR pathway function—including receptor synthesis/trafficking, LDL binding, clathrin-mediated endocytosis, and receptor recycling. (taranto2023geneticheterogeneityof pages 2-4, fularski2024unveilingfamilialhypercholesterolemia—review pages 4-5)

LDLR functional classes: LDLR variants are commonly conceptualized as five mechanistic classes: absence of receptor, maturation/transport defects, impaired LDL binding, impaired endocytosis, and defective recycling. (taranto2023geneticheterogeneityof pages 2-4, suryawanshi2023familialhypercholesterolemiaa pages 2-4)

2.2 Dysregulated pathways

(a) Receptor-mediated endocytosis & endosomal sorting/lysosomal degradation: - PCSK9 is a secreted factor that binds LDLR and shifts LDLR fate away from recycling toward intracellular degradation. In a primary mechanistic study, the PCSK9–LDLR complex is described as “internalized via clathrin-mediated endocytosis and then routed to lysosomes.” (wang2012molecularcharacterizationof pages 1-2) - Qian et al. showed that “Secreted PCSK9 mediated cell surface LDLR degradation” and that PCSK9 endocytosis shows endosomal–lysosomal localization; knockdown of ARH/LDLRAP1 reduced PCSK9 endocytosis, supporting LDLR–ARH-mediated internalization as a route to receptor loss. (qian2007secretedpcsk9downregulates pages 1-2)

(b) LDL retention, modification, and inflammatory atherogenesis: Chronic LDL exposure increases deposition of LDL in the subendothelial arterial intima (especially at disturbed-flow sites), where LDL is oxidatively modified to oxLDL and triggers endothelial activation, monocyte recruitment, foam cell formation, and plaque progression. (fularski2024unveilingfamilialhypercholesterolemia—review pages 5-7, thangasparan2024unravellingthemechanisms pages 3-5)

2.3 Cellular processes affected

Endothelial activation/dysfunction → chemokine release and leukocyte adhesion/migration. (fularski2024unveilingfamilialhypercholesterolemia—review pages 5-7, thangasparan2024unravellingthemechanisms pages 3-5)
Monocyte-to-macrophage differentiation in intima and uptake of modified lipoproteins → foam cell formation. (fularski2024unveilingfamilialhypercholesterolemia—review pages 5-7, thangasparan2024unravellingthemechanisms pages 3-5)
Smooth muscle cell (SMC) migration/phenotypic switching and lipid uptake; SMCs contribute substantially to foam cell populations. (jin2024mechanismsmodulatingfoam pages 1-2, francis2023thegreatlyunderrepresented pages 1-2)
Sustained inflammation with cytokine secretion, necrotic core formation, fibrous cap remodeling, and potential plaque rupture. (fularski2024unveilingfamilialhypercholesterolemia—review pages 5-7, galindo2023lipidladenfoamcells pages 1-3)

3) Key molecular players (genes/proteins, cells, anatomy, chemicals)

Gene (HGNC)	Role / Inheritance	Molecular Defect / Mechanism	Key Mechanistic Quote	Citation
LDLR	Main causative gene; Autosomal Dominant (AD)	Dysfunction classified into 5 classes: defects in synthesis, ER-to-Golgi transport, LDL ligand binding, internalization, or recycling.	"LDLR defects occur at multiple steps: post-translational transport... impaired LDL binding... reduced clathrin-coated pit–mediated endocytosis, and abnormal LDLR recycling"	Fularski et al., 2024 (fularski2024unveilingfamilialhypercholesterolemia—review pages 4-5)
APOB	Ligand for LDLR; Autosomal Dominant (AD)	Missense mutations (e.g., R3500Q) reduce the affinity of the ApoB protein on LDL particles for the LDLR, preventing uptake.	"pathogenic variants that impair ApoB binding to LDLR, notably in exons 26 and 29"	Taranto & Fortunato, 2023 (taranto2023geneticheterogeneityof pages 2-4)
PCSK9	Regulator of LDLR stability; Autosomal Dominant (AD)	Gain-of-function variants increase LDLR degradation. PCSK9 binds cell-surface LDLR and directs the complex to lysosomes instead of recycling.	"[PCSK9] binds the extracellular domain of the LDLR... internalized via clathrin-mediated endocytosis and then routed to lysosomes via a mechanism that does not require ubiquitination"	Wang et al., 2012 (wang2012molecularcharacterizationof pages 1-2)
LDLRAP1 (ARH)	Endocytic adaptor; Autosomal Recessive (AR)	Loss of function prevents the LDLR-LDL complex from clustering in clathrin-coated pits for internalization.	"ARH is required for endocytosis of the LDLR–LDL complex via its interaction with clathrin"	Maxwell et al., 2005 (maxwell2005overexpressionofpcsk9 pages 1-2)
APOE	Ligand (rare cause); Autosomal Dominant (AD)	Rare variants (e.g., p.Leu167del) result in an FH-like phenotype (FH phenocopy) via impaired clearance.	"a specific APOE variant was described as causative of FH, contributing to increase FH genetic heterogeneity"	Taranto & Fortunato, 2023 (taranto2023geneticheterogeneityof pages 2-4)

Table: This table summarizes the primary genes associated with Familial Hypercholesterolemia, their inheritance patterns, specific molecular defects, and direct mechanistic evidence from primary literature.

3.1 High-confidence causal genes/proteins

LDLR (HGNC:6547): impaired LDL binding/endocytosis/recycling, reducing LDL uptake. (fularski2024unveilingfamilialhypercholesterolemia—review pages 4-5, taranto2023geneticheterogeneityof pages 2-4)
APOB (HGNC:603): LDL ligand; variants reduce LDLR binding. (taranto2023geneticheterogeneityof pages 2-4, fularski2024unveilingfamilialhypercholesterolemia—review pages 4-5)
PCSK9 (HGNC:20001): binds LDLR and promotes lysosomal routing/degradation. (wang2012molecularcharacterizationof pages 1-2, qian2007secretedpcsk9downregulates pages 1-2)
LDLRAP1/ARH (HGNC:18640): adaptor for clathrin-mediated internalization of LDLR–LDL complexes; its deficiency causes autosomal recessive hypercholesterolemia. (maxwell2005overexpressionofpcsk9 pages 1-2, canuel2013proproteinconvertasesubtilisinkexin pages 1-2)
APOE (HGNC:613): rare causative variants/heterogeneity contributor. (taranto2023geneticheterogeneityof pages 2-4, fularski2024unveilingfamilialhypercholesterolemia—review pages 2-4)

3.2 Key cell types (mechanistic involvement)

Hepatocytes: site of LDLR-mediated LDL clearance and key therapeutic target for LDLR upregulation and PCSK9 inhibition. (qian2007secretedpcsk9downregulates pages 1-2, suryawanshi2023familialhypercholesterolemiaa pages 2-4)
Endothelial cells: barrier/transcytosis and inflammatory activation. (fularski2024unveilingfamilialhypercholesterolemia—review pages 5-7, thangasparan2024unravellingthemechanisms pages 3-5)
Monocyte-derived macrophages: major foam cell source via scavenger receptor uptake of oxLDL. (fularski2024unveilingfamilialhypercholesterolemia—review pages 5-7, thangasparan2024unravellingthemechanisms pages 3-5)
Vascular smooth muscle cells (VSMCs/SMCs): major contributor to intimal thickening and foam cell pool; recent syntheses note “more than half of the foam cells present in atherosclerotic lesions are of SMC origin.” (jin2024mechanismsmodulatingfoam pages 1-2, francis2023thegreatlyunderrepresented pages 1-2)

3.3 Anatomical locations

Liver (LDLR-mediated clearance). (suryawanshi2023familialhypercholesterolemiaa pages 2-4)
Arterial intima / subendothelial space (LDL deposition/oxLDL formation/foam cells). (fularski2024unveilingfamilialhypercholesterolemia—review pages 5-7, jin2024mechanismsmodulatingfoam pages 1-2)
Aortic valve/aorta (notably in HoFH: aortic disease/stenosis). (cuchel20232023updateon pages 1-2)
Tendons/skin/cornea (xanthomas, corneal arcus). (fularski2024unveilingfamilialhypercholesterolemia—review pages 4-5, cuchel20232023updateon pages 1-2)

3.4 Chemical entities / therapeutically relevant molecules

LDL-C: dominant causal exposure in FH atherogenesis. (fularski2024unveilingfamilialhypercholesterolemia—review pages 5-7)
Oxidized LDL (oxLDL): key modified particle driving inflammation and foam cell formation. (thangasparan2024unravellingthemechanisms pages 3-5, duan2023attenuatinglipidmetabolism pages 1-2)
Therapies: statins, ezetimibe, PCSK9 inhibitors, inclisiran, bempedoic acid, evinacumab, lomitapide, LDL apheresis. (fularski2024unveilingfamilialhypercholesterolemia—review pages 7-9, dingman2024evinacumabmechanismof pages 2-4, suryawanshi2023familialhypercholesterolemiaa pages 8-9)

4) Biological processes and cellular components (GO-oriented)

A knowledge-base oriented mapping is provided below.

Category	Entity / Term	Ontology ID	Context / Source
Disease Identifiers	Familial Hypercholesterolemia	MONDO:0007750	(taranto2023geneticheterogeneityof pages 2-4, fularski2024unveilingfamilialhypercholesterolemia—review pages 4-5)
	Homozygous Familial Hypercholesterolemia	MONDO:0018328	(cuchel20232023updateon pages 1-2, fularski2024unveilingfamilialhypercholesterolemia—review pages 2-4)
Key Genes	LDLR (Low Density Lipoprotein Receptor)	HGNC:6547	(taranto2023geneticheterogeneityof pages 2-4, wang2012molecularcharacterizationof pages 1-2)
	APOB (Apolipoprotein B)	HGNC:603	(taranto2023geneticheterogeneityof pages 2-4, fularski2024unveilingfamilialhypercholesterolemia—review pages 4-5)
	PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9)	HGNC:20001	(taranto2023geneticheterogeneityof pages 2-4, qian2007secretedpcsk9downregulates pages 1-2)
	LDLRAP1 (LDLR Adaptor Protein 1)	HGNC:18640	(taranto2023geneticheterogeneityof pages 2-4, canuel2013proproteinconvertasesubtilisinkexin pages 1-2)
	APOE (Apolipoprotein E)	HGNC:613	(taranto2023geneticheterogeneityof pages 2-4, abifadel2023geneticandmolecular pages 1-2)
Biological Processes	Receptor-mediated endocytosis	GO:0006898	(qian2007secretedpcsk9downregulates pages 1-2, wang2012molecularcharacterizationof pages 1-2)
	Low-density lipoprotein particle clearance	GO:0034383	(taranto2023geneticheterogeneityof pages 2-4, suryawanshi2023familialhypercholesterolemiaa pages 2-4)
	Cholesterol homeostasis	GO:0042632	(srivastava2023areviewof pages 1-2)
Cellular Components	Clathrin-coated pit	GO:0005905	(canuel2013proproteinconvertasesubtilisinkexin pages 1-2, wang2012molecularcharacterizationof pages 1-2)
	Plasma membrane	GO:0005886	(wang2012molecularcharacterizationof pages 1-2)
	Lysosome	GO:0005764	(jang2020cyclaseassociatedprotein1 pages 14-15, wang2012molecularcharacterizationof pages 1-2)
Phenotypes	Hypercholesterolemia	HP:0003124	(fularski2024unveilingfamilialhypercholesterolemia—review pages 4-5, abifadel2023geneticandmolecular pages 1-2)
	Tendon xanthoma	HP:0001388	(fularski2024unveilingfamilialhypercholesterolemia—review pages 4-5, abifadel2023geneticandmolecular pages 1-2)
	Corneal arcus	HP:0001023	(fularski2024unveilingfamilialhypercholesterolemia—review pages 4-5, abifadel2023geneticandmolecular pages 1-2)
	Premature coronary artery atherosclerosis	HP:0004416	(fularski2024unveilingfamilialhypercholesterolemia—review pages 4-5, cuchel20232023updateon pages 1-2)
Cell Types	Hepatocyte	CL:0000182	(suryawanshi2023familialhypercholesterolemiaa pages 2-4, qian2007secretedpcsk9downregulates pages 1-2)
	Macrophage (Foam cell precursor)	CL:0000235	(fularski2024unveilingfamilialhypercholesterolemia—review pages 5-7, thangasparan2024unravellingthemechanisms pages 3-5)
	Smooth muscle cell (Foam cell source)	CL:0000192	(jin2024mechanismsmodulatingfoam pages 1-2, francis2023thegreatlyunderrepresented pages 1-2)
	Endothelial cell	CL:0000115	(thangasparan2024unravellingthemechanisms pages 3-5, galindo2023lipidladenfoamcells pages 1-3)
Anatomy	Liver	UBERON:0002107	(suryawanshi2023familialhypercholesterolemiaa pages 2-4)
	Tunica intima (Arterial intima)	UBERON:0002523	(fularski2024unveilingfamilialhypercholesterolemia—review pages 5-7, jin2024mechanismsmodulatingfoam pages 1-2)
	Tendon	UBERON:0000043	(fularski2024unveilingfamilialhypercholesterolemia—review pages 4-5)
Chemicals / Drugs	Low-density lipoprotein cholesterol	CHEBI:47774	(fularski2024unveilingfamilialhypercholesterolemia—review pages 4-5, suryawanshi2023familialhypercholesterolemiaa pages 2-4)
	Statins (HMG-CoA reductase inhibitors)	CHEBI:87631	(srivastava2023areviewof pages 1-2, fularski2024unveilingfamilialhypercholesterolemia—review pages 7-9)
	Ezetimibe	CHEBI:63553	(fularski2024unveilingfamilialhypercholesterolemia—review pages 7-9)
	Evinacumab	[monoclonal antibody]	(dingman2024evinacumabmechanismof pages 2-4, beliard2024evinacumabandcardiovascular pages 1-3)
	Inclisiran	[siRNA]	(fularski2024unveilingfamilialhypercholesterolemia—review pages 7-9)

Table: This table maps key concepts in Familial Hypercholesterolemia (FH) to standard biomedical ontologies (MONDO, HGNC, GO, HP, CL, UBERON, CHEBI) to support knowledge graph integration.

Key disrupted processes include receptor-mediated endocytosis (LDLR internalization), LDL particle clearance, and cholesterol homeostasis, while key cellular compartments include clathrin-coated pits, endosomes, and lysosomes that govern receptor/ligand trafficking and degradation. (wang2012molecularcharacterizationof pages 1-2, canuel2013proproteinconvertasesubtilisinkexin pages 1-2)

5) Disease progression: sequence of events from trigger to clinical disease

Stage 1: Genetic lesion → impaired LDL clearance from birth

Pathogenic variants in LDLR/APOB/PCSK9/LDLRAP1 (and rarer loci) reduce LDL uptake or increase receptor degradation, causing lifelong LDL-C elevation (“from conception” in HoFH). (cuchel20232023updateon pages 1-2, fularski2024unveilingfamilialhypercholesterolemia—review pages 2-4)

Stage 2: Cumulative LDL exposure → arterial LDL deposition and oxidation

At disturbed-flow regions (bifurcations/curvatures), endothelial barrier dysfunction facilitates LDL deposition in the subendothelial space; chronic high LDL-C increases intimal LDL accumulation. (fularski2024unveilingfamilialhypercholesterolemia—review pages 5-7)

Stage 3: Endothelial activation → immune cell recruitment

Endothelial damage promotes chemoattractant release, monocyte recruitment, and entry into the intima. (fularski2024unveilingfamilialhypercholesterolemia—review pages 5-7, thangasparan2024unravellingthemechanisms pages 3-5)

Stage 4: Foam cell formation and plaque growth

In the intima, monocytes differentiate into macrophages that generate oxidants, producing oxLDL; “Ox-LDL-C… is then absorbed via macrophages… [leading to] foam cells,” which amplify inflammation and drive lesion growth. (fularski2024unveilingfamilialhypercholesterolemia—review pages 5-7)

Parallel SMC mechanisms are increasingly recognized: diffuse intimal thickening (pre–fatty streak) is enriched in lipid-loaded SMCs and proteoglycans, and SMCs can constitute the majority of foam cells in advanced plaques. (jin2024mechanismsmodulatingfoam pages 1-2, francis2023thegreatlyunderrepresented pages 1-2)

Stage 5: Complications

Progressive plaque burden yields premature coronary heart disease, and in HoFH, frequent aortic disease/calcific aortic stenosis and early cardiovascular events. (cuchel20232023updateon pages 1-2, fularski2024unveilingfamilialhypercholesterolemia—review pages 4-5)

6) Phenotypic manifestations (clinical phenotypes and mechanistic links)

Key phenotypes reflect (i) systemic LDL-C excess and (ii) tissue lipid deposition and atherosclerosis: - Hypercholesterolemia (HP:0003124) from impaired clearance. (fularski2024unveilingfamilialhypercholesterolemia—review pages 4-5) - Tendon/skin xanthomas from cholesterol deposition; correlate with severe LDL burden. (fularski2024unveilingfamilialhypercholesterolemia—review pages 4-5, cuchel20232023updateon pages 1-2) - Corneal arcus. (fularski2024unveilingfamilialhypercholesterolemia—review pages 4-5) - Premature ASCVD (coronary, carotid, peripheral), with vascular inflammation and foam cell biology as key mediators. (fularski2024unveilingfamilialhypercholesterolemia—review pages 5-7, galindo2023lipidladenfoamcells pages 1-3)

7) Recent developments and latest research (prioritizing 2023–2024)

7.1 Updated disease architecture and genetic heterogeneity

Recent syntheses emphasize expanded genetic heterogeneity (rare APOE causation; LDLRAP1 recessive FH; phenocopies and modifiers) and phenotype variability even for identical genotypes. (taranto2023geneticheterogeneityof pages 2-4, abifadel2023geneticandmolecular pages 1-2)

7.2 Increasing emphasis on SMC biology and extracellular matrix in early atherogenesis

2023–2024 reviews highlight that SMCs and their proteoglycans dominate early human intimal thickening and contribute heavily to foam cell pools. This refines purely macrophage-centric models and suggests new mechanisms/targets centered on LDL retention and SMC phenotypic switching. (jin2024mechanismsmodulatingfoam pages 1-2, francis2023thegreatlyunderrepresented pages 1-2)

7.3 LDLR-independent LDL-C lowering for HoFH (ANGPTL3 inhibition)

Evinacumab (anti-ANGPTL3) is emphasized as an LDLR-independent therapy that can reduce LDL-C by ~50% at 15 mg/kg IV every 4 weeks across adult/adolescent/pediatric HoFH, addressing the unmet need in patients with minimal LDLR function. (dingman2024evinacumabmechanismof pages 2-4, wiegman2024evinacumabforpediatric pages 1-2)

8) Current applications and real-world implementations

8.1 Screening and clinical management

Consensus/guideline sources emphasize screening and multi-pronged lipid-lowering therapy initiated at diagnosis for HoFH, ideally via multidisciplinary care. (cuchel20232023updateon pages 1-2, cuchel20232023updateon media 7c520ae7)

8.2 Guideline-driven lipid-lowering strategy (implementation)

A practical approach summarized in recent FH review/guideline synthesis: high-intensity statin plus ezetimibe early; then PCSK9 inhibitors for those not reaching LDL-C goals; the ACC (2022) is reported to consider inclisiran or bempedoic acid if further LDL-C reduction is needed; apheresis remains an option for refractory cases under specialist care. (fularski2024unveilingfamilialhypercholesterolemia—review pages 7-9)

9) Statistics and recent data (2023–2024)

Topic	Key Data / Statistics	Notes / Real-World Implications	Source
Prevalence	HeFH: ~1:250–300 HoFH: ~1:250,000–360,000	HoFH estimates vary by region (e.g., ~1:300,000). Higher prevalence in founder populations.	Fularski et al., 2024 (fularski2024unveilingfamilialhypercholesterolemia—review pages 1-2); Taranto et al., 2023 (taranto2023geneticheterogeneityof pages 2-4)
Diagnostic Thresholds (DLCN)	LDL-C >8.5 mmol/L (>325 mg/dL): 8 pts LDL-C 6.5–8.4 mmol/L (251–325 mg/dL): 5 pts	Based on Dutch Lipid Clinic Network criteria. Definite FH score >8.	Fularski et al., 2024 (fularski2024unveilingfamilialhypercholesterolemia—review pages 1-2)
CAD Risk	Odds Ratio: 10–20x higher vs non-FH	Highlights the critical need for early diagnosis and aggressive lipid lowering.	Harada-Shiba et al., 2023 (haradashiba2023guidelinesforthe pages 1-2)
Treatment Targets (Adult)	High Risk: LDL-C <1.8 mmol/L (<70 mg/dL) Very High Risk: LDL-C <1.4 mmol/L (<55 mg/dL)	Both targets also require ≥50% reduction from baseline. Based on ESC/EAS guidelines.	Fularski et al., 2024 (fularski2024unveilingfamilialhypercholesterolemia—review pages 7-9)
Pediatric Targets	LDL-C <3.5 mmol/L (<135 mg/dL)	Recommended target for children >10 years old initiating statins.	Fularski et al., 2024 (fularski2024unveilingfamilialhypercholesterolemia—review pages 7-9)
Evinacumab (Adult HoFH)	LDL-C reduction: 56% (sustained ~3.5 yrs) CV Events: 0% vs 24% in controls	First long-term real-world data showing sustained efficacy and improved CV event-free survival.	Béliard et al., 2024 (beliard2024evinacumabandcardiovascular pages 1-3)
Evinacumab (Pediatric HoFH)	LDL-C reduction: -48.3% at week 24	Efficacy demonstrated in children aged 5–11 years with LDL-C >130 mg/dL despite optimized therapy.	Wiegman et al., 2024 (wiegman2024evinacumabforpediatric pages 1-2)

Table: A summary of recent epidemiological data, diagnostic thresholds, guideline targets, and therapeutic outcomes for Familial Hypercholesterolemia from 2023-2024 literature.

Selected highlights: - Prevalence: HeFH ~1:250–300; HoFH ~1:250,000–360,000. (fularski2024unveilingfamilialhypercholesterolemia—review pages 1-2) - FH CAD risk: odds ratio reported ~10–20× compared with non-FH. (haradashiba2023guidelinesforthe pages 1-2) - Evinacumab real-world long-term cohort (HoFH): LDL-C reduction 56% at 6 months sustained over median 3.5 years; 0 events on evinacumab vs 24% experiencing events in matched controls (4 years). (beliard2024evinacumabandcardiovascular pages 1-3)

10) Expert opinions / authoritative analysis

A central expert consensus is that lifetime LDL-C exposure drives premature ASCVD in FH and mandates early, intensive, combination therapy. In HoFH, the EAS consensus emphasizes immediate “multi-prong lipid lowering therapy starting at diagnosis,” including apheresis, oral agents, and biologics, and underscores underdiagnosis/undertreatment and inequities across countries. (cuchel20232023updateon pages 1-2, cuchel20232023updateon media 7c520ae7)

11) Evidence items (mechanistic statements; PMID where available in retrieved text)

PCSK9 → LDLR lysosomal degradation (primary mechanistic studies)

Qian et al., J Lipid Res (2007-07). DOI: https://doi.org/10.1194/jlr.M700071-JLR200. Key mechanistic statements include “Secreted PCSK9 mediated cell surface LDLR degradation…” and support for LDLR–ARH-mediated endocytosis and endosomal–lysosomal localization. PMID not shown in retrieved excerpt. (qian2007secretedpcsk9downregulates pages 1-2)
Wang et al., J Lipid Res (2012-09). DOI: https://doi.org/10.1194/jlr.M028563. Key mechanistic statement: PCSK9–LDLR complex “internalized via clathrin-mediated endocytosis and then routed to lysosomes.” PMID not shown in retrieved excerpt. (wang2012molecularcharacterizationof pages 1-2)
Canuel et al., PLoS ONE (2013-05). DOI: https://doi.org/10.1371/journal.pone.0064145. Summarizes ARH binding to LDLR NPVY motif and clathrin/AP-2 for recruitment into clathrin-coated pits; notes endosomes/lysosomes as the degradation destination. PMID not shown in retrieved excerpt. (canuel2013proproteinconvertasesubtilisinkexin pages 1-2)

LDL oxidation and foam cell biology (recent mechanistic reviews)

Thangasparan et al., IJMS (2024-12). DOI: https://doi.org/10.3390/ijms252413292. Details oxLDL-driven endothelial dysfunction, monocyte recruitment, scavenger receptor uptake, foam cell formation, and inflammatory perpetuation. (thangasparan2024unravellingthemechanisms pages 3-5, thangasparan2024unravellingthemechanisms pages 2-3)
Duan et al., Frontiers in Pharmacology (2023-03). DOI: https://doi.org/10.3389/fphar.2023.1161657. Describes ROS-driven LDL oxidation and oxLDL effects on endothelium and smooth muscle migration/proliferation. (duan2023attenuatinglipidmetabolism pages 1-2)

Note on PMID coverage

Several retrieved primary papers did not display PMIDs in the extracted text chunks; however, some PMIDs are explicitly visible in a secondary mechanistic excerpt list (e.g., Fisher et al. PMID: 17493938; Saavedra et al. PMID: 23105118), indicating where PubMed identifiers exist even if not consistently shown in all excerpts. (poirier2016traffickingdynamicsof pages 22-23, poirier2016traffickingdynamicsof pages 24-24)

12) Visual evidence

The EAS 2023 HoFH consensus graphical abstract summarizes genetics (LDLR/APOB/PCSK9/LDLRAP1), clinical features, and the multi-pronged treatment framework for HoFH, serving as a high-level schematic of disease pathophysiology and management. (cuchel20232023updateon media 7c520ae7)

References

(fularski2024unveilingfamilialhypercholesterolemia—review pages 4-5): Piotr Fularski, Joanna Hajdys, Gabriela Majchrowicz, Magdalena Stabrawa, Ewelina Młynarska, Jacek Rysz, and Beata Franczyk. Unveiling familial hypercholesterolemia—review, cardiovascular complications, lipid-lowering treatment and its efficacy. International Journal of Molecular Sciences, 25:1637, Jan 2024. URL: https://doi.org/10.3390/ijms25031637, doi:10.3390/ijms25031637. This article has 25 citations.
(abifadel2023geneticandmolecular pages 1-2): Marianne Abifadel and Catherine Boileau. Genetic and molecular architecture of familial hypercholesterolemia. Journal of Internal Medicine, 293:144-165, Oct 2023. URL: https://doi.org/10.1111/joim.13577, doi:10.1111/joim.13577. This article has 153 citations and is from a domain leading peer-reviewed journal.
(fularski2024unveilingfamilialhypercholesterolemia—review pages 2-4): Piotr Fularski, Joanna Hajdys, Gabriela Majchrowicz, Magdalena Stabrawa, Ewelina Młynarska, Jacek Rysz, and Beata Franczyk. Unveiling familial hypercholesterolemia—review, cardiovascular complications, lipid-lowering treatment and its efficacy. International Journal of Molecular Sciences, 25:1637, Jan 2024. URL: https://doi.org/10.3390/ijms25031637, doi:10.3390/ijms25031637. This article has 25 citations.
(cuchel20232023updateon pages 1-2): Marina Cuchel, Frederick J Raal, Robert A Hegele, Khalid Al-Rasadi, Marcello Arca, Maurizio Averna, Eric Bruckert, Tomas Freiberger, Daniel Gaudet, Mariko Harada-Shiba, Lisa C Hudgins, Meral Kayikcioglu, Luis Masana, Klaus G Parhofer, Jeanine E Roeters van Lennep, Raul D Santos, Erik S G Stroes, Gerald F Watts, Albert Wiegman, Jane K Stock, Lale S Tokgözoğlu, Alberico L Catapano, and Kausik K Ray. 2023 update on european atherosclerosis society consensus statement on homozygous familial hypercholesterolaemia: new treatments and clinical guidance. European Heart Journal, 44:2277-2291, May 2023. URL: https://doi.org/10.1093/eurheartj/ehad197, doi:10.1093/eurheartj/ehad197. This article has 345 citations and is from a highest quality peer-reviewed journal.
(fularski2024unveilingfamilialhypercholesterolemia—review pages 1-2): Piotr Fularski, Joanna Hajdys, Gabriela Majchrowicz, Magdalena Stabrawa, Ewelina Młynarska, Jacek Rysz, and Beata Franczyk. Unveiling familial hypercholesterolemia—review, cardiovascular complications, lipid-lowering treatment and its efficacy. International Journal of Molecular Sciences, 25:1637, Jan 2024. URL: https://doi.org/10.3390/ijms25031637, doi:10.3390/ijms25031637. This article has 25 citations.
(taranto2023geneticheterogeneityof pages 2-4): Maria Donata Di Taranto and Giuliana Fortunato. Genetic heterogeneity of familial hypercholesterolemia: repercussions for molecular diagnosis. International Journal of Molecular Sciences, 24:3224, Feb 2023. URL: https://doi.org/10.3390/ijms24043224, doi:10.3390/ijms24043224. This article has 47 citations.
(suryawanshi2023familialhypercholesterolemiaa pages 2-4): Yasha N Suryawanshi and Rupesh A Warbhe. Familial hypercholesterolemia: a literature review of the pathophysiology and current and novel treatments. Cureus, Nov 2023. URL: https://doi.org/10.7759/cureus.49121, doi:10.7759/cureus.49121. This article has 17 citations.
(wang2012molecularcharacterizationof pages 1-2): Yan Wang, Yongcheng Huang, Helen H. Hobbs, and Jonathan C. Cohen. Molecular characterization of proprotein convertase subtilisin/kexin type 9-mediated degradation of the ldlr. Journal of Lipid Research, 53:1932-1943, Sep 2012. URL: https://doi.org/10.1194/jlr.m028563, doi:10.1194/jlr.m028563. This article has 141 citations and is from a peer-reviewed journal.
(qian2007secretedpcsk9downregulates pages 1-2): Yue-Wei Qian, Robert J. Schmidt, Youyan Zhang, Shaoyou Chu, Aimin Lin, He Wang, Xiliang Wang, Thomas P. Beyer, William R. Bensch, Weiming Li, Mariam E. Ehsani, Deshun Lu, Robert J. Konrad, Patrick I. Eacho, David E. Moller, Sotirios K. Karathanasis, and Guoqing Cao. Secreted pcsk9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis published, jlr papers in press, april 20, 2007. Journal of Lipid Research, 48:1488-1498, Jul 2007. URL: https://doi.org/10.1194/jlr.m700071-jlr200, doi:10.1194/jlr.m700071-jlr200. This article has 308 citations and is from a peer-reviewed journal.
(fularski2024unveilingfamilialhypercholesterolemia—review pages 5-7): Piotr Fularski, Joanna Hajdys, Gabriela Majchrowicz, Magdalena Stabrawa, Ewelina Młynarska, Jacek Rysz, and Beata Franczyk. Unveiling familial hypercholesterolemia—review, cardiovascular complications, lipid-lowering treatment and its efficacy. International Journal of Molecular Sciences, 25:1637, Jan 2024. URL: https://doi.org/10.3390/ijms25031637, doi:10.3390/ijms25031637. This article has 25 citations.
(thangasparan2024unravellingthemechanisms pages 3-5): Sahsikala Thangasparan, Yusof Kamisah, Azizah Ugusman, Nur Najmi Mohamad Anuar, and Nurul ‘Izzah Ibrahim. Unravelling the mechanisms of oxidised low-density lipoprotein in cardiovascular health: current evidence from in vitro and in vivo studies. International Journal of Molecular Sciences, 25:13292, Dec 2024. URL: https://doi.org/10.3390/ijms252413292, doi:10.3390/ijms252413292. This article has 24 citations.
(jin2024mechanismsmodulatingfoam pages 1-2): Hong Jin, Robert C. Bauer, La Chica, MT Lhoëst, La Chica Lhoëst, Martinez, Claudi Garcia, Polishchuk Piñero Vilades Guerra Sanz Rotllan Escolà-Gil Benitez-Amaro, Llorente-Cortés. This, M. T. La, Chica Lhoëst, A. Martínez, L. Claudí, E. Garcia, A. Benitez-Amaro, A. Polishchuk, J. Pinero, D. Viladés, J. M. Guerra, F. Sanz, N. Rotllan, J. Escolà-Gil, and V. Llorente-Cortés. Mechanisms modulating foam cell formation in the arterial intima: exploring new therapeutic opportunities in atherosclerosis. Frontiers in Cardiovascular Medicine, Jun 2024. URL: https://doi.org/10.3389/fcvm.2024.1381520, doi:10.3389/fcvm.2024.1381520. This article has 17 citations and is from a peer-reviewed journal.
(francis2023thegreatlyunderrepresented pages 1-2): Gordon A. Francis. The greatly under-represented role of smooth muscle cells in atherosclerosis. Current Atherosclerosis Reports, 25:741-749, Sep 2023. URL: https://doi.org/10.1007/s11883-023-01145-8, doi:10.1007/s11883-023-01145-8. This article has 35 citations and is from a peer-reviewed journal.
(galindo2023lipidladenfoamcells pages 1-3): Cristi L Galindo, Saifur R Khan, Xiangyu Zhang, Yu-Sheng Yeh, Ziyang Liu, and Babak Razani. Lipid-laden foam cells in the pathology of atherosclerosis: shedding light on new therapeutic targets. Expert Opinion on Therapeutic Targets, 27:1231-1245, Nov 2023. URL: https://doi.org/10.1080/14728222.2023.2288272, doi:10.1080/14728222.2023.2288272. This article has 47 citations and is from a peer-reviewed journal.
(maxwell2005overexpressionofpcsk9 pages 1-2): Kara N. Maxwell, Edward A. Fisher, and Jan L. Breslow. Overexpression of pcsk9 accelerates the degradation of the ldlr in a post-endoplasmic reticulum compartment. Proceedings of the National Academy of Sciences of the United States of America, 102 6:2069-74, Feb 2005. URL: https://doi.org/10.1073/pnas.0409736102, doi:10.1073/pnas.0409736102. This article has 550 citations and is from a highest quality peer-reviewed journal.
(canuel2013proproteinconvertasesubtilisinkexin pages 1-2): Maryssa Canuel, Xiaowei Sun, Marie-Claude Asselin, Eustache Paramithiotis, Annik Prat, and Nabil G. Seidah. Proprotein convertase subtilisin/kexin type 9 (pcsk9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (lrp-1). PLoS ONE, 8:e64145, May 2013. URL: https://doi.org/10.1371/journal.pone.0064145, doi:10.1371/journal.pone.0064145. This article has 276 citations and is from a peer-reviewed journal.
(duan2023attenuatinglipidmetabolism pages 1-2): Huxinyue Duan, Pan Song, Ruolan Li, Hong-guang Su, and Lisha He. Attenuating lipid metabolism in atherosclerosis: the potential role of anti-oxidative effects on low-density lipoprotein of herbal medicines. Frontiers in Pharmacology, Mar 2023. URL: https://doi.org/10.3389/fphar.2023.1161657, doi:10.3389/fphar.2023.1161657. This article has 34 citations.
(fularski2024unveilingfamilialhypercholesterolemia—review pages 7-9): Piotr Fularski, Joanna Hajdys, Gabriela Majchrowicz, Magdalena Stabrawa, Ewelina Młynarska, Jacek Rysz, and Beata Franczyk. Unveiling familial hypercholesterolemia—review, cardiovascular complications, lipid-lowering treatment and its efficacy. International Journal of Molecular Sciences, 25:1637, Jan 2024. URL: https://doi.org/10.3390/ijms25031637, doi:10.3390/ijms25031637. This article has 25 citations.
(dingman2024evinacumabmechanismof pages 2-4): Robert Dingman, Sébastien Bihorel, Viktoria Gusarova, Jeanne Mendell, and Robert Pordy. Evinacumab: mechanism of action, clinical, and translational science. Clinical and Translational Science, Jun 2024. URL: https://doi.org/10.1111/cts.13836, doi:10.1111/cts.13836. This article has 17 citations.
(suryawanshi2023familialhypercholesterolemiaa pages 8-9): Yasha N Suryawanshi and Rupesh A Warbhe. Familial hypercholesterolemia: a literature review of the pathophysiology and current and novel treatments. Cureus, Nov 2023. URL: https://doi.org/10.7759/cureus.49121, doi:10.7759/cureus.49121. This article has 17 citations.
(srivastava2023areviewof pages 1-2): Rai Ajit K. Srivastava. A review of progress on targeting ldl receptor-dependent and -independent pathways for the treatment of hypercholesterolemia, a major risk factor of ascvd. Cells, 12:1648, Jun 2023. URL: https://doi.org/10.3390/cells12121648, doi:10.3390/cells12121648. This article has 42 citations.
(jang2020cyclaseassociatedprotein1 pages 14-15): Hyun-Duk Jang, Sang Eun Lee, Jimin Yang, Hyun-Chae Lee, Dasom Shin, Hwan Lee, Jaewon Lee, Sooryeonhwa Jin, Soungchan Kim, Seung Ji Lee, Jihye You, Hyun-Woo Park, Ky-Youb Nam, Sang-Hak Lee, Sahng Wook Park, Jin-Soo Kim, Sang-Yeob Kim, Yoo-Wook Kwon, Soo Heon Kwak, Han-Mo Yang, and Hyo-Soo Kim. Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9. European Heart Journal, 41:239-252, Aug 2020. URL: https://doi.org/10.1093/eurheartj/ehz566, doi:10.1093/eurheartj/ehz566. This article has 112 citations and is from a highest quality peer-reviewed journal.
(beliard2024evinacumabandcardiovascular pages 1-3): Sophie Béliard, Samir Saheb, Stéphanie Litzler-Renault, Alexandre Vimont, René Valero, Éric Bruckert, Michel Farnier, and Antonio Gallo. Evinacumab and cardiovascular outcome in patients with homozygous familial hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 44:1447-1454, Jun 2024. URL: https://doi.org/10.1161/atvbaha.123.320609, doi:10.1161/atvbaha.123.320609. This article has 25 citations and is from a domain leading peer-reviewed journal.
(wiegman2024evinacumabforpediatric pages 1-2): MD PhD Albert Wiegman, MD PhD Albert Wiegman, MD Susanne Greber-Platzer, PharmD Shazia Ali, MD M. Doortje Reijman, MD Eliot A Brinton, MD Min-Ji Charng, PhD Shubha Srinivasan, PhD Carissa Baker-Smith Md, Mph Seth Baum Md, MD Julie A. Brothers, MD Jacob Hartz, M. P. M. Md, MD Jeanne Mendell, Mph Sébastien Bihorel PhD, P. Banerjee, PhD Richard T. George, MD Boaz Hirshberg, and MD Robert Pordy. Evinacumab for pediatric patients with homozygous familial hypercholesterolemia. Circulation, 149:343-353, Jan 2024. URL: https://doi.org/10.1161/circulationaha.123.065529, doi:10.1161/circulationaha.123.065529. This article has 98 citations and is from a highest quality peer-reviewed journal.
(cuchel20232023updateon media 7c520ae7): Marina Cuchel, Frederick J Raal, Robert A Hegele, Khalid Al-Rasadi, Marcello Arca, Maurizio Averna, Eric Bruckert, Tomas Freiberger, Daniel Gaudet, Mariko Harada-Shiba, Lisa C Hudgins, Meral Kayikcioglu, Luis Masana, Klaus G Parhofer, Jeanine E Roeters van Lennep, Raul D Santos, Erik S G Stroes, Gerald F Watts, Albert Wiegman, Jane K Stock, Lale S Tokgözoğlu, Alberico L Catapano, and Kausik K Ray. 2023 update on european atherosclerosis society consensus statement on homozygous familial hypercholesterolaemia: new treatments and clinical guidance. European Heart Journal, 44:2277-2291, May 2023. URL: https://doi.org/10.1093/eurheartj/ehad197, doi:10.1093/eurheartj/ehad197. This article has 345 citations and is from a highest quality peer-reviewed journal.
(haradashiba2023guidelinesforthe pages 1-2): Mariko Harada-Shiba, Hidenori Arai, Hirotoshi Ohmura, Hiroaki Okazaki, Daisuke Sugiyama, Hayato Tada, Kazushige Dobashi, Kota Matsuki, Tetsuo Minamino, Shizuya Yamashita, and Koutaro Yokote. Guidelines for the diagnosis and treatment of adult familial hypercholesterolemia 2022. Journal of Atherosclerosis and Thrombosis, 30:558-586, May 2023. URL: https://doi.org/10.5551/jat.cr005, doi:10.5551/jat.cr005. This article has 100 citations and is from a peer-reviewed journal.
(thangasparan2024unravellingthemechanisms pages 2-3): Sahsikala Thangasparan, Yusof Kamisah, Azizah Ugusman, Nur Najmi Mohamad Anuar, and Nurul ‘Izzah Ibrahim. Unravelling the mechanisms of oxidised low-density lipoprotein in cardiovascular health: current evidence from in vitro and in vivo studies. International Journal of Molecular Sciences, 25:13292, Dec 2024. URL: https://doi.org/10.3390/ijms252413292, doi:10.3390/ijms252413292. This article has 24 citations.
(poirier2016traffickingdynamicsof pages 22-23): Steve Poirier, Hocine Ait Hamouda, Louis Villeneuve, Annie Demers, and Gaétan Mayer. Trafficking dynamics of pcsk9-induced ldlr degradation: focus on human pcsk9 mutations and c-terminal domain. PLoS ONE, 11:e0157230, Jun 2016. URL: https://doi.org/10.1371/journal.pone.0157230, doi:10.1371/journal.pone.0157230. This article has 51 citations and is from a peer-reviewed journal.
(poirier2016traffickingdynamicsof pages 24-24): Steve Poirier, Hocine Ait Hamouda, Louis Villeneuve, Annie Demers, and Gaétan Mayer. Trafficking dynamics of pcsk9-induced ldlr degradation: focus on human pcsk9 mutations and c-terminal domain. PLoS ONE, 11:e0157230, Jun 2016. URL: https://doi.org/10.1371/journal.pone.0157230, doi:10.1371/journal.pone.0157230. This article has 51 citations and is from a peer-reviewed journal.

Ask OpenScientist

OpenScientist Report

Inheritance

Subtypes

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Treatments

Environmental Factors

Biochemical Markers

Source YAML

References & Deep Research

References

Deep Research

Disease Pathophysiology Research Template

Target Disease

Research Objectives

Required Information

1. Core Pathophysiology

2. Key Molecular Players

3. Biological Processes (for GO annotation)

4. Cellular Components

5. Disease Progression

6. Phenotypic Manifestations

Citation Requirements

Output Format

Familial Hypercholesterolemia (FH) Pathophysiology Research Report (Mendelian)

1) Key concepts and definitions (current understanding)

2) Core pathophysiology (molecular and cellular mechanisms)

2.1 Primary pathophysiological mechanism: impaired LDL particle clearance

2.2 Dysregulated pathways

2.3 Cellular processes affected

3) Key molecular players (genes/proteins, cells, anatomy, chemicals)

3.1 High-confidence causal genes/proteins

3.2 Key cell types (mechanistic involvement)

3.3 Anatomical locations

3.4 Chemical entities / therapeutically relevant molecules

4) Biological processes and cellular components (GO-oriented)

5) Disease progression: sequence of events from trigger to clinical disease

Stage 1: Genetic lesion → impaired LDL clearance from birth

Stage 2: Cumulative LDL exposure → arterial LDL deposition and oxidation

Stage 3: Endothelial activation → immune cell recruitment

Stage 4: Foam cell formation and plaque growth

Stage 5: Complications

6) Phenotypic manifestations (clinical phenotypes and mechanistic links)

7) Recent developments and latest research (prioritizing 2023–2024)

7.1 Updated disease architecture and genetic heterogeneity

7.2 Increasing emphasis on SMC biology and extracellular matrix in early atherogenesis

7.3 LDLR-independent LDL-C lowering for HoFH (ANGPTL3 inhibition)

8) Current applications and real-world implementations

8.1 Screening and clinical management

8.2 Guideline-driven lipid-lowering strategy (implementation)

9) Statistics and recent data (2023–2024)

10) Expert opinions / authoritative analysis

11) Evidence items (mechanistic statements; PMID where available in retrieved text)

PCSK9 → LDLR lysosomal degradation (primary mechanistic studies)

LDL oxidation and foam cell biology (recent mechanistic reviews)

Note on PMID coverage

12) Visual evidence